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Chapter 1
Introduction
1.1 History of purine and pyrimidine receptors
Physiological actions of adenosine were first described by Drury and Szent-Gyo¨rgyi in
1929.[1] They found that adenosine and adenosine 5’-monophosphate (AMP) exert a
large number of biological effects upon the mammalian heart, including lowering of arterial
pressure, slowing of the rate of heart beating and impairing of the conduction from auricle
to ventricle. In 1970, Sattin and Rall[2] reported that adenosine mediates an increase of
cAMP level in slices of guinea pig brain, and the effect of adenosine could be blocked by
methylxanthines. These results strongly suggested that adenosine receptors exist in the
central nervous system (CNS).
Van Calker et al.[3] proposed the first subclassification of adenosine receptors. Accor-
ding to their results, adenosine could regulate the cAMP level in the brain cells of rats
through two different receptors: A1 and A2 receptors. The A1 receptor subtype mediates
the inhibition of the accumulation of cAMP, and the A2 receptor subtype mediates the
stimulation of the accumulation of cAMP. At the same time, Londos et al. similarly
proposed two receptor subtypes as Ri- and Ra-receptors.
[4] In this case, R stands for
ribose since a virtually intact ribose moiety was needed for the adenylate cyclase activity.
The ”i” stands for the inhibition of adenylate cyclase activity, while ”a” stands for the
activation of adenylate cyclase activity.
The A2 receptor was further divided into two receptor subtypes by Daly et al. in
1983.[5] Based on the adenylate cyclase (AC) assay, they postulated that there was a
high-affinity A2 receptor (localized in striatal membranes) and a low-affinity A2 receptor
(overall) for adenosine in rat brain. Almost at the same time, Elfmann et al.[6] reported
that a high-affinity A2 receptor in cultured neuroblastoma cells and a low-affinity A2
receptor in glioma cells was found. Later on, the existence of these receptors was proven
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via the cloning and sequencing from various species including rat, mouse and human.
In 1986, Bruns et al. proposed the terms A2A- and A2B-receptors based on labelling
experiments with [3H]NECA of A2A receptors in rat striatal membranes.
[7]
Unlike the A1, A2A and A2B receptors, which were first discovered and classified by
studying of agonist pharmacology, followed by confirming their existence and classification
by cloning, sequencing and expression, the A3 receptor was first discovered by molecular
biology studies in 1992 from rat striatal cells by Zhou et al.[8] Like the A1 receptor, the
A3 receptor is also coupled to adenylate cyclase in an inhibitory manner.
[9]
In 1992, Cornfield et al.[10] proposed an A4 receptor subtype based on the pharma-
cological results of agonist binding profiles. But there was also evidence disputing this
proposal.[11] So the existence of a new adenosine receptor subtype is still unclear, and
needs to be further examined.
Simultaneously with the discovery of adenosine receptors, Gillespie[12] gave the first
indication of different actions of ATP in 1934 after research on the structure-activity
relationships of adenine compounds. He concluded that ATP causes the increase in blood
pressure in rabbit and cat, which was rarely or never observed with AMP or adenosine.
Holton[13] reported in 1959 that ATP was released to produce vasodilatation of rabbit
ear arteries during antidromic stimulation of sensory nerves. This result gave the first
hint that ATP might be a neurotransmitter. Two years later Gaarder et al.[14] identified
ADP as an active component in red blood cell extract, which gave the first indication of
the presence of receptors for ADP.
In 1972 Burnstock[15] postulated that ATP was released as the principal neurotrans-
mitter from some non-adrenergic, non-cholinergic (NANC) nerves, and these nerves were
tentatively termed ”purinergic”. In 1978 he made an important suggestion[16] that there
are two classes of purinergic receptors in membranes of peripheral cells: namely P1-
purinoceptors, which are selective for adenosine, act through adenylate cyclase, and are
antagonized by lower concentrations of methylxanthines than those which produce phos-
phodiesterase inhibition; P2-purinoceptors, which are selective for adenine nucleotides.
Pyrimidine receptors (UTP, UDP) were later found in 1993 by Lin et al in NG108-15
cells.[17]
P2-purinoceptors were suggested to be further divided into P2X and P2Y subtypes by
Burnstock and Kennedy in 1985,[19] based on the rank order of agonist potency of struc-
tural analogues of ATP and also on the activity of antagonists at the P2-purinoceptors.
The detailed classification of P1 and P2 receptors will be discussed in the following
chapter.
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1.2 Overview of purine and pyrimidine receptors
Membrane receptors for physiological purine and pyrimidine derivatives are subdivided
into two separate families:[18] purine P1 receptors or adenosine receptors (AR), which
are the only extracellular nucleoside membrane receptors described so far; purine and
pyrimidine P2 receptors, a big family of nucleotide receptors with ATP, ADP, UDP and/or
UTP or other nucleotides as physiological agonists.
P1 receptors were further divided into four subtypes according to their genetic and
pharmacological character. They are A1, A2A, A2B and A3 adenosine receptors (ARs).
P2 receptors were subdivided into two families based on the signal transduction mech-
anisms and molecular structure:[20], [21] a P2X receptor family consisting of ligand-gated
cation channels; and a P2Y receptor family consisting of G-protein coupled receptors. Up
to now, seven mammalian P2X receptor subunits P2X1−7, and eight P2Y receptors P2Y1,
P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14 have been cloned, pharmacologically
characterized and accepted as valid members of the P2 receptor family. Table 1.1 shows
the overview of the purine and pyrimidine receptors.
Table 1.1: Purine and pyrimidine receptors [22], [23]
P1 receptors P2 receptors
(Nucleoside Receptors) (Nucleotide Receptors)
Natural Agonists Adenosine ATP, ADP, UTP, UDP
and diadenine nucleotides
Subgroups P2X P2Y
Type G-protein coupled Ion channel G-protein coupled
Subtype A1,A2A,A2B,A3 P2X1−7 P2Y1,P2Y2,P2Y4
P2Y6,P2Y11,P2Y12
P2Y13,P2Y14
1.3 P1 (adenosine) receptors
Adenosine (P1) receptors belong to the superfamily of G-protein coupled receptors.[18]
Up to now, four subtypes A1, A2A, A2B and A3 have been identified. All subtypes are
coupled with adenylate cyclase (AC) through G-proteins. A1 and A3 ARs preferably
inhibit adenylate cyclase (AC) via Gi/o proteins, whereas A2A and A2B ARs activate
adenylate cyclase (AC) via Gs proteins.
[24], [25] Table 1.2 gives a summary of the subtypes
of ARs.
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Table 1.2: Subtypes of adenosine receptors (P1)[26]–[30]
A1 A2A A2B A3
Selective agonists CHA , CPA CGS21680, APEC / PENECA, AB-
MECA
Selective antago-
nists
DPCPX, KFM-19,
XAC, KW-3902
CSC, MSX-2, ZM-
241385
/ PSB-11, MRS1067,
MRS-1097
G-Protein coupling G
i/o Gs Gs Gi, Gq
Effectors ↓ cAMP ↑ cAMP ↑cAMP ↓cAMP
Phospholipase C: ↑ IP3 ↑ IP3 ↑ IP3
Ion channels: ↑ K+, ↓ Ca2+
Tissue distribution in humans
High levels Brain (hippocam-
pus, cortex)
Brain (striatum,
nucleus accum-
bens), olfactory
tubercle
Caecum, large
intestine, urinary
bladder
Liver, lung
Low levels Heart, kidney,
lung, testis, fat
cells
Liver, lung, heart,
kidney
Brain, fibroblasts,
heart, lung
Brain, heart,
testis, kidney
Potential therapeutic application
Therapeutic applica-
tion for agonists
Pain, antiepileptic,
neuroprotective,
Vasodilator, anti-
hypertensive, anti-
inflammatory
Antiinflammatory,
septic shock
Cardioprotective,
antiinflammatory,
asthma
Therapeutic applica-
tion for antagonists
Alzheimer’s dis-
ease, antihyperten-
sive, asthma
Morbus Parkinson,
hypotension
Asthma, type II
diabetes, Morbus
Alzheimer
Stroke, glaucoma,
asthma
Adenosine receptors show ubiquitous distribution and are involved in a variety of bio-
logical processes. The effects of activation of ARs by endogenous ligands can be modulated
by agonists and antagonists.
All adenosine receptor agonists are derivatives of the nucleoside adenosine (Figure 1.1),
three positions in the molecule may be modified to increase affinity to specific receptor
subtypes without destroying the agonistic activity: these are the 2- and N6-positions of
the purine and the 5’-position of the ribose. The agonistic effects of different substitutions
at different positions were reviewed recently by experts.[26], [31]
In contrast to agonists, adenosine receptor antagonists have different structures. Nor-
mally they are divided into xanthine and non-xanthine derivatives. The first reported
xanthine antagonists were the naturally occurring caffeine and theophylline.[32] Until now
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Figure 1.1: Structure of adenosine, showing the effects of structural modifications
at various sites on receptor binding
a large number of xanthines has been synthesized in the quest of potent and selective
ligands, among which selective antagonists for A2B- and A3-ARs are still sparse, since
A2B is a low affinity receptor and A3 is quite a new subtype. Antagonists and agonists
for both of these two AR subtypes are to be further studied. Experts have published a
lot of reviews about the antagonists of each subtype of ARs.[27], [33]–[37]
J. W. Daly[38] gave the first prospective review about the potential use of adenosine
receptors as drug targets in 1982. After that, different reviews about the therapeutic
aspects of the agonists and antagonists of adenosine receptors have been published.[39]–[46]
Despite great success in finding new antagonists, only a few xanthine antagonists have
been approved as drugs, including the well-known caffeine and theophylline, useful for
their CNS-stimulating, diuretic and bronchodilating effects, respectively. Their effects are
mainly mediated by A2A and A1 receptor antagonism, perhaps also by A2B antagonism.
DPCPX is in clinical trials as an orphan drug for the treatment of cystic fibrosis.[28], [29]
Further selective adenosine receptor ligands are currently in clinical development.
1.4 P2 receptors
P2 receptors are subdivided into two main classes: P2X and P2Y subtypes. The P2X
receptors belong to the ligand-gated cation channel family, whereas the P2Y receptors are
members of the seven transmembrane G-protein coupled receptor (Table 1.3).[47]
Almost all current synthetic P2 agonists are variations of the physiological nucleotides
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ATP or UTP (Figure 1.2) with modifications at one or more positions in the purine or
pyrimidine ring system, the ribose moiety, or the triphosphate chain. Aim of these mod-
ifications is usually to improve the ligand’s potency, enzymatic stability and/or receptor
subtype selectivity.[48]
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Figure 1.2: Structures of UTP and ATP
Antagonists at these receptors are structurally more diverse, ranging from polyaro-
matic polysulfonated suramin, NF023, PPADS etc. to various 2’- or 3’-deoxy adenosine
bisphosphate derivatives, e.g. MRS 2179 (Figure 1.3). Most of these compounds exhibit
low potency, and only marginal selectivity for one type of P2 receptor over another. Be-
sides this, they may interact with other nucleotide (ATP) binding sites and modulate the
activity of other receptors, thus their usefulness is limited.[49]
In comparison with the adenosine receptors, much less is known about the specific
effects of P2 receptors. Studies of P2 receptors are hindered by several factors, e.g.
general lack of selective and effective agonists and antagonists, the coexistence of different
P2 receptors, fast enzymatic nucleotide degradation and interconversion,[48] and the lack
of reliable binding assays, although functional fluorescent imaging (FLIPR) in cell lines
transfected with rat or human P2 receptors has proven to be useful.[50]
A lot of experts published reviews about P2 receptors, including agonists, antagonists,
and their potential therapeutical applications.[48], [49], [51]–[55]
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Table 1.3: Subtypes of P2 receptors [25]
P2X P2Y
Receptor type Ion channel G-Protein coupled
Signaling pathway / PLC, AC, PLA2,
K+ channels, PLD,
PKC, MAPK
Effectors Ca2+  Na+  K+ ↑ IP3, ↑ Ca2+, ↑ DAG,
↓cAMP
Agonists(selected) Nonselective ATP, ATPγS,
2 MESATP, Ap4A
ATP, ATPγS,
2 MESATP, Ap4A
P2X/P2Y-
selective
α, β-meATP,
β,γ-meATP, BzATP
ADP, UTP, UDP,
2Cl-ADP, 2MeSADP,
ADPβS
Antagonists
(selected)
Nonselective Suramin, PPADS,
Reactive Blue 2
Suramin, PPADS,
Reactive Blue 2
P2X/P2Y-
selective
NF023, NF279, KN-62 ARL67085, MRS2179,
2-cyclohexylthio-ATP

Chapter 2
Introduction of the project
2.1 Introduction of P1 antagonists containing sul-
fonic acid groups
Up to now, a series of mono- and di-substituted 8-phenylxanthine derivatives were syn-
thesized and their potency and selectivity as antagonists at A1-, A2A-, A2B- and A3-
adenosine receptors were evaluated. One obstacle that inhibits the progress of these an-
tagonists in drug application is their low bioavailablity due to their hydrophobicity and
low water-solubility, and attempts to generate hydrophilic antagonists usually results in
a substantial loss of affinity.[29]
Daly et al.[56] had the idea of introducing polar substituents in the 8-phenyl position
of xanthines. 8-p-Sulfophenyltheophylline has a very good water solubility which reaches
more than 20 mM. So far, different 1,3-substituted derivatives of 8-p-sulfophenylxanthine
have been synthesized.[57]–[59], [63] Figure 2.1 gives some examples of 1-monosubstituted
and 1,3-disubstituted 8-p-sulfophenylxanthine which have been reported up to now.
Comparing the Ki values of these 1-monosubstituted and 1,3-disubstituted 8-p-sulfo-
phenylxanthines with those of the corresponding 8-phenylxanthine derivatives (Table 2.1),
it is obvious that the introduction of a p-sulfo substituent in the 8-phenyl xanthine de-
creases the A1 and A2A affinity heavily, and the A2B-affinity was also decreased. For ex-
ample, if we compare 1-propyl-8-phenylxanthine with 1-propyl-8-p-sulfophenylxanthine[63]
(PSB-1115), the introduction of a p-sulfo acid group results in a loss of affinity at the re-
ceptors at A1: 71-fold, A2A: 13-fold and A2B: 11-fold. So attempts to generate these
hydrophilic antagonists usually result in a substantial loss of receptor affinity. But
the A1/A2B receptor selectivity increases from 7-fold to 41-fold, and the A2A/A2B se-
lectivity increases from 97-fold to 453-fold. Therefore the p-sulfo substitution in the
10 Introduction of the project
SO3H
N
NN
N
O
O
R
R
H
1
3
7
1
2
R1 R2 Name
Methyl Methyl 1,3-Dimethyl-8-(p-sulfophenyl)xanthine
Ethyl Ethyl 1,3-Diethyl-8-p-(sulfophenyl)xanthine
Propyl Propyl 1,3-Dipropyl-8-p-(sulfophenyl)xanthine
Propyl H 1-Propyl-8-(p-sulfophenyl)xanthine
Butyl H 1-Butyl-8-(p-sulfophenyl)xanthine
H Methyl 3-Methyl-8-(p-sulfophenyl)xanthine
H Propyl 3-Propyl-8-(p-sulfophenyl)xanthine
Figure 2.1: Examples of 1,3-substituted 8-p-sulfophenylxanthines
Table 2.1: Comparison of Ki values of 1-monosubstituted or 1,3-disubsustituted 8-
phenylxanthines and 1-monosubstituted or 1,3-disubsustituted 8-p-sulfophenylxanthines
Compound Ki[nM] or % inhibition of
radioligand binding at 10 µM
A1 A2A A2B A3
1,3-Dimethyl-8-phenylxanthine 89[65]a(86[60]a) 830[65]a(850[60]a) n.d. n.d.
1,3-Dimethyl-8-(p-sulfophenyl)xanthine 14000[60]a 14000[60]a 1200[59]b 11000[59]
1,3-Dipropyl-8-phenylxanthine 10[60]a 180[60]a n.d. n.d.
1,3-Dipropyl-8-(p-sulfophenyl)xanthine 210[60]a 1400[60]a 250[61]c 183[62]d
(90100[66]e)
1-Propyl-8-phenylxanthine 67[64]a(31[63]f) 1900[64]a(458[63]f) 4.7[63]f n.d.
1-Propyl-8-(p-sulfophenyl)xanthine 2200[64]a 24000[64]a 53.4[63]f 14 %[63]f
1-Butyl-8-phenylxanthine 40[63]f 642[63]f 11.8[63]f n.d
1-Butyl-8-(p-sulfophenyl)xanthine 475[63]f 8070[63]f 70[63]f 39 %[63]f
n.d. not determined
a [3H]PIA was used as A1-radioligand and [3H]NECA as A2A-radioligand, at rat cortical and striatal brain mem-
brane preparations respectively.
b Inhibition of adenosine-induced stimulation of adenylate cyclase in human-CHO cell membranes.
c Inhibition of NECA-induced stimulation of adenylate cyclase in human fibroblast cells.
d Sheep A3 receptors, [125I]ABA as A3-radioligand.
e [125I]ABA-MECA as the A3-radioligand, rat-CHO cell membranes.
f [3H]CCPA was used as A1-radioligand, [3H]MSX-2 as A2A-radioligand, [3H]ZM241385 as A2B-radioligand and
[3H]PSB-11 as A3-radioligand; A1and A2A: rat cortical and striatal membrane preparations respectively, A2Band
A3: human-CHO cell membranes.
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8-phenylxanthine decreases the affinity at ARs, but the selectivity for A2B is greatly en-
hanced. PSB-1115 is one of the most selective A2B antagonists described to date. The
sulfonic acid group appears to contribute to the high selectivity of the compound versus
the other AR subtypes, especially versus A1 ARs.
Compared with other xanthines which are badly water-soluble, these 8-p-sulfophenyl-
xanthine derivatives have much better parenteral bioavailability because of their excellent
water solubility, thus they play a role as very important pharmacological tools. Sul-
fophenylxanthine derivatives are deprotonated under physiological condition due to the
low pKa (pKa < 1
[67]) value of free sulfonic acid groups, which means that they do not
penetrate into the central nervous system (CNS) and are only peripherally active, thus
the central stimulant properties of theophylline and caffeine can be avoided.[68], [70] And
because of their polarity, they will not penetrate into cells and hence will not affect phos-
phodiesterases or calcium-release channels.[71] Due to their polar character they might
probably only locally exert their activity in the intestine if perorally applied. For sys-
temic effects they are only parenterally applicable and can not be applied as peroral
drugs.
8-p-Sulfonamidophenylxanthines (Figure 2.2) were first synthesized by Hamilton et
al.[57]They concluded that sulfonamidophenylxanthines exhibit higher affinity for adeno-
sine receptors in the rat brain than free 8-p-sulfophenylxanthines. These sulfonamide
derivatives are expected to be soluble across a wide pH range and have a potential to be
well absorbed because of their amphoteric nature.
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Figure 2.2: 1,3-Disubstituted-8-p-sulfoamidophenylxanthine derivatives
After that publication,[57] no further research on these p-sulfonamidophenylxanthines
has been reported, especially no research on the 1-monosubstituted sulfonamidophenyl-
xanthine derivatives. However, 1,8-disubstituted xanthine derivatives have now become
of particular interest due to their high A2B adenosine receptor affinity and selectivity.
[63]
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2.2 Introduction of P2 antagonists containing sul-
fonic acid groups
So far, seven P2X (P2X1−7) and eight P2Y receptors (PY1, P2Y2, P2Y4, P2Y6, P2Y11,
P2Y12, P2Y13 and P2Y14) have been cloned and expressed, they are distinct molecular
entities that elicit functional responses. Pharmacological characterization of P2 receptors
has generally been based on the rank order of their activation by agonists related to ATP
and UTP since the majority of available P2 receptor antagonists are relatively weak and
only marginally selective for one P2 receptor subtype over another.[55] These antagonists
also interact with other ATP recognition sites and with other receptor classes and signal
transduction systems.[48]
Compared with the successful development of P1 antagonists, there has been a lacking
of highly selective, competitive P2-purinoceptor antagonists. Novel P2 antagonists have
been synthesized recently, belonging to different structural classes. If we compare the
structure of these antagonists, we can see that most of them contain one or several anionic
sulfonate groups from the oldest suramin up to the recent developments, such as PPADS,
NF023 etc. (Figure 2.3).
Suramin (8-(3-benzamido-4-methylbenzamido)naphthalene-1,3,5-trisulfonic acid) is the
most widely used P2 antagonist ever since its introduction by Dunn and Blakeley as
a reversible P2 purinoceptor antagonist in the mouse vas deferens.[72] Actually it is a
nonselective antagonist, since it has potency as antagonist for both P2X and P2Y recep-
tors,[25] although its sensitivity at subtypes of P2X or P2Y is different.[73]–[76] Furthermore,
suramin inhibits ecto-nucleotidase[77], [78] and neutral ecto-diadenosine polyphosphate hy-
drolase activity.[79] Besides, suramin is currently investigated in clinical trials against
AIDS and cancer, due to its anti-angiogenic activity, thus it shows interesting pharmaco-
logical properites.[80]
NF023 (8,8’-carbonyl-bis-imino-3,1-phenylene-bis-1,3,5-naphtalene trisulfonic acid) is
moderately selective as an antagonist of P2X receptors of the rat mesenteric arterial
bed, rat bladder, rat and rabbit vas deferens, rat saphenous artery and aorta as well
as heterologously expressed P2X receptors.[81]−[85] Like the parent compound suramin,
NF023 inhibits ecto-nucleotidase activity.[77]
Reactive blue 2 is a non-competitive P2 receptor antagonist which does not discri-
minate adequately between P2X and P2Y subtypes.[25] It has micromolar affinity and
some selectivity for endothelial P2Y1 and smooth muscle P2Y1-like receptors versus other
vascular P2X and P2Y receptors.[86]
XAMR 0721 (3’,5’-dinitro-phenylenecarbonylimino-1,3,5-naphthalene trisulfonic acid)
inhibited the binding of ADPβ35S to turkey erythrocytes with relatively high potency (Ki
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Figure 2.3: Selected structures of P2 receptor antagonists
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19 µM).[87] But in the taenia coli, it antagonized ADPβS-induced, i.e. P2Y-receptor-
mediated, relaxation only at 1000 µM .[88] The compound has very little affinity for the
P2X receptor of rat vas deferens. It was also found that it does not inhibit ectonucleoti-
dases.[77]
PPADS (pyridoxal-5’-phosphate-6-phenylazo-2,4-disulfonic acid) was originally put
forward as a P2X-selective antagonists,[89]–[92] but unfortunately it has now to be accepted
that it is in fact a non-selective (but non-universal) P2 receptor antagonist.[25]
KN62 (1-N,O-bis-1,5-isoquinolinesulfonyl-N-methyl-L-tyrosly-4-phenylpiperazine) is a
calcium-calmodulin-dependent protein kinase-II (Camk-II) inhibitor,[93] it inhibits the
ability of P2Y7 receptors to activate phospholipase D in THP-1 monocytes.
[94] It is also a
potent antagonist of the P2X7 receptor on human lymphocytes.
[95], [96] Unlike suramin and
analogues, which contain free sulfonic acid groups, it features two isoquinoline-5-sulfonyl
moieties which act as an ”ATP mimic”,[97] and it seemed that this sulfonyl moiety plays
an important role in its antagonistic activity.
2.3 Aim of the project
As discussed above, many pharmacologically active compounds contain polar sulfonate
groups, which are in many cases essential for their pharmacological activities and/or
selectivities. These compounds belong to the P1 and P2 receptor antagonists. Therefore
the whole project is divided into two parts: P1 antagonists and P2 antagonists.
In the P1 field, 8-p-sulfophenylxanthine derivatives have favorable pharmacological
properties, e.g. increased selectivity for A2B adenosine receptors, and exhibit high water-
solubility, but on the other hand, they cannot be applied as peroral drugs, and are only
parenterally applicable. Therefore we plan to make some structural changes on the sulfonic
acid group, that is, introduce a prodrug concept for these sulfophenylxanthine derivatives.
Prodrugs of these 8-p-sulfophenylxanthine derivatives should be applicable as peroral
drugs. They should have the following characteristics: 1.) be more lipophilic than their
parent drugs, thus they can better cross the cell membranes; 2.) since these prodrugs are
designed as oral drugs, they should be able to resist the gastric acid media in the stomach
and keep intact as prodrugs before they are absorbed and reach the target cell; 3.) they
should be capable to release the parent active drugs in vivo, preferably by an enzymatic
mechanism.
Sulfonamidophenylxanthine derivatives were also set as a synthesis aim of the P1
antagonists, since we want to investigate if differently substituted sulfonamidophenylx-
anthines possess different AR antagonistic activities. Thus we can have a wide overview
about the antagonist properties of xanthines which contain sulfur, from free sulfonic acid,
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sulfonate esters to sulfonamides.
In the P2 field, several novel P2 antagonists which contain anionic sulfonate groups
have been reported, and it is proven that they are more or less selective at P2X or P2Y
receptors. But because of the polarity of sulfonic acid, they are not able to cross the
cell membrane, thus are only parenterally applicable. Therefore the design and synthesis
of the prodrugs of these P2 antagonists was planned, in order to 1.) improve the in
vivo applicability of these drugs; 2.) investigate whether the antagonistic activity at P2
receptors will be changed if the sulfonic acid is esterified to yield sulfonate esters.

Chapter 3
Stability tests of model sulfonate esters
3.1 Results and discussion
Two kinds of sulfonic acid derivatives are conceivable as potential prodrugs: sulfonamides
or sulfonate esters. However, sulfonamides are generally very stable in vivo, the sulfon-
amide bond cannot be cleaved under physiological conditions. Compared with sulfon-
amides, sulfonate esters are relatively unstable at least in vivo, their instability greatly
depends on the substitution pattern, therefore stable sulfonate esters might be obtained
by suitable substitution.
As discussed above in chapter 2, one of the aims of the project can be described
as follows (Figure 3.1). Esters of P1 and P2 antagonists bearing a sulfonate group are
expected to be potential prodrug and/or antagonists with improved properties.
R'O
S
R
O O
P1 xanthine derivative
or P2 antagonist
R =
Figure 3.1: Simplified target structure
An important factor is the choice of the R’ group. Before working on the aimed P1 and
P2 antagonists, some model compounds were designed, that is, instead of the xanthine
derivatives or P2 antagonists, which are normally big molecules, the simple structure of
R = tosylate was chosen as a model compound.
Hydrolysis and stability tests of different sulfonates have been reported before.[98]–[103]
What we can clearly see from these articles is that the nitrophenyl sulfonate ester is one
of the most stable esters among differently substituted sulfonates. But there is no further
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report about the comparison of the hydrolysis constants of o-, m- and p-nitrophenyl
sulfonates under different pH values. Therefore the synthesis and stability tests of these
model compounds, i.e. o-, m- and p-nitrophenyltosylate were first performed.
o-, m- and p-Nitrophenyltosylates were synthesized by reacting toluene sulfonyl chlo-
ride with o-, m- and p-nitrophenol in dichloromethane in the presence of triethylamine
(TEA) as described,[104] and their stabilities were investigated.
Since these esters are not water-soluble, acetonitrile was used as a co-solute for the
stability test. The ratio of acetonitrile to buffer was 10 : 90 and 5 : 95 respectively, in
order to see if the co-solute acetonitrile has any significant effect on the hydrolysis rate.
Five different pH values were tested, namely pH 1, 6, 7, 8 and 9.8, reaching from acidic to
alkaline media. Reaction rates (K) were measured spectro-photometrically by following
the appearance of the absorption due to released o-, m- and p-nitrophenolate. It was
proven that all the hydrolysis were first-order reactions. Plots of log (At -A0) versus time
were linear for three half-lives, the slopes yielding the rate constants. Figure 3.2 gives the
rate constants (K) of the three sulfonate esters at 5 different pH values in acetonitrile :
buffer (5 : 95) and acetonitrile : buffer (10 : 90).
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Figure 3.2: Hydrolysis rate of o-, m- and p-substituted nitrophenyl tosylates in
different media as a function of pH
It was proven that the co-solute didn’t significantly affect the hydrolysis of the sul-
fonate esters, since the K values were almost the same under the two conditions. In
Figure 3.2 we can see that the m-nitrophenyl tosylate is the most stable ester among
these three differently substituted sulfonate esters. Therefore the m-nitrophenol was used
as the relevant phenol for the synthesis of the xanthine sulfonate prodrugs.
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3.2 Experimental part
Apparatus: HP 8452A Diode-Array spectrophotometer
Buffers: KCl-HCl buffer, 50 mM, pH 1
KH2PO4 buffer, 50 mM, pH 6, pH 7, pH 8
H3BO3-KCl, 50 mM, pH 9.8
Wavelength: 400 nm: p-nitrophenolate
376 nm: m-nitrophenolate
400 nm: o-nitrophenolate
Esters were dissolved in a certain amount of acetonitrile, then diluted with different
buffers in a ratio of 10 : 90 or 5 : 95, the final concentration reached 5 × 10−5 M. Hydrol-
ysis rate constants were measured by following the appearance of the hydrolysis product
continuously at fixed wavelength using a HP 8452A Diode-Array spectrophotometer. All
reactions were carried out under pseudo-first-order conditions while the buffer concentra-
tion was maintained in large excess over that of the esters. Rate constants were calculated
as the slope of plots of log (At -Ao) vs. time.

Chapter 4
Syntheses, stabilities and
pharmacological tests of sulfonate
esters of P1 (adenosine) receptor
antagonists
4.1 Syntheses ofm-nitrophenylsulfonate esters of xan-
thine derivatives
The preparation of 5,6-diamino-1,3-dimethyluracil 3a was carried out according to the
classical synthetic route,[105], [106] i.e. condensation of 1,3-dimethylurea with cyanoacetic
acid, ring closure by means of sodium hydroxide, nitrosation using sodium nitrite in acetic
acid, followed by reduction with sodium dithionite in aqueous ammonia.
6-Amino-1,3-dimethyl-5-(p-sulfobenzamido)uracil 1a was obtained when 5,6-diamino-
1,3-dimethyluracil was reacted with the potassium salt of p-sulfobenzoic acid by using
water-soluble N-dimethylaminopropyl-N’-ethylcarbodiimide-HCl (EDC) as the condens-
ing agent. The uracil 1a was cyclized to 1,3-dimethyl-8-p-sulfophenylxanthine 1b by
using 2.5 M NaOH solution.[56], [57]
Esterification was supposed to be performed by converting the 1,3-dimethyl-8-p-sulfo-
phenylxanthine 1b to chlorosulfonylphenylxanthine 1c, followed by esterification with
phenol or phenoxide under basic condition. In fact, chlorination of the sulfophenylxan-
thine was easy to be performed by refluxing it with thionyl chloride, which can be con-
firmed by the mass spectrum of the product. But subsequent esterification of the chloro-
sulfonylphenylxanthine 1c with an excess of m-nitrophenol or sodium m-nitrophenoxide
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could not be achieved even though different reaction conditions, e.g. triethylamine or
pyridine as base catalysts, at different temperatures ranging from -30 ◦C to 30 ◦C, were
tried (Figure 4.1).
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(a) anhydrous acetic acid, 80 °C, 2 h; (b) 1.) 10 % NaOH, 50 % EtOH, 85 °C, 2 hr; 2.) NaNO2, 50 %
acetic acid; (c) Na2S2O4, 25 % NH3·H2O, 30 min; (d) EDC, water, 1 hr, 67 % yield; (e) 2.5 N NaOH,
10 min, 65 % yield; (f) SOCl2, 2 h; (g) MeI, DMF, K2CO3, overnight, 35 % yield; (h) m-nitrophenol or
sodium m-nitrophenoxide
Figure 4.1: Attempted synthesis of xanthine m-nitrophenylsulfonate ester
It was reported[107] that methylation of xanthine substituted in the 8-position with a
naphthalene carboxylic acid using methyl iodide in the presence of potassium carbonate
in DMF gave not only a methylation in the 7-position, but also a methyl ester of the
carboxylic acid group. So methylation of 1b by means of methyl iodide was tried as well,
to see if the same reaction will happen when applied to a p-sulfophenylxanthine. But in
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fact, only the 7-position of the xanthine was methylated, the para-position of the 8-phenyl
substituent was still occupied by the free sulfonic acid group, 1,3,7-trimethyl-8-p-sulfo-
phenylxanthine 1d was obtained (Figure 4.1).
Since the normal way of esterification of sulfonic acids was not successful, an alternative
synthesis was planned (Figure 4.2).
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Figure 4.2: Synthesis of xanthine m-nitrophenylsulfonate esters
First, p-sulfobenzoic acid potassium salt was chlorinated using chlorosulfonic acid
under low temperature.[108], [109] Then this sulfonyl chloride was converted to 4-[[m-
nitrophenoxy]sulfonyl]benzoic acid 2.[110]
5,6-Diamino-1,3-disubstituted uracils 3a, 3b were synthesized from corresponding 1,3-
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disubstituted urea with cyanoacetic acid according to the Figure 4.1. 5,6-Diamino-3-
substituted uracils 3c - 3e were synthesized via alkylation of 6-aminouracil according to
the reported methods.[111], [112]
Compound 2 was used to form the benzamido derivatives 4a - 4e with different 5,6-
diamino-1,3-substituted uracil derivatives 3a - 3e utilizing EDC as the condensing agent.
Many different methods have been reported for the ring closure to get xanthines, e.g.
with NaOH in MeOH,[56] with HMDS,[63] with PPSE,[63] or with triethyloxonium tetraflu-
oroborate (Meerwein’s reagent).[113] At last it was found that refluxing of 4a - 4e in
PPSE at 160 ◦C - 180 ◦C for 1 - 1.5 h, the desired xanthine sulfonate esters 5a - 5e could
be obtained without destroying the sulfonate ester, since PPSE is a powerful, but mild
condensing agent and has been used successfully in the closure of imidazole rings.[114]–[116]
4.2 Novel strategy for the synthesis of 1-substituted
8-p-sulfophenyl xanthine derivatives
The synthesis of 1-substituted 8-p-sulfophenylxanthine derivatives, such as 1-propyl and 1-
butyl-8-p-sulfophenylxanthines has already been reported by using different methods.[63], [64]
But actually it is difficult to practically handle the synthesis, since 1-substituted, 3-
unsubstituted carboxamidouracils have a relatively low reactivity. It is difficult to per-
form the ring closure to get 1-substituted 8-p-sulfophenylxanthine derivatives, therefore
the reaction conditions which have been reported were very hard, e.g. reflux with HMDS
for more than 50 h. Besides, if the PPSE method which has been reported, was applied,
it is difficult to isolate the desired product since PPSE and p-sulfophenylxanthine are
both well soluble in water and methanol. The reproducibility of the reaction is not as
good as expected. The 1-substituted 8-p-sulfophenylxanthines have a good pharmaceu-
tical potential because of their high water-solubility and high selectivity at A2B ARs.
[63]
Thus gram amounts of the compounds were needed for further pharmacological investi-
gation including animal experiments. But the required large amounts were difficult to be
prepared if the reported methods were applied.
In order to find a convenient way to synthesize 1-substituted-8-p-sulfophenylxanthine
derivatives, hydrolysis of the 1-substituted-8-[4’-[[m-nitrophenoxy]sulfonyl]phenyl]xanthine
was applied (Figure 4.3). Simultaneously the stability of these sulfonate esters towards
aqueous alkaline solution was also investigated.
1-Methyl-8-[4’-[[m-nitrophenoxy]sulfonyl]phenyl]xanthine 5c and 1-propyl-8-[4-[[m-ni-
trophenoxy]sulfonyl]phenyl]xanthine 5d were subjected to the hydrolysis. If the hydrolysis
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Figure 4.3: Hydrolysis of 1-substituted xanthine m-nitrophenyl sulfonate esters to
1-substituted-8-p-sulfophenylxanthine derivatives.
was allowed to proceed for 10 min in 2 M NaOH at 70 ◦C, the xanthine sulfonate esters
still could be identified by TLC. Only when the hydrolysis time was prolonged to 20 min,
the reaction was completely performed and no sulfonate ester could be identified by TLC.
Yield of the isolated hydrolysis product reached ca. 80 %.
Besides the recrystallization from H2O for the purification of the 1-substituted 8-p-
sulfophenylxanthines which has been reported,[63], [64] preparative HPLC was also used for
the purification. Figure 4.4 shows the chromatogram of the purification of 1-propyl-8-p-
sulfophenylxanthine 6d with prepative HPLC.
At the same time, capillary electrophoresis was also used for the purity determination
of 1,3-substituted-8-p-sulfophenylxanthines. Figure 4.5 shows the CE spectrum of the
synthesized 1-propyl-8-p-sulfophenylxanthine 6d. From this figure we can see that the
purity of the synthesized sulfophenylxanthine derivative reaches 100 %.
Thus, hydrolysis of esters is a convenient practical method to get large gram amount
of 1-substituted-8-p-sulfophenylxanthine derivatives. On the other side, we realized that
these sulfonate esters are relatively stable, since the complete hydrolysis lasted as long as
20 min at 70 ◦C in 2 M NaOH.
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Figure 4.4: HPLC chromatogram of compound 6d (preparative HPLC)
Condition: column: Eurospher 100, C18, 10 µm, 250 × 20 mm ID
precolumn: Eurospher 100, C18, 5 µm, 30 × 20 mm ID
injection speed: 10 ml/min
mobile phase A: 35 % methanol + 65 % H2O
mobile phase B: H2O
gradient: 0 min: A: 50 % B: 50 %(equal:17.5 % methanol)
20 min: A: 100 % B: 0 %
elution speed: 20 ml/min
Retention time: 11 min
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Figure 4.5: CE spectrum for the purity determination of compound 6d
Condition: buffer phosphate buffer 20 mM, pH 7.4
voltage: 10 kV
Migration time: 3.175 min
Purity: 100 %
4.3 Synthesis of xanthine p-nitrophenylsulfonate es-
ters and 8-p-sulfonamidophenylxanthine deriva-
tives
8-p-Sulfonamidophenylxanthines were first introduced by Hamilton et al. because of their
amphoteric nature. These sulfonamidophenylxanthine derivatives were expected to be
soluble across a wide pH range and have a potential to be well absorbed.[57]
Normally, preparation of sulfonamides is performed by converting the sulfonic acids
to the corresponding chlorosulfonyl derivatives with thionyl chloride or phosphorus pen-
tachloride, then these chlorosulfonyl derivatives are reacted with ammonia or amine to
obtain the desired sulfonamides,[57], [117]–[125] These methods gave good yields of sulfon-
amides at ambient temperature[118], [123], [125] or with reflux.[124], [126] But when these meth-
ods were applied to xanthine derivatives, most of the syntheses did not work. N-Benzyl-
4-(2,6-dioxo-1-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-benzenesulfonamide (Figure 4.6)
was the only substance which could be synthesized by applying the standard method,
but hard reaction condition had to be used, i.e. stirring of the reactants in pyridine for 4
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days at r.t. followed by reflux for 3 h, nevertheless the yields reached only 14 %, and the
purification was very difficult even by column chromatography.[127]
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Figure 4.6: Structure of N-benzyl-4-(2,6-dioxo-1-propyl-2,3,6,7-tetrahydro-1H-
purin-8-yl)benzenesulfonamide
In order to improve the synthesis of the desired 8-p-sulfonamidophenylxanthine deriva-
tives, aminolysis of xanthine sulfonate esters to xanthine sulfonamides was tried, in order
to investigate whether the nitrophenylester was a good leaving group for the aminolysis.
First, 1,3-dimethyl-8-[4’-[[m-nitrophenoxy]sulfonyl]phenyl]xanthine 5a and 1-methyl-8-
[4’-[[m-nitrophenoxy]sulfonyl]phenyl]xanthine 5c were used for the aminolysis (Figure 4.7).
But unfortunately both compounds did not react, even though different alkaline catalysts
were tried. No expected sulfonamide was obtained, only some unidentified compounds
could be seen in the NMR spectrum. This means that the m-nitrophenyl is not a suitable
leaving group for the aminolysis.
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Figure 4.7: Attempted aminolysis by using m-nitrophenyl as a leaving group
Therefore another suitable leaving group had to be found for the aminolysis reac-
tion. According to the stability test results of the model compounds in chapter 3, p-
nitrophenyl sulfonate esters are less stable than the m-nitrophenyl sulfonate esters, so
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Compd. R1 R2 Yield (%)
9a Methyl Methyl 38
9b Propyl Propyl 31
9c Methyl H 83
9d Propyl H 65
9e Butyl H 76
(a) 1.) ClSO2H, overnight; 2.) chipped ice; (b) p-nitrophenol, THF, pH 8 - 9, ca 4 h;
(c) EDC, MeOH; (d) PPSE, 1.5 - 2 h.
Figure 4.8: Synthesis of xanthine p-nitrophenyl sulfonate esters
the p-nitrophenyl group may be used as an effective leaving group. The synthetic route
of xanthine p-nitrophenyl sulfonate esters is almost the same as for the xanthine m-
nitrophenyl sulfonate esters (Figure 4.8). Through the synthesis of these compounds, it
was also proven that the synthetic method for the sulfonate esters is very convenient and
applicable for this kind of xanthine sulfonate esters.
Altogether five differently substituted xanthine p-nitrophenyl sulfonate esters were
synthesized. They are less stable than xanthine m-nitrophenyl sulfonate esters according
to the stability results of chapter 3, so p-nitrophenyl should be a better leaving group for
the aminolysis to prepare the expected sulfonamides.
First, 1,3-dimethyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine 9a was used for the
aminolysis (Figure 4.9). Stirring of the ester with the appropriate amine in DMSO, first
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at r.t. for 30 min, then heating at 150 ◦C for 3 h, yielded the corresponding sulfonamide
which were purified by flash chromatography (dichloromethane : methanol = 50 : 1 or 20
: 1).
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(a) DMSO, 1.) r.t. 30 min; 2.) 150 °C, 3 h.
Figure 4.9: Synthesis of 1,3-dimethyl-substituted xanthine sulfonamide derivatives
Table 4.1 gives an overview of the synthesized 1,3-dimethyl-substituted xanthine sul-
fonamide derivatives. Compounds 10d and 10e are especially interesting, because they
have polar -OH and -COOH substituents, which increase the hydrophilicity of the com-
pounds. Therefore they may exert favorable pharmacokinetic properties.
Table 4.1: Synthesized 1,3-dimethyl-substituted xanthine sulfonamide derivatives
Compd. R1-NH2 Yield (%)
10a
CH3
CH3
61
10b 44
10c 44
10d OH 51
10e COOH 28
It has been reported that 1,8-disubstituted xanthines generally possess high affinity
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to A2B adenosine receptors.
[63] So it is necessary to perform the aminolysis also at the
1-substituted xanthines. Normally 1-substituted xanthines are less reactive than 1,3-
disubstituted xanthines, so harder reaction condition should be applied to achieve this
aminolysis. It was proven that, after the heating time was prolonged to 5 h at 150 ◦C
in DMSO, or ca. 72 h at r.t. in DMSO under the protection of argon, 1-substituted
xanthine sulfonamide derivatives could be successfully obtained and purified by flash
chromatography (dichloromethane : methanol = 40 : 1 or 20 : 1) (Figure 4.10).
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Figure 4.10: Synthesis of 1-propyl-substituted xanthine sulfonamide derivatives
In table 4.2 the synthesized 1-propyl-substituted xanthine sulfonamide derivatives are
collected.
From tables 4.2 and 4.1 it can be clearly concluded that using p-nitrophenyl sulfonate
as a leaving group is a very efficient way for synthesizing sulfonamides, since the yields
generally reach more than 30 %, in some cases even 88 % (11b). Not only primary amines
can easily be reacted but also the secondary amines, which have lower reactivity, can also
be easily employed and the yield reaches 33 % (compound 11e).
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Table 4.2: Synthesized 1-propyl-substituted xanthine sulfonamide derivatives
Compd. R1 R2 Yield (%)
11a H 65
11b H 88
11c OH H 53a, 28b
11d COOH H 34
11e CH3 CH3 33
11f H 40
11g
COOH
H 44
a r.t. under argon
b 150 ◦C, 5h
4.4 Stability tests of m-nitrophenylsulfonate esters
of xanthine derivatives
For a designed, effective oral prodrug, it must be: 1.) resistant enough to any hydrolysis
that might occur before it reaches the bloodstream; 2.) lipophilic enough to cross the
gastrointestinal wall; 3.) capable to release the active parent drug in the body through
enzymatic biotransformation. So, studying the chemical and the biological in vitro sta-
bilities of the prodrug plays an important role in the whole project.
The most popular instruments for stability tests is HPLC. But because the synthesized
sulfonate esters are very lipophilic, they are insoluble in most of the common solvents for
HPLC, e.g. methanol, acetonitrile, water etc. Therefore it is impossible to use HPLC for
the stability tests. So capillary electrophoresis (CE) was chosen as an alternative for the
stability test.
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4.4.1 Short introduction to capillary electrophoresis (CE)
Electrophoresis has been a mainstay of biochemical separation methods since the mid-
1930s when it was first described by Tiselius.[128] Electrophoresis refers to the migration of
charged electrical species when dissolved, or suspended, in an electrolyte through which an
electric current is passed. Cations migrate toward the negatively charged electrode (cath-
ode) and anions are attracted toward the positively charged electrode (anode). Neutral
solutes are not attracted to either electrode.
The advantages of conducting electrophoresis in capillaries was highlighted in the
early 1980s by the work of Jorgenson and Lukacs[129], [130]who popularized the use of CE.
Compared with other analytic techniques, capillary electrophoresis has advantages of
speed, versatility, low running costs and high separation efficiency. The application field
of CE is not only in the separation of proteins, DNA fragments, carbohydrates, but also in
various drugs and drug metabolism studies. In stability tests, CE has its advantage such
as not requiring any sample pretreatment so that the incubation solution can directly be
injected e.g. without centrifugation to remove proteins.
Briefly, the principle of CE are the following: separations are carried out in a capillary
tube, normally the length of this capillary is in the range of 20 to 50 cm, the diameter
of it is from 20 µm to 80 µm. The capillary is filled with running buffer and the sample
is introduced by dipping one end of the capillary into the sample solution and applying
an electric field (electrokinetic injection) or by applying gas pressure (pressure injection).
Migration through the capillary is driven, directly or indirectly, by an electric field. An-
alytes are detected as they pass the window at the far end. Detection is normally by UV
absorbance or fluorescence (Figure 4.11).
CE can be further divided into several subgroups according to their different sep-
aration modes. These include: capillary zone electrophoresis (CZE), free solution CE
(FSCE), whose separation is based on size and charge differences between analytes; mi-
cellar electrokinetic capillary chromatography (MECC or MEKC), which separates neutral
compounds using surfactant micelles; capillary gel electrophoresis (GCE), which sieves so-
lutes through a gel network; and capillary isoelectric focusing (CIEF), whose separation
of zwitterionic solutes is performed within a pH gradient.[132]
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Figure 4.11: Simple principle of Capillary Electrophoresis (CE)[131]
4.4.2 Chemical stability tests
At first, chemical stability of nitrophenyl sulfonic acid esters was investigated. The de-
composition pathways and kinetic data of compounds 5a - 5e were studied at 37 ◦C in
0.001 M NaOH in order to determine their chemical stability.
A 2 mM DMSO stock solution was applied since the prodrugs are very well soluble in
DMSO. In order to eliminate the influence of DMSO, stock solutions were then diluted
with different aqueous buffer solutions at a ratio of 1 : 100. However, if this dilution ratio
was applied, esters were precipitated again at a concentration of 0.02 mM.
Therefore different conditions had to be applied. The xanthine sulfonate esters are
soluble in alkaline aqueous media because the 7-N position of the xanthines can be depro-
tonated. So 0.001 M NaOH (pH 11) was used for the incubation. It is known that esters
are less stable in alkaline media than in neutral media. It is likely that, if they are stable
in alkaline medium, they will also be stable in neutral media.
Hydrolysis products of these sulfonate esters are the corresponding 8-p-sulfophenyl-
xanthine and m-nitrophenol (Figure 4.12). This can be confirmed from the CE spectrum,
since the free xanthine sulfonic acid and m-nitrophenol appear in the spectrum after
several hours of incubation (Figure 4.13).
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Figure 4.12: Chemical hydrolysis of xanthine m-nitrophenyl sulfonate esters
We found that the hydrolysis reaction of the esters is a first order reaction. This
means:
t1/2 = ln2/K (K : slope of the hydrolysis curve) (4.1)
Two kinds of buffers were chosen for the separation. One was 20 mM phosphate buffer
(pH 7.4) plus 100 mM sodium dodecylsulfate (SDS), the other one was 100 mM borate
buffer (pH 8) plus 50 mM SDS. It was proven that borate buffer was better suitable for
the separation, because the migration time of the esters was about 9 min by using borate
buffer, compared to about 25 to 30 min when using phosphate buffer. The applied voltage
for the separation was 10 kV (Figure 4.13).
Measurement of the hydrolysis kinetics revealed an exponential decay of first order for
all esters. These are documented by the diagrams in Figure 4.14 - 4.18 in which ln(C/C0)
(C = concentration of compound, C0 = concentration at time zeros) plotted over the time
(t); the diagrams show linear relationships for all esters under the condition of 0.001 M
NaOH. Table 4.3 gives the half-lives (t1/2) of each ester, it can be concluded that the
synthesized sulfonate esters are very stable, since the half-lives of all esters reach about
20 hours.
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Figure 4.13: CE spectrum of compound 1-propyl-8-[4’-[[m-nitrophenoxy]sulfonyl]-
phenyl]xanthine (5d) before incubation and after 26 hours of incubation in 0.001 M
NaOH at 37 ◦C
Condition: buffer Borate buffer 100 mM + SDS 50 mM, pH 8
voltage: 10 kV
Migration: a: m -Nitrophenol, 4.9 min
b: Internal standard, 5.1 min
c: 1-Propyl-8-p -sulfophenylxanthine, 5.3 min
d: Compound 5d, 8.8 min
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Table 4.3: Stability of compounds 5a - 5e towards 0.001 M aqueous NaOH solution
at 37 ◦C
N
N
H
N
N
O
O
R
S
O
O
O
R NO2
1
2
compd. R1 R2 t1/2 (h) K
5a Methyl Methyl 20.8 9.24 × 10−6
5b Propyl Propyl 21.1 9.1 × 10−6
5c Methyl H 20.1 9.6 × 10−6
5d Propyl H 23.8 8.1 × 10−6
5e Butyl H 19.1 10.1 × 10−6
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Figure 4.14: Hydrolysis rate of 1,3-dimethyl-8-[4’-[[m-nitrophenoxy]sulfonyl]phen-
yl]xanthine (5a). Slope of the curve, -0.03328; t1/2 = 20.8 h; r
2 = 0.9956
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Figure 4.15: Hydrolysis rate of 1,3-dipropyl-8-[4’-[[m-nitrophenoxy]sulfonyl]phen-
yl]xanthine (5b). Slope of the curve, -0.03296; t1/2 = 21.1 h; r
2 = 0.9963
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Figure 4.16: Hydrolysis rate of 1-methyl-8-[4’-[[m-nitrophenoxy]sulfonyl]phenyl]-
xanthine (5c). Slope of the curve, -0.03441; t1/2= 20.1 h; r
2 = 0.993
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Figure 4.17: Hydrolysis rate of 1-propyl-8-[4’-[[m-nitrophenoxy]sulfonyl]phenyl]-
xanthine (5d). Slope of the curve, -0.02911; t1/2 = 23.8 h; r
2 = 0.996
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Figure 4.18: Hydrolysis rate of 1-butyl-8-[4’-[[m-nitrophenoxy]sulfonyl]phenyl]-
xanthine (5e). Slope of the curve, -0.03634; t1/2 = 19.1 hr; r
2 = 0.996
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4.4.3 Biological in vitro stability tests
Since the chemical structure of these esters is similar, i.e. m-nitrophenyl sulfonate ester,
their stability properties should be almost the same. This was confirmed in the chemical
stability tests, as there was no great difference between the half-lives of these esters.
Therefore only one compound was selected for the further biological in vitro stability
tests.
1-Propyl-8-[4’-[[m-nitrophenoxy]sulfonyl]phenyl]xanthine 5d was chosen as an example
to study its biological stability at 37 ◦C in: i.) fetal calf serum; ii.) simulated gastric acid;
iii.) rat liver homogenate. These various media are thought to be valid biological in vitro
models for the degradation that may affect the prodrugs during oral application.
4.4.3.1 Stability in fetal calf serum
To eliminate interference of the proteins from the fetal calf serum, different CE separation
conditions were used than in the chemical stability test.
Firstly, the buffer used was 100 mM borate buffer (pH 8) plus 100 mM SDS instead
of 50 mM SDS used in the chemical stability tests, thus the migration times of the ester
and hydrolyzed product could be clearly distinguished from that of the proteins in fetal
calf serum.
Secondly, 320 nm wavelength was chosen for the detection instead of 254 nm used
in the chemical stability test, since the UV absorbance of the protein in fetal calf serum
reaches 300 nm maximally, therefore at a wavelength of 320 nm one can eliminate the
interference of the protein absorption during the investigation.
Thirdly, p-aminosalicylate sodium salt was used as the internal standard instead of
diclofenac sodium salt, which was used in the chemical stability test, because the latter
one doesn’t have any absorbance at a wavelength of 320 nm.
Table 4.4 shows the migration times of the ester and the hydrolysis products. We can
see that there is no interference with the ester and the internal standard under the CE
test conditions.
Table 4.4: Migration times of prodrug, parent drug and internal standard
prodrug free sulfonic acid m-nitrophenol internal standard
(p-aminosalicylate Na)
migration time (min) 12.89 5.85 6.304 5.00
However no hydrolyzed products could be detected in the CE spectrum after the
hydrolysis in fetal calf serum (Figure 4.19). The only change that could be detected was
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the decrease of the peak area of the ester with the prolongation of the incubation time.
Figure 4.19 gives the CE spectrum of ester 5d in fetal calf serum before incubation and
after 24 h of incubation at 37 ◦C.
The reason why no hydrolyzed product could be detected by CE analysis is not clear.
Two possible explanations are reasonable: one is that the pH value of the fetal calf serum
is ca. 6.9 - 7.6, so the hydrolysis products of the free xanthine sulfonic acid and the
m-nitrophenol are not charged and stay as neutral molecules in the fetal calf serum,
therefore they are not detectable by CE; the other possibility is that both hydrolyzed
products interacted with the proteins in the fetal calf serum, forming neutral insoluble
compounds, thus they are not detectable anymore by CE either. It seemed that the
second explanation is more reasonable, because, if the free sulfonic acid of xanthine and
m-nitrophenol were mixed with fetal calf serum in a separate experiments, precipitation
could be observed after some time.
The hydrolysis is documented by the diagram in figure 4.20 in which C/C0 (C =
concentration of compound, C0 = concentration at time zero) is plotted over the time (t);
the diagram shows linear relationships for 5d under the conditions in fetal calf serum, i.e.
the hydrolysis of 5d in fetal calf serum is a zero-order reaction. Therefore the half-life is
as follows:
t1/2 = 1/2K (K : slope of the hydrolysis curve) (4.2)
From figure 4.20 we can get the slope = 0.03058, therefore the half-life time of com-
pound 5d in fetal calf serum is ca. 16.4 hours.
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Figure 4.19: CE spectrum of 1-propyl-8-[4’-[[[m-nitrophenoxy]sulfonyl]phenyl]-
xanthine 5d before incubation and after 24 hours of incubation in fetal calf serum
at 37 ◦C
Condition: buffer Borate buffer 100 mM + SDS 100 mM, pH 8
voltage: 15 kV
Migration: a: internal standard, 4.9 min
b: compound 5d, 15 min
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Figure 4.20: Hydrolysis rate of 1-propyl-8-[4’-[[[m-nitrophenoxy]sulfonyl]phenyl]-
xanthine 5d in fetal calf serum at 37 ◦C
Slope of the curve, -0.03058 ; t1/2 = 16.4 h; r
2 = 0.995
4.4.3.2 Stability in simulated gastric acid
When simulated gastric acid was applied as the biological medium, only 4 hours of in-
cubation was done. Drugs will generally remain in the stomach for less than 4 hours, so
4 hours of incubation will be enough for the stability tests of the prodrug in simulated
gastric acid. The simulated gastric acid consisted of hydrochloride acid, sodium chloride,
pepsin dissolved in water.[133] Stability of the sulfonic acid ester 5d was determined by
CE. It was ovserved that migration time of the prodrug was delayed for about 2 - 3 min
after each test, so after several measurements the migration time of the prodrug was pro-
longed to more than 20 min and the peak became wider. However it is difficult to exactly
determine the peak area if the peak is too wide. The longer the migration time is, the
wider the peak is, and the more difficult is the determination.
The delay of the migration time can be possibly explained by a jam in the capillary.
An alkaline borate buffer (pH 8) was applied as the balance buffer, but pepsin in simulated
gastric acid is not stable anymore at pH > 6. When the denatured pepsin precipitates in
the capillary, it induces a change of the capillary’s surface. Thus, the migration time of
the compound will be delayed after each test.
It was proven that after 4 hours of incubation at 37 ◦C in simulated gastric acid, there
are still 94 % of 5d remaining in the solution. Therefore, it can be concluded that the
m-nitrophenylsulfonate esters are likely to be very stable in the stomach.
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4.4.3.3 Stability in rat liver homogenate
Fresh rat liver was collected directly after slaughtering, homogenized in DPBS (pH 7.2),
centrifuged at 4 ◦C at 9000 × g for 30 min to obtain the rat liver homogenate containing
32 % of homogenized liver. The final protein concentration was 16 mg/ml as determined
by the Bradford method.[137]
Compared with the tests in fetal calf serum and simulated gastric acid, different CE
separation conditions were used to eliminate interference of the protein in rat liver ho-
mogenate. Borate buffer (100 mM) plus 150 mM SDS (pH 8) was used instead of 50 mM
or 100 mM SDS in the previous studies. In place of 15 kV voltage for the separation
in fetal calf serum and simulated gastric acid, 12 kV voltage was used in the rat liver
homogenate test in order to eliminate the influence of proteins in rat liver homogenate.
It was proven that the hydrolysis in rat liver homogenate is a first order reaction
(Figure 4.21), the half-life (t1/2) of compound 5d being about 41 min. Like the test in
fetal calf serum, no decomposition products could be seen in the CE spectrum, only the
decrease of the peak area of 5d with the prolongation of time was detected. Again no
exact reason was found, only the supposition described in Chapter 4.4.3.1.
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Figure 4.21: Hydrolysis of compound 5d in rat liver homogenate at 37 ◦C.
Slope of the curve, -0.0168; t1/2 = 41 min; r
2 = 0.96
Since no hydrolyzed p-sulfophenylxanthine and m-nitrophenol could be detected from
the CE spectra during the stability test in rat liver homogenate, in order to prove whether
the ester can be hydrolyzed to the parent drugs through enzymatic hydrolysis, TLC
analysis of the hydrolysis products was performed. It was proven that after ca. 2 hours of
incubation in rat liver homogenate at 37 ◦C, the p-sulfophenylxanthine could be detected
by TLC using dicloromethane : methanol = 4 : 1 as mobile phase. This means that the
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ester is cleaved to the active parent drug through enzymatic biotransformation.
4.4.4 Conclusions
The synthesized xanthine m-nitrophenyl sulfonate esters are relatively stable, since half-
life of these esters in 0.001 M NaOH at 37 ◦C reaches 20 h on average. The 1-propyl-8-[4’-
[[m-nitrophenoxy]sulfonyl]phenyl]xanthine 5d showed high stability in artificial gastric
acid and in serum as well. However, the ester was cleaved by incubation with liver
homogenate indicating that nitrophenyl esters have a potential as peroral prodrugs of
sulfonic acid drugs.
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4.5.1 Results and discussion
The synthesized xanthines were tested in radioligand binding assays for their affinity to
A1, A2A, A2B and A3 adenosine receptors in rat cortical membrane, rat striatal membrane
and CHO-cell preparations which recombinantly express the human A2B and A3 adenosine
receptors, respectively.
The A1 AR radioligand binding assay was performed in rat cortical membranes, with a
protein content of about 70 µg/mL. [3H]2-Chloro-N6-cyclopentyladenosine (CCPA, conc:
0.5 nM) was used as selective A1 radioligand.
The A2A AR affinity test was performed using the A2A-selective radioligand [
3H]3-
(3-hydroxypropyl)-8-(m-methoxystyryl)-7-methyl-1-propargyl xanthine (MSX-2, conc: 1
nM) at rat striatal membranes, which are used with a protein content of 70 µg/mL.
The A2B affinity test was performed using the A2B-selective radioligand [
3H]8-((4-
(2-hydroxyethylamino)-2-oxo-ethoxy)phenyl)-1-propyl xanthine (PSB-298, conc: 5 nM),
membranes of human CHO-cells transfected with human A2B-adenosine receptor were
used with a protein content of 100 µg/mL.
The A3 affinity test was performed using the A3-selective radioligand [
3H]2-(2’,3’,5’-
trichlorophenyl)-8-ethyl-4-methyl-(8R)-4,5,7,8-tetrahydro-1H -imidzo[2,1-i ]purin-5-one (P
SB-11, conc: 0.5 nM), membranes of CHO-cells transfected with human A3-adenosine re-
ceptor were used with a protein content of 50 µg/mL.
Inhibition of receptor radioligand binding was determined by 7 concentrations of the
compounds in triplicate in at least three separate experiments. The Cheng-Prusoff equa-
tion and KD values of 0.2 nM for the [
3H]CCPA,[136] 8 nM for [3H]MSX-2,[138] 56 nM
for [3H]PSB-298[139] and 4.9 nM for [3H]PSB-11[140] were used to calculate the Ki values
from IC50 values, determined by the nonlinear curve fitting program GraphPad Prism
TM ,
version 2.0 (GraphPad, San Diego, California, USA).
4.5.1.1 Results of xanthine nitrophenylsulfonate esters
The determined affinities of synthesized 1,3-substituted-8-[4’-[[m-nitrophenoxy]sulfonyl]-
phenyl]xanthines 5a - 5e are collected in table 4.5. Figures 4.22 - 4.23 show the inhibition
curves of 5a - 5e at A1 and A2A ARs.
The determined affinities of the synthesized 1,3-substituted-8-[4’-[[p-nitrophenoxy]sulfo-
nyl]phenyl]xanthines 9a - 9e are collected in table 4.6. Figures 4.24 - 4.25 give the inhi-
bition curves of 9a - 9e at A1 and A2A ARs.
46 P1 (adenosine) receptor antagonists
10 -9 10 -8 10 -7 10 -6 10 -5
0
25
50
75
100
5c
5d
5e
5a
5b
conc, M
%
s
p
e
c
if
ic
b
in
d
in
g
o
f
[3
H
]C
C
P
A
Figure 4.22: Binding of compounds 5a - 5e to the A1 adenosine receptor of rat
brain cortical membranes
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Figure 4.23: Binding of compounds 5a - 5e to the A2A adenosine receptor of rat
brain striatal membranes
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Figure 4.24: Binding of compounds 9a - 9e to the A1 adenosine receptor of rat
brain cortical membranes
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Figure 4.25: Binding of compounds 9a - 9e to the A2A adenosine receptor of rat
brain striatal membranes
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Table 4.5: Affinity of compounds 5a - 5e towards A1, A2A and A3 ARs
N
N
H
N
N
O
O
R
S
O
O
O
R NO2
1
2
Ki ± SEM [nM] or % inhibition of
radioligand binding at 10 µM
compd. R1 R2 A1-Affinity A2A-Affinity A3-Affinity
Rat Rat Human
[3H]CCPA [3H]MSX-2 [3H]PSB-11
(n = 3) (n = 3) (n = 2)
5a Methyl Methyl 21 ± 5 117 ± 22 25 % ± 1.2
5b Propyl Propyl 4.4 ± 0.3 28 ± 29 66 % ± 6.6
5c Methyl H 18 ± 2 63 ± 29 11 % ± 4.3
5d Propyl H 6.5 ± 0.9 54 ± 5 14 % ± 3.1
5e Butyl H 5.7 ± 0.1 21 ± 3 21 % ± 1.3
Comparing the Ki values of the xanthine m-nitrophenylsulfonates 5a - 5e and the
xanthine p-nitrophenylsulfonates 9a - 9e, we can see that p-nitrophenyl sulfonate xan-
thines have at least two fold higher potency at A1 than m-nitrophenylsulfonate xanthines.
Especially p-nitrophenylsulfonate xanthines have a very high affinity for A1 ARs roughly
from 2.7 nM (9b) to 7.7 nM (9a). 1,3-Disubstituted and 1-methyl-substituted xanthine
p-nitrophenylsulfonate esters (9a, 9b, 9c)have higher affinity at A2A ARs than the cor-
responding xanthine m-nitrophenylsulfonate esters (5a, 5b, 5c) , but the 1-propyl and
1-butyl-substituted xanthine p-nitrophenylsulfonate esters (9d, 9e) have a less affinity
at A2A AR than 1-propyl and 1-butyl-substituted xanthine m-nitrophenylsulfonate es-
ters (5d, 5e). Except for the 1-propyl-substituted xanthine derivative, all xanthine m-
nitrophenylsulfonate esters are more potent than xanthine p-nitrophenylsulfonate esters
at A3 AR.
Both of these two kinds of esters have a higher affinity at A1 ARs than at A2A ARs,
but the selectivity between the two receptors is not great, A1/A2A selectivity ranging from
3-fold (5e) to 30 fold (9e). So these two types of xanthine sulfonate esters are potent but
not selective A1 AR antagonists.
The 1,3-dipropyl substituted compound (5b) has almost the highest A1, A2A and A3
affinity among the five m-nitrophenylsulfonate esters, which reaches Ki values of 4.4 nM
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Table 4.6: Affinity of compounds 9a - 9e towards A1, A2A and A3 ARs
N
N
H
N
N
O
O
R
S
O
O
O NO2
R1
2
Ki ± SEM [nM] or % inhibition of
radioligand binding at 10 µM
compd. R1 R2 A1-Affinity A2A-Affinity A3-Affinity
Rat Rat Human
[3H]CCPA [3H]MSX-2 [3H]PSB-11
(n = 3) (n = 3) (n = 2)
9a Methyl Methyl 7.7 ± 0.6 99 ± 21 16 % ± 9
9b Propyl Propyl 2.7 ± 0.1 16 ± 10 44 % ± 2.4
9c Methyl H 6.3 ± 7 34 ± 12 5 % ± 3
9d Propyl H 3.6 ± 0.1 74 ± 2 51 % ± 9
9e Butyl H 2.6 ± 0.3 78 ± 18 9 % ± 8.6
at A1 ARs and 28 nM at A2A ARs, and the inhibition of A3 AR at the concentration of 10
µM reaches 66 %. So does compound 9b, it has also similarly high A1, and A2A affinity,
which is 2.7 nM affinity at A1 ARs and 16 nM at A2A ARs. The A3 AR affinity of 9b
is 44 % inhibition at 10 µM , a little less than for the 1-propyl substituted compound 9d
with 51 % inhibition at 10 µM concentration. The 1,3-dimethyl substituted compound
5a has the lowest A1 and A2A affinity among the five m-nitrophenylsulfonate esters, which
reaches a Ki value of 21 nM at A1 and 117 nM at A2A AR, and so does the compound
9a, which has the lowest A1 and A2A ARs affinity among the five p-nitrophenylsulfonate
esters, with a Ki of 7.7 nM at A1 AR and 99 nM at A2A AR. The lowest affinity at A3 ARs
exhibit the 1-methyl substituted compounds 5c, 9c, which show only 11 %, 5 % inhibition
respectively of radioligand binding at 10 µM concentration. So the introduction of a 3-
propyl substituent increases the affinity to A1, A2A and A3 subtypes, but the introduction
of a 3-methyl substituent decreases the affinity to the A1 and A2A AR subtypes, but not
the A3 AR affinity.
One thing needs to be mentioned, 1-methyl substituted xanthine p-nitrophenylsulfonate
ester (9c) has two times or three times lower A1 affinity than 1-propyl (9d) and 1-butyl
(9e) substituted xanthines, but it has a two times higher A2A affinity than the other two
1-substituted compounds. But the A1 and A2A AR affinity of m-nitrophenylsulfonate
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ester 5c is reversed with respect to 9c.
As we see, there is no great difference between 1-propyl- and 1-butyl-substituted xan-
thines 5d, 5e at A1 ARs (6.5 nM, 5.7 nM) and 9d, 9e at A1 (3.6 nM, 2.6 nM), but the
1-propyl m-nitrophenyl xanthine 5d has a lower A2A AR affinity (54 nM) than 1-butyl
m-nitrophenyl xanthine 5e (21 nM). On the contrary, there is no difference between 9d
and 9e with respect to the A2A affinity.
The introduction of an 8-phenyl residue in xanthines leads to a large increase in re-
ceptor affinity and A1 selectivity of the compounds, and further introduction of a p-
sulfophenyl moiety in that 8-position of xanthines results in a decrease in activity and
selectivity at A1 receptors. In our studies, the substitution on the 8-position with a big ni-
trophenylsulfonylphenyl ester molecule leads to an even higher increase in A1 AR affinity,
on the average all of these esters reach A1 and A2A ARs affinities of < 10 nM. Figure 4.26
gives the comparison of pKi values at A1 ARs of differently 8-substituted 1,3-substituted
xanthines.
Compared with 8-phenylxanthine, the biggest affinity increase at A1 AR is observed
with 1-methyl-8-(p-nitrophenylsulfonyl)xanthine 9c, which reaches 40 times, and com-
pared with 8-sulfophenylxanthine, the greatest affinity increase at A1 AR exhibits com-
pound 9a, which reaches ca. 1820 times.
The introduction of a polar sulfonate substitution at 1,3-substituted 8-phenyl xan-
thines has almost the same effect for A2A ARs as for A1 ARs, that is the potency greatly
decreased (from 7 fold to 65 fold). After the sulfonate substitution was substituted by
big nitrophenyl residues, the A2A affinity greatly increased, from 30-fold (9d) to 350-fold
(9c)(See figure 4.27).
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Figure 4.26: Comparison of differently 1,3,8-substituted xanthines at rat A1 ARs
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Figure 4.27: Comparison of differently 1,3,8-substituted xanthines at rat A2A ARs
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4.5.1.2 Results of sulfonamidophenylxanthines
Determined A1, A2A and A3 affinities of synthesized sulfonamidophenyl xanthines 10a -
10e and 11b - 11f are collected in table 4.7. Figures 4.28 - 4.29 show the A1 and A2A
affinity curves of compounds 10a - 10e.
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Figure 4.28: Binding of 1,3-dimethylsulfonamidophenylxanthines 10a - 10e to A1
adenosine receptors of rat brain cortical membranes
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Figure 4.29: Binding of 1,3-dimethylsulfonamidophenylxanthines 10a-10e to A2A
adenosine receptors of rat brain striatal membranes
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Table 4.7: Affinity of compounds 10a - 10e and 11b - 11f towards A1, A2A and
A3 ARs
N
N
H
N
N
O
O
R
S
O
O
N
R
R
R
1
2
3
4
Ki ± SEM [nM] or % inhibition of
radioligand binding at 10 µM
co. R1 R2 R3 R4 A1-Affinity A2A-Affinity A3-Affinity
Rat Rat Human
[3H]CCPA [3H]MSX-2 [3H]PSB-11
(n = 3) (n = 3) (n = 2)
10a Methyl Methyl
CH3
CH3
H 75 ± 9 283 ± 13 27 % ± 0.6
10b Methyl Methyl H 12 ± 1 113 ± 9 66 % ± 5
10c Methyl Methyl H 27 ± 2 165 ± 69 43 % ± 9
10d Methyl Methyl OH H 98 ± 2 347 ± 37 49 % ± 3
10e Methyl Methyl COOH H 64 ± 4 182 ± 65 41 % ± 0.3
11b Propyl H H 10 ± 2 297 ± 81 68 % ± 8
11c Propyl H OH H 45 ± 7 287 ± 15 36 % ± 22
11d Propyl H COOH H 100 ± 15 320 ± 32 25 % ± 13
11e Propyl H CH3 CH3 5.5 ± 2 42 ± 3 not determined
11f Propyl H H 1.8 ± 1 23 ± 13 not determined
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Comparing the A1 affinity of differently N-substituted 1,3-dimethyl sulfonamidophenyl
xanthines 10a - 10e (Figure 4.28), it can be seen that N-phenylethyl-substituted sul-
fonamide xanthine 10b has the highest A1 AR affinity (12.3 nM), N-2-hydroxyethyl-
substituted sulfonamide 10d has the lowest A1 affinity (98 nM), N-carboxymethyl substi-
tuted sulfonamide 10e has a 64 nM affinity at A1 AR. The difference between 10b, 10d,
10e is only 5-fold to 8-fold. This means that the introduction of a polar -OH or -COOH to
the sulfonamide does not decrease the A1 AR affinity greatly, comparing the introduction
of a polar -COOH or -SO3H in 8-phenylxanthine which induced a large decrease in A1
affinity.
Comparing the affinity of 1,3-dimethylsulfonamidophenylxanthines 10a - 10e at rat
striatal A2A AR (Figure 4.29) no great difference between these five sulfonamidophenyl-
xanthines can be observed. The Ki values reach from 113 nM (10b) to 347 nM (10d), so
the different substitutions at the nitrogen have little effect on the A2A affinity. Like at A1
AR, the N-phenylethyl substituted sulfonamide 10b has the highest affinity among these
five xanthines.
Comparing the A3 AR affinity of 1,3-dimethyl substituted sulfonamidophenylxan-
thines, the N-phenylethyl sulfonamide 10b has the highest affinity with a 65 % inhi-
bition at a concentration of 10 µM . No great difference between the other N-substituted
sulfonamides can be seen.
Like the xanthine sulfonate esters described before, there is also no selectivity of
these 1,3-dimethylsulfonamidophenylxanthine for A1 or A2A ARs. The A1/A2A selectivity
ranges from 3-fold (10e) to 10-fold (10b).
Figure 4.30 - 4.31 give the A1 and A2A affinity curves of the different N-substituted 1-
propyl-p-sulfonamidoxanthines. From these curves it can be concluded that compound 11f
has the highest A1 affinity among all of the 1-propyl-p-sulfonamidoxanthines which reaches
1.8 nM, and the A2A affinity is also high reaching 23 nM. N-Disubstituted compound
11e also has very high A1 and A2A affinity among these five 1-propyl substituted p-
sulfonamidoxanthine derivatives, reaching 5.6 nM for A1 and 42 nM for A2A. But the
A1/A2A selectivity of these 1-propyl-p-sulfoamidoxanthine derivatives is very low, ranging
from 30-fold (11b) to 3-fold (11d). The introduction of a polar -OH or -COOH decreases
the affinity at A1 affinity and to a low extent at A2A AR.
So the introduction of an N-phenyl (11g) or N-dipropyl subsituted amine (11f) in the
sulfonamidoxanthine greatly increases the A1 and A2A affinity. Besides this, there is no
great difference between the other N-mono-substituted sulfonamidoxanthines concerning
the A1, A2A and A3 AR affinity. That means that a polar substitution does not affect the
ARs affinity greatly.
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Figure 4.30: Binding of 1-propyl-p-sulfonamidophenylxanthines 11b - 11f to A1
adenosine receptors of rat brain cortical membranes
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Figure 4.31: Binding of 1-propyl-p-sulfonamidophenylxanthines 11b - 11f to A2A
adenosine receptors of rat brain striatal membranes
56 P1 (adenosine) receptor antagonists
4.5.1.3 Results of nitrophenylsulfonate esters at human CHO-A2B ARs
Compounds 5d and 9d were selected for the human CHO-A2B binding tests. Figure 4.32
give the inhibition curves of the two compounds at human CHO-A2B ARs.
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Figure 4.32: Binding of compound 5d and 9d to to human CHO-A2B adenosine
receptors
From the curves we can see that both compounds have a relative high affinity at A2B
ARs. The Ki value of compound 9d reaches 5.43 ± 4.3 nM , and compound 5d has a
13.3 ± 3.6 nM Ki value at human CHO-A2B ARs.
4.5.2 Conclusions
The synthesized sulfonate esters and sulfoamidoxanthine derivatives were tested in ra-
dioligand binding assays for their affinity to A1, A2A and A3 adenosine receptors, two
sulfonate esters (5d, 9d) were selected to be tested for A2B receptors as well. It was
concluded that all the sulfonate esters and sulfonamide derivatives are very potent A1
and A2A AR antagonists, but the A1/A2A selectivity is not high, ranging from 3-fold (5e)
to 30-fold (9e). And the two compounds which tested for the A2B showed high potency as
well, which have a Ki value of 5.43 nM and 13.3 nM respectively. Most of the compounds
don’t have activity at A3 receptors.
Chapter 5
Syntheses of sulfonate esters of P2
receptor antagonists
This project was focused on developing a prodrug concept for phenylsulfonic acids and
related pharmacologically active sulfonic acid derivatives. Sulfonate groups appear to
be essential for receptor affinity and/or selectivity of many P2 purine and pyrimidine
receptor antagonists. Therefore, after the work on the sulfonate esters of P1 receptor
antagonists which described in Chapter 4, efforts were made to synthesize sulfonate esters
of P2 receptor antagonists as well.
As previously discussed in Chapter 1 and 2, P2 antagonists have been developed
including suramin, NF023, PPADS and XAMR analogues etc., which contain one or
several anionic sulfonate groups. But no further research was reported about the esters
of these sulfonates which may be applied as effective sulfonate prodrugs.
Two kinds of P2 antagonists were chosen for the synthesis of the sulfonate esters,
these are XAMR and NF023 analogues. Because of the lack of naphthalene trisulfonic
acid monosodium salt as starting materials, analogues e.g. sulfanilic acid sodium salt and
2-amino-1,4-benzenedisulfonic acid monosodium salt were applied for the syntheses.
5.1 Synthesis of sulfonate esters of XAMR analogues
XAMR analogues (Figure 5.1) were first selected because they belong to the simplest
P2 receptor antagonists which contain sulfonic acids. Such analogues with different
substituents at the phenyl residue had been synthesized and tested at different P2Y-
purinoceptors.[87] Some of them have a good prospect as competitive antagonists for P2
purinoceptor, e.g. XAMR 0721 shows a high affinity for the P2Y purinoceptors (Ki value
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Figure 5.1: Examples of XAMR analogues
of 19 µM) inhibiting the binding of the radioligand ADPβ35S to P2Y purinoceptors on
turkey erythrocyte membranes. XAMR 0716 is inactive (> 1000 µM) at P2Y purinocep-
tor on the same membranes.[87] XAMR 0721 is weak at the P2Y-receptor of the guinea pig
taenia coli, with a Kd value of 785.5 µM against ADPβ
35S.[88] But XAMR 0721 has good
selectivity on P2 purinoceptors and is inactive in inhibiting ecto-nucleotidase activity.[85]
Therefore it still plays an important role in the research of P2 purinoceptor-mediated
effects.
In this project, sulfonate esters of two XAMR analogues are synthesized. One is
the ester of XAMR 0721 which has the highest P2 antagonist affinity among XAMR
analogues, the other is the ester of XAMR 0716.
5.1.1 Synthesis of 4-benzoylamino-1-benzenesulfonic acid m-ni-
trophenyl ester (14a)
An aqueous solution of sulfanilic acid was treated at pH 3 with a solution of benzoyl
chloride in toluene to obtain benzamides 13a (Figure 5.2). It was reported[144] that the
hydrolyzed benzoic acid, which formed as a by-product, could be removed completely
by extracting the solution with diethyl ether at pH 3. But due to the lack of a special
diethyl ether extracting apparatus, extracting of the water phase with enough toluene
was applied, until no more benzoic acid could be detected by TLC in the water phase.
The synthesis of the desired sulfonate ester was accomplished in the usual way: chlo-
rination of the free sulfonic acid was followed by esterification of the resulting sulfonyl--
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(c) sodium m-nitrophenoxide, TEA, CH2Cl2.
Figure 5.2: Synthesis of 4-benzoylamino-1-benzenesulfonic acid m-nitrophenyl ester
14a
chloride (Figure 5.2). The sodium sulfonate 13a was converted to the corresponding
sulfonyl chloride by first converting the sodium sulfonate to the pyridinium sulfonate,
then chlorination by heating it with phosphorus pentachloride.[145], [146] Then the sulfonyl
chloride was reacted with sodium m-nitrophenoxide to yield the expected sulfonate ester
14a.
Confirmation of the structure
The 1H-NMR of compound 14a is shown in Figure 5.3. Integration of the protons
displays the signals of fourteen protons. The amide NHCO signal is at 10.65 ppm as one
proton. The four protons of the sulfonate ester can be assigned according to the previous
P1 sulfonate esters which are described in Chapter 4. The four protons of the main phenyl
ring are an AA’BB’-system, the chemically but not magnetically equivalent protons H2
and H6 form the AA’part, and because of the effect from sulfur (S), they appear at lower
field than H3 and H5, the signal of H2 and H6 being at 8.09 ppm (the JAB or JA′B′
coupling is 9.14 Hz). The signal of H3 and H5 is at 7.9 ppm (the JBA or JB′A′ coupling
is 8.51 Hz). The five protons of the benzamide residue are an ABXB’A’system, the H4’
couples with the other two ortho protons, therefore the coupling constant reaches 8.35
Hz, and the signal appears at 7.63 ppm. H3’ and H5’ have the same chemical shifts, and
they are also coupled with the ortho position protons, therefore they are at 7.55 ppm.
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H2’and H6’ as the AA’ have also the same chemical shifts, the signal is at 7.96 ppm.
(ppm)
7.57.67.77.87.98.08.18.28.3
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6.46.87.27.68.08.48.89.29.610.010.410.811.211.6
Figure 5.3: Part of the 1H-NMR spectrum of 14a in DMSO-d6
Figure 5.4 - 5.5 show the 13C-NMR and DEPT 13C-NMR spectra of 14a. The 13C-
NMR spectra displayed signals of fifteen carbon atoms, and DEPT 13C-NMR subspectra
indicated that there are nine methyl and six quaternary carbon atoms. At 166.5 ppm the
signal of CONH appears clearly. Figure 5.6 gives the assignment of proton and carbon
signals for compound 14a.
(ppm)
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Figure 5.4: Part of the 13C-NMR spectrum of 14a in DMSO-d6
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Figure 5.5: Part of the DEPT 13C-NMR spectrum of 14a in DMSO-d6
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Figure 5.6: Assignment of proton and carbon signals for compound 14a
5.1.2 Synthesis of 2-(3’,5’-dinitrobenzoylamino)benzene-1,4-di-
sulfonic acid bis-m-nitrophenyl ester (14b)
An aqueous solution of the 2-amino-1,4-benzenedisulfonic acid monosodium salt was
treated at pH 4.5 with a solution of 3,5-dinitrobenzoyl chloride in toluene to obtain
the benzamide 13b. The disodium sulfonate 13b was converted to the corresponding
bis-sulfonyl chloride by heating it directly with phosphorus pentachloride, then pour it
was carefully poured onto chipped ice. The bis-sulfonyl chloride was subsequently reacted
with the sodium m-nitrophenoxide to get the desired sulfonate ester 14b (Figure 5.7).
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Figure 5.7: Synthesis of 2-(3’,5’-dinitro-benzoylamino)benzene-1,4-disulfonic acid
bis-m-nitrophenyl ester 14b
Confirmation of the structure:
Figures 5.8 - 5.9 show the HH-COSY and HMQC spectra of compound 14b. Integra-
tion of the protons displays fourteen protons, there are altogether twenty-three carbon
signals in the 13C-NMR spectrum. The NHCO signal cannot be seen in the 1H-NMR
spectrum, but it appears in the 13C-NMR at 157.09 ppm. Since the two sulfonate esters
are in different position of the main body, they have quite different chemical shifts for
protons and also for carbons. The benzamide signals can easily be distinguished, because
they moved to lower field with the influence of the NO2 group.
With the help of the 1H-NMR, 13C-NMR, DEPT 13C-NMR, HHCOSY and HMQC
spectra, all chemical shifts of each proton and carbon can be assigned (Figure 5.10).
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Figure 5.8: Part of the HH-COSY spectrum of 14b in DMSO-d6
Figure 5.9: Part of the HMQC spectrum of 14b in DMSO-d6
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Figure 5.10: Assignment of proton and carbon signals for compound 14b
5.2 Synthesis of sulfonate esters of NF023 analogues
As we known, most P2 antagonists are symmetrical polysulfonate compound, e.g. suramine,
NF023 etc. But there is no report about the isophthaloylamido-bisnaphthalen trisulfonic
acid, although it is one of the simplest symmetrical compounds (Figure 5.11). Sulfanilic
acid sodium salt and 2-amino-1,4-benzenedisulfonic acid monosodium salt were used as
the starting materials for the synthesis instead of naphthalene trisulfonic acid, because of
the lack of 1,3,5-naphtalene trisulfonic acid as the raw material.
N
H
O
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H
O
SO3 Na
SO3 Na
SO3 Na
SO3 Na
NaO3S
NaO3S
Figure 5.11: Structure of isophthaloyl bisnaphthalene trisulfonic acid
5.2.1 Synthesis of isophthaloyl-N,N-bis-(1-benenesulfonic acid)-
m-nitrophenyl ester (16a)
The synthetic route is shown in Figure 5.12. Sulfanilic acid reacted with isophthaloyl
dichloride at pH 3 yielding the free sulfonic acid sodium salt 15a. Then this sulfonate
sodium salt was chlorinated to sulfonyl chloride with PCl5, and the produced sulfonyl
chloride reacted with sodium m-nitrophenoxide using TEA as a base catalyst to get the
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desired ester 16a.
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(a) H2O/Toluene, pH 3; (b) 1.) PCl5, 150°C 2 h; 2.) chipped ice; (c) sodium m-nitrophenoxide, TEA,
CH2Cl2.
Figure 5.12: Synthesis of isophthaloyl-N,N-bis-(1-benenesulfonicacid)-m-nitro-
phenyl ester 16a
Confirmation of the structure:
Figures 5.13 - 5.15 show the 1H-NMR, 13C-NMR and DEPT 13C-NMR spectra of com-
pound 16a. The compound is symmetrical, therefore integration of the protons displayed
signals of twenty protons, and fifteen carbon signals. The amide NHCO signal is at 10.65
ppm as one proton, the m-nitrophenyl ester residue can be assigned after comparison
with the other sulfonate esters. The main body is an AA’BB’system, see chapter 5.1, the
coupling constants of JAB or JA′B′ is 9.14 Hz. Because of the influence of the carboxamido
group, C2’H is shifted downfield to 8.55 ppm, coupled with H4’ and H6’ as 1.3 Hz, with
H5’ as 1.57 Hz.
The 13C-NMR showed signals of fifteen carbon atoms, and the DEPT 13C-NMR indi-
cated nine methyl, and six quaternary carbon atoms. The NHCO signal appears at 165.86
ppm. The rest can be assigned after comparison with the previous described sulfonate
ester analogues 14a.
After comparison of the 1H-NMR, 13C-NMR and DEPT 13C-NMR spectra, the chem-
ical shifts of protons and carbons of compound 16a can be assigned (Figure 5.16).
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Figure 5.13: Part of the 1H-NMR spectrum of compound 16a in DMSO-d6
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Figure 5.14: Part of the 13C NMR spectrum of compound 16a in DMSO-d6
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Figure 5.15: Part of DEPT 13C-NMR spectrum of compound 16a in DMSO-d6
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Figure 5.16: Assignment of proton and carbon signals for compound 16a
5.2.2 Synthesis of isophthaloyl-N,N-bis-(benzene-1,4-disulfonic
acid)-m-nitrophenyl ester (16b)
The synthetic route is shown in Figure 5.17. 2-Amino-1,4-benzene disulfonic acid mono-
sodium salt reacted with isophthaloyl dichloride at pH 3 to yield the free sulfonic acid
sodium salt 15b. Then this sodium sulfonate was chlorinated to sulfonyl chloride by means
of PCl5, and subsequently reacted with the sodium m-nitrophenoxide to yield the ester
16b. Unfortunately no clean 16b was obtained even though flash chromatography was
done several times, but the NMR spectra confirmed that the esterification had happened.
The problem in this procedure is the isolation and purification of this product.
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Figure 5.17: Synthesis of isophthaloylamino-N,N-bis-benzene-1,4-disulfonic acid
m-nitrophenyl ester 16b
5.3 Synthesis of NF023 analogues
NF023 (8,8’-(carbonyl-bis-(imino-4-methyl-3,1-phenylene)carbonylimino)-bis-(1,3,5-naph-
thalenetrisulfonic acid)) was first introduced by Nickel et al. in 1986.[144] Instead of
1,3,5-naphthalenetrisulfonic acid, sulfanilic acid and 2-amino-1,4-benzenedisulfonic acid
monosodium salt were used as raw materials for the synthesis. The esterification of these
NF023 analogues was not done up because macromolecular compounds were not the target
compounds of our research, so only these NF023 analogues were synthesized.
5.3.1 Synthesis of 4,4-(carbonylbis-(imino-1’,3’-phenylene)carbo-
nylimino)bis-1-sulfonic acid sodium salt (19a)
The synthetic route of the aimed compound is showed in Figure 5.18. An aqueous solution
of sulfanilic acid was treated at pH 3 with a solution of 3-nitrobenzoyl chloride in toluene
to get benzamide 17a. 4-(3’-Amino-benzoylamino)-benzenesulfonic acid sodium salt 18a
was obtained by hydrogenation of 4-(3’-nitro-benzoylamino)-benzenesulfonic acid sodium
salt 17a in water at pH 8 using palladium/charcoal as the catalyst. Later the urea was
prepared by treating the amides with phosgene.[148] During the whole phosgene reaction,
pH 3 was strictly controlled by automatic addition of 2 M Na2CO3. When the reaction
happened, the reaction color turned from yellow to white, and large amounts of precipitate
were formed from the solution. Unfortunately it was impossible to push the reaction to
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Figure 5.18: Synthesis of 4,4-(carbonylbis-(imino-1’,3’-phenylene)carbonylimino)-
bis-1-sulfonic acid sodium salt 19a
completion, even when a very large excess of phosgene was used (30 moles per mole of
18a), the starting material could still be detected on TLC, but all these starting materials
stay in solution, and the precipitated substance at this pH value was only the desired urea
which produced.
Confirmation of the structure:
Figure 5.19 - 5.21 show the 1H-NMR, 13C-NMR and DEPT 13C-NMR spectra of
compound 19a. The compound is symmetrical, therefore integration of the protons dis-
played signals of ten protons. There are twelve carbon signals in the 13C-NMR spectrum,
and six methyl carbon, and six quaterary carbon from the DEPT 13C-NMR spectrum.
The NHCONH signal appears at 9.1 ppm in 1H-NMR and at 152.79 ppm in 13C-NMR.
The CONH signal is seen at 10.3 ppm in 1H-NMR and at 165.86 ppm in the 13C-NMR
spectraum.
The chemical shifts of protons and carbons of the compound 19a can be assigned
according to the 1H-NMR and 13C-NMR spectra (see Figure 5.27).
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Figure 5.19: Part of the 1H-NMR spectrum of compound 19a in DMSO-d6
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Figure 5.20: Part of 13C NMR spectrum of compound 19a in DMSO-d6
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Figure 5.21: DEPT 13C-NMR spectrum of compound 19a in DMSO-d6
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Figure 5.22: Assignment of proton and carbon signals of 19a
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5.3.2 Synthesis of 2,2-(carbonylbis-(imino-1’,3’-phenylene)carbo-
nylimino)-bis-1,4-disulfonic acid monosodium salt (19b)
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Figure 5.23: Synthesis of 2,2-(carbonylbis-(imino-1’,3’-phenylene)carbonylimino)-
bis-1,4-disulfonic acid monosodium salt 19b
The synthetic route of the desired compound is shown in Figure 5.23. The synthetic
procedure is almost the same as for compound 19a. The only difference is the reaction
with phosgene, since the 2-(3’-amino-benzoylamino)benzene-1,4-disulfonic acid sodium
salt 18b has a better water-solubility than 4-(3’-amino-benzoylamino)-benzenesulfonic
acid sodium salt 18a, therefore all the reactants are well soluble in water, thus the reaction
proceeds to completion.
Comfirmation of the structure:
Figure 5.24 - 5.26 show the 1H-NMR, 13C-NMR and DEPT 13C-NMR spectra of com-
pound 19b. The compound is symmetrical, therefore integration of the proton displayed
signals of nine protons. There are thirteen carbon signals in 13C-NMR spectrum, and
seven methyl carbons, and six quaterary carbons in the DEPT 13C-NMR spectrum. The
NHCONH signal is at 9.66 ppm in the 1H-NMR and at 152.84 ppm in the 13C-NMR,
the CONH signal is at 11.33 ppm in the 1H-NMR and at 164.02 ppm in the 13C-NMR
spectrum.
The chemical shifts of protons and carbons of compound 19b can be assigned according
to the 1H-NMR, 13C-NMR and DEPT 13C-NMR spectra (see Figure 5.27).
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Figure 5.24: Part of 1H-NMR spectrum of compound 19b in DMSO-d6
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Figure 5.25: Part of 13C-NMR spectrum of compound 19b in DMSO-d6
74 P2 receptor antagonists
(ppm)
102030405060708090100110120130140150160170180190
Figure 5.26: Part of DEPT 13C-DEPT spectrum of compound 19bin DMSO-d6
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Figure 5.27: Assignment of proton and carbon signals of 19b
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5.4 Pharmacological results and discussion
Some of the synthesized compounds were tested at the P2Y2 receptor of NG108-15 (mouse
neuroblastoma x rat glioma) hybrid cells in our group by Andrea Hunder and Marko
Kaulich. Table 5.1 gives the percentage of inhibition of UTP-stimulated increase in intra-
cellular calcium release mediated by P2Y2 receptors. The compounds were investigated
at a concentration of 100 µM .
Table 5.1: Antagonist activity of compounds 13a - 19b towards P2Y2 receptors (n =
2).
NH
O
R
R
R
R'
R'
R'
1
2
3
1
3
2
compd. R1 R2 R3 R’1 R’2 R’3 % inhibition ± SEM
13a H SO3Na H H H H 19 ± 12
14a H m-NPSa H H H H 100 ± 5
17a H SO3Na H NO2 H H 8.2 ± 2
13b SO3Na H SO3Na NO2 H NO2 7.9 ± 1.3
14b m-NPSa H m-NPSa NO2 H NO2 34 ± 7.8
17b SO3Na H SO3Na NO2 H H 18 ± 5.4
N
H
O
N
H
O
R
R
R
R'
R'
R'
1
2
3 3
1
2
15a H SO3Na H H SO3Na H 11.6 ± 7.6
16a H m-NPSa H H m-NPSa H 49 ± 10
15b SO3Na H SO3Na SO3Na H SO3Na 4.8 ± 1.4
76 P2 receptor antagonists
N
H
O
N
H
O
N
H
N
O
H
R
R
R R'
R'
R'1
2
3
1
2
3
compd. R1 R2 R3 R’1 R’2 R’3 % inhibition ± SEM
19a H SO3Na H H SO3Na H 27.3 ± 3.8
19b SO3Na H SO3Na SO3Na H SO3Na 4.8 ± 0.7
a m-NPS: m-nitrophenylsulfonate
It was shown that most of these sulfonic acids and sulfonate esters are inactive at P2Y2
receptors except compound 14a which shows 100 % inhibition at the concentration of 100
µM . The inhibition of the other compounds are less than 50 % at 100 µM concentration.
The IC50 of compound 14a was determined by stimulation of intracellular calcium
release with 3 µM UTP. It was shown that the IC50 of 14a reaches 8.6 ± 1.0 µM . Further
antagonist activity tests towards other P2 receptor subtypes are still in progress.
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5.5 Conclusions
In the P2 receptor antagonist field, new XAMR analogues and NF023 analogues using sul-
fanilic acid and 2-amino-1,4-benzenedisulfonic acid monosodium salt as starting material
were synthesized.
Synthesis of these sulfonic acid analogues could be easily performed according to the
reported method with some modification, i.e the pH value during the synthesis of com-
pounds 13a, 13b, 15a and 16b had not need to be strictly controlled, manual addition
of 2 M Na2CO3 was sufficient. For the synthesis of urea compounds 19a and 19b by
using phosgene, a pH value of 3 had to be strictly controlled by automatical addition of 2
M Na2CO3, otherwise no products could be obtained. During the synthesis of compounds
13a, 13b, 15a and 16b, by-product of hydrolyzed benzoic acid could be removed by
extracting the solution with toluene several times without the specific ether extraction
apparatus which was described in the literature.[144]
The m-nitrophenyl sulfonate esters of the XAMR analogues and some of the NF023
analogues 14a, 14b and 16a were synthesized by chlorination and esterification of the
sulfonic acid derivatives 13a, 13b and 15a.
The inhibitory potency of some of the synthesized potential P2 receptor antagonists
was tested at P2Y2 receptors of NG108-15 cells. It is concluded that the sulfanilic acid and
2-amino-1,4-benzene disulfonic acid monosodium salts of XAMR and NF023 analogues
are inactive at P2Y2 receptors. The sulfonate esters of XAMR and NF023 derivatives are
inactive at the P2Y2 receptor as well except compound 14a which has an IC50 of 8.6 µM
(stimulation with 3 µM UTP).
Comparing the inhibition by the free sulfonic acid derivatives and the sulfonate ester
derivatives ( 13a, 14a have 19 % and 100 % inhibition respectively; 13b, 14b have 7.9 %
and 34 % inhibition respectively; 15a, 16a have 11.6 % and 48 % inhibition respectively
at the concentration of 100 µM), we can conclude that sulfonate esters have somewhat
higher antagonistic activity than the free sulfonic acids at P2Y2 receptors.

Chapter 6
Experimental Part
6.1 Stability - experimental part
6.1.1 Materials and instruments
6.1.1. 1 Materials
The xanthine derivatives were synthesized according to chapter 4.1. Stock solutions of
the xanthines were prepared in DMSO at concentrations of 2 mM, 20 mM and 50 mM
respectively and stored at 4 ◦C. For the chemical stability test, diclofenac-Na was used as
internal standard at a concentration of 1 mg/mL. p-Aminosalicylate sodium was used as
internal standard at a concentration of 1 mg/mL for fetal calf serum, and at a concentra-
tion of 0.1 mg/mL for simulated gastric acid and rat liver homogenate.
Fetal calf serum was bought from Sigma (F 7524), and stored at -20 ◦C before use.
Simulated gastric acid was prepared as described.[133] To 3.20 g pepsin, 2.0 g NaCl
and 80 mL HCl (1 mol/L), distilled water was added to get a volume of 1000 mL. The
solution had a pH value of 2. This solution was stored at 4 ◦C before use.
Rat liver homogenate was prepared as described with small changes.[134], [135] Fresh rat
liver (6.5 g) was homogenized in DPBS buffer, and centrifuged at 9000 × g for 30 min at
4 ◦C. The supernant was carefully decanted to get the rat liver homogenate containing 32
% of homogenized liver. The protein concentration was 16 mg/mL measured by methods
of Bradford.[137] Rat liver homogenate was kept at -80 ◦C before use.
80 Experimental Part
6.1.1. 2 Buffer
DPBS buffer (Dulbecco’s Phosphate Buffered Saline):
CaCl2 · 2 H2O: 132.5 mg, MgCl2 · 6 H2O: 100 mg, KCl: 200 mg, KH2PO4: 200 mg,
NaCl: 8000 mg, Na2HPO4: 1500 mg filled with H2O to 1000 mL.
6.1.1. 3 Instruments
Centrifuge Beckman AvantiTM J-201
Homogenizer IKA Labortechnic RW 16
pH-meter WTW pH 197
Pipettes Eppendorf (10 - 100 µL, 100 - 1000 µL)
Waterbath Memmert WB/OB 7-45 WBO 45
Software Prism, version 3.0, Graph Pad, San Diego, California, USA
Thermomixer Thermoxixer comfort, Eppendorf
Vortexer IKA Labortechnic MS1 minishaker
6.1.2 Capillary electrophoresis conditions
Apparatus: Beckmann P/ACE 5000 station
Capillary: Fused silica capillary; length: 30/37 cm; diameter: 75 µm
Detector: Diode-Array Detector (DAD)
Voltage: 10 kV (chemical stability)
12 kV (rat liver homogenate stability)
15 kV (fetal calf serum and simulated gastric acid stability)
Buffer: a) Chemical stability
20 mM phosphate buffer + 100 mM SDS (pH 7.4)
100 mM borate buffer + 50 mM SDS (pH 8)
b) Fetal calf serum and simulated gastric acid stability
100 mM borate buffer + 100 mM SDS (pH 8)
c) Rat liver homogenate stability
100 mM borate buffer + 150 mM SDS (pH 8)
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6.1.3 Stability tests
6.1.3. 1 Chemical stability test
DMSO stock solution of compound 5d (2 mM, 1 mL) was incubated with 99 mL of 0.001
M NaOH at 37 ◦C in a water bath. At certain time intervals, 4.8 mL of incubation solution
was withdrawn and mixed with 0.1 mL of internal standard for CE analysis. The final
concentration of the test solution was 1.96 × 10−5 M.
6.1.3. 2 Fetal calf serum stability test
DMSO stock solution of compound 5d (50 mM, 30 µL) was added to 1470 µL of fetal
calf serum, and incubated at 37 ◦C with a rotation speed of 900 rpm. At certain time
intervals, 100 µL of incubation solution was withdrawn and diluted with 4.7 mL of H2O,
and 50 µL of internal standard. After vortexing, it was analyzed by CE. The final drug
concentration was 2.1 × 10−5 M.
6.1.3. 3 Simulated gastric acid stability test
DMSO stock solution of compound 5d (2 mM, 150 µL) was added to 9850 µL of simulated
gastric acid and incubated at 37 ◦C with a rotation speed of 900 rpm. At certain time
intervals, 400 µL of incubation solution was withdrawn and mixed with 100 µL of internal
standard. After vortexing, it was analyzed by CE. The final drug concentration was 2.4
× 10−5 M.
6.1.3. 4 Rat liver homogenate stability test
DMSO stock solution of compound 5d (20 mM, 10 µL) was added to 990 µL of rat
liver homogenate, and incubated at 37 ◦C with a rotation speed of 900 rpm. At certain
time intervals, 50 µL of incubation solution was withdrawn, and 100 µL of 0.1 % TFA
to precipitated the denaturate proteins, 250 µL of DPBS buffer and 100 µL of internal
standard were added. The quenched sample was shortly vortexed and directly analyzed
by CE. The final drug concentration was 2 × 10−5 M.
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6.2 Radioligand binding assays - experimental part
6.2.1 Materials and instruments
Cell-harvester Brandell MP-48, Gaithersburg, Maryland, USA
Centrifuge Beckmann AvantiTM J-201
Filter Whatman GF/B, 57 × 303 m
Glasfaserfilter Whatman GF/B, fired, FDP-148, Brandell, Geithersburg, MD USA
Harvester Brandell M24, Gaithersburg, MD, USA
Brandell M48, Gaithersburg, MD, USA
Homogenizer IKA Labortechnik RW16 basic
Incubator Jouan IG 850
LSC Tri-Carb Model 2100 TR, Canberra Packard
LSC Cocktail Ultima Gold TM, Canberra Packard
Multipipette Eppendorf Multipipette plus
PE-vials Polyethylene vials 4 mL
Photometer Beckmann DU 530
pH-meter WTW pH 197
Pipette Eppendorf research (10 - 100 µL, 100 - 1000 µL)
Pipettepoint Plastibrand, Greiner
Software Prism, version 3.0, Graph Pad, San Diego, California, USA
Ultraturray IKA Labortechnic T25 basic
Vortex IKA Labortechnic MS1 minishaker
Waterbath GFL 1083
ADA Sigma, Typ IV from calf intestinal mucosa, 2000 IU/1.4 mL
[3H]CCPA NEN life science (54.9 Ci/mmol)
DMSO Sigma
DMEM F12 D-6421, Sigma
Fetal Calf Serum F-7524, Sigma
HCl 37 % Merck
[3H]MSX-2 Amersham (85 Ci/mmol)
NECA Sigma
Penicillin
Streptomycin Sigma, P-0781
[3H]PSB-11 Amersham (53 Ci/mmol)
Trizma (Tri-salt) Sigma
Typsin EDTA T-3924, Sigma
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TRIS-HCl buffer (50 mM, pH 7.4):
TRIS-base 6.05 g is dissolved in 1 L H2O, the pH is adjusted to 7.4 by 37 % HCl.
PBS-free buffer (pH 7.2):
NaCl: 8 g, KCl: 0.2 g, Na2HPO4: 1.4 g, KH2PO4: 0.2 g filled with H2O to 1000 mL,
pH adjusted to 7.2 by 1 M HCl.
6.2.2 Membrane preparations
6.2.2. 1 Preparation of cortical membranes of rat brain for A1-binding as-
says[141]
Rat brains (unstripped, code 56004-2, Lot 32220, 25ea, Pel Freez Biological, Rogers,
Arkansas, USA) were thawed slowly at 0 - 4 ◦C, then they were put into ice-cold 0.32 M
sucrose solution.
The cerebral cortex of each brain was carefully scraped off and stored in an ice-cold
sucrose solution, then the cortex and sucrose solution were homogenized for 2 min at full
speed. The homogenate was centrifuged for 10 min at 1,000 g at 4 ◦C. The supernatant
was centrifuged again at 37,000 g for 1 h at 4 ◦C. Membrane pellets were resuspended in
50 mM TRIS-buffer (pH 7.4) and shortly homogenized. These procedures: centrifuging at
37,000 g, pellet suspension, homogenization were repeated twice. In the end the membrane
preparation was resuspended in 50 mM TRIS-buffer (pH 7.4), and stored at -80 ◦C before
use.
6.2.2. 2 Preparation of striatal membranes of rat brain for A2A-binding as-
says[142]
The rat striata are separated from the same rat brains and stored in 50 mM TRIS buffer
(pH 7.4), homogenized at stage 3 for 10 sec. The homogenate was centrifuged at 37,000
g for 15 min at 4 ◦C, the membrane pellets were resuspended in small amounts of TRIS-
buffer, and homogenized again for 2 sec at stage 3. This procedure: centrifugation,
resuspension, was repeated once. At last the membrane pellet was suspended in 50 mM
TRIS buffer (pH 7.4), and stored at -80 ◦C before use.
6.2.2. 3 Membranes from CHO cells for A2B-binding assays
[143]
Chinese Hamster Ovary (CHO) cells stably transfected with the human A2B-adenosine
receptors were grown and maintained at 37 ◦C in 5 % CO2 and 95 % air on petri dishes.
Then cells were washed with PBS free buffer and frozen at -80 ◦C till preparation of
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membrane. For the preparation of membranes for A2B receptor binding, the frozen cells
were thawed and scraped off in ice-cold Tris buffer (50 mM Tris-HCl, pH 7.4), The cell
suspension was homogenized (Ultra-Turrax, 2 × 15 s, at full speed) and the homogenate
was spun for 10 min at 1,000 g. The supernatant was then centrifuged for 45 min at
45,000 g. The membrane pellet was resuspended in 50 mM Tris-HCl, pH 7.4, frozen in
liquid nitrogen at a protein concentration of 1 - 3 mg/mL and stored at -80 ◦C.
6.2.2. 4 Membranes from CHO cells for A3-binding assays
[143]
Chinese Hamster Ovary (CHO) cells stably transfected with the human A3-adenosine
receptors were grown and maintained at 37 ◦C in 5 % CO2 and 95 % air on petri dishes.
Then cells were washed with PBS free buffer and frozen at -80 ◦C till preparation of
membrane. For the preparation of membranes for A3-receptor binding, the frozen cells
were thawed and scraped off in ice-cold hypotonic buffer (5 mM TRIS-HCl, 2 mM EDTA,
pH 7.4), The cell suspension was homogenized (Ultra-Turrax, 2 × 15 s, at full speed) and
the homogenate was spun for 10 min at 1,000 g. The supernatant was then centrifuged
for 40 min at 50,000 g. The membrane pellet was resuspended in 50 mM TRIS-HCl, pH
8.25, containing 1 mM EDTA and 10 mM MgCl2, frozen in liquid nitrogen at a protein
concentration of 1 - 3 mg/mL and stored at -80 ◦C.
6.2.3 Binding assays
6.2.3. 1 Radioligand binding assay at A1-adenosine receptors with [
3H]CCPA
using cortical membranes of rat brain
25 µL DMSO, CADO (25 µM), or diluted test substance
800 µL 50 mM TRIS buffer (pH 7.4)
75 µL [3H]CCPA (end concentration 0.5 nM, KD 0.2 nM)
100 µL Rat brain cortical membrane (protein concentration: 70 µg/mL)
in TRIS-buffer, 15 min preincubation with 0.12 IU ADA
1000 µL End volume
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Dilution scheme:
Compounds 5a - 5e
1 mM Stock solution
solution(µL) DMSO (µL) conc. in assay (µM)
1 60 940 1.5
2 300 600 0.5
3 300 700 0.15
4 300 600 0.05
5 300 700 0.015
6 300 700 0.005
7 200 800 0.001
Compounds 9a - 9e
0.1 mM Stock solution
solution(µL) DMSO (µL) conc. in assay(µM)
1 200 300 1
2 300 700 0.3
3 300 600 0.1
4 300 700 0.03
5 300 600 0.01
6 300 700 0.003
7 300 600 0.001
Compounds 10a - 10e, 11b-11f
0.4 mM Stock solution
solution(µL) DMSO (µL) conc. in assay(µM)
1 300 700 3
2 300 600 1
3 300 700 0.3
4 300 600 0.1
5 300 700 0.03
6 300 600 0.01
7 300 700 0.003
The test compounds were dissolved in DMSO, and diluted according to the above
dilution schemes. Rat brain cortex membrane was suspended in 50 mM TRIS-buffer (pH
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7.4) and preincubated for 20 min with 0.12 IU/mL ADA in order to remove endogenous
adenosine, which would otherwise compete for the binding sites.[7] DMSO (to determine
the total binding), CADO (to determine the unspecific binding) and the test compound
solutions were pipetted in triplicate into test tubes. 50 mM TRIS-HCl buffer (pH 7.4),
radioligand and protein suspension were added and the mixture was mixed. The suspen-
sion was filtered through glass fiber filters (GFB) using the harvester after incubation at
r.t. for 90 min. The filters were washed with ice-cold ca. 10 mL 50 mM TRIS-buffer (pH
7.4) twice. The filter papers were punched out and transferred to scintillation vials and 2
mL scintillation fluid was added. After 6 hours of incubation, radioactivity was counted
with a liquid scintillation counter.
6.2.3. 2 Radioligand binding assay at A2A-adenosine receptors with [
3H]MSX-2
using striatal membranes of rat brain
25 µL DMSO, NECA (50 µM), or diluted test substance
800 µL 50 mM TRIS buffer (pH 7.4)
75 µL [3H]MSX-2 (end concentration 1 nM, KD 8 nM)
100 µL Rat brain cortical membrane (protein concentration: 70 µg/mL)
in TRIS-buffer 15 min incubation with 0.12 IU ADA
1000 µL End volumn
Dilution scheme:
Compounds 5a - 5e and Compounds 9a - 9e were the same as the A1 assay
Compounds 10a - 10e, 11b-11f
1 mM Stock solution
solution(µL) DMSO (µL) conc. in assay(µM)
1 200 300 10
2 300 700 3
3 300 600 1
4 300 700 0.3
5 300 600 0.1
6 300 700 0.03
7 300 600 0.01
This assay was performed in the same manner as the A1 radioligand binding assay,
except that the incubation time at r.t was shortened to 30 min, the filter paper was
immersed in 0.3 % aqueous PEI solution for 1 hour before filtering in order to reduce
non-specific binding.
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6.2.3. 3 Radioligand binding assay at A2B-adenosine receptors with [
3H]PSB-
298 using CHO-A2B membranes
10 µL DMSO, NECA (50 µM), or diluted test substance
70 µL 50 mM TRIS buffer (pH 7.4)
50 µL [3H]PSB-298 (end concentration 5 nM, KD 56 nM)
70 µL CHO-A2B (protein concentration: 100 µg/mL)
in TRIS-buffer 15 min incubation with 0.22 IU ADA
200 µL End volumn
Dilution scheme:
Compounds 5d, 9d
0.02 mM 20 % DMSO stock solution
solution(µL) 20 % DMSO (µL) conc. in assay(µM)
1 300 700 0.3
2 300 600 0.1
3 300 700 0.03
4 300 600 0.01
5 300 700 0.003
6 300 600 0.001
This assay was performed in the same manner as the A1 radioligand binding assay. The
dilution solution using 20 % DMSO, the end concentration of radioligand is 5 nM, CHO-
A2B was preincubated for 30 min with 0.22 IU/mL ADA in order to remove endogenous
adenosine. The suspension was filtered through glass fiber filter (GFB) using the harvester
after 90 min incubation at r.t.
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6.3 Chemistry - experimental part
6.3.1 Instruments, materials and methods
6.3.1. 1 1H-NMR and 13C-NMR spectra
Apparatus: Bruker Advance 500 MHz spectrometer
The chemical shifts δ were given in ppm. The coupling constants J are given in Hz.
Chemical shifts of the deuterated solvents served as internal standards for spectra recorded
in DMSO-d6: δ
1H 2.51 ppm, δ 13C 39.7 ppm. Tetramethylsilane was used as internal
standard for spectra recorded in D2O and CD3COCD3.
6.3.1. 2 Melting points
Melting points were taken on a Buechi 530 melting point apparatus and were uncorrected.
6.3.1. 3 Thin layer chromatography
TLC-Aluminum Plates: Silica gel 60 F254
Merck, Art No. 1.05554
Mobile phase: S 1: Dichloromethane : methanol = 4 : 1
S 2: Dichloromethane : methanol = 8 : 1
S 3: Dichloromethane : methanol = 20 : 1
S 4: Dichloromethane : methanol = 40 : 1
S 5: Dichloromethane : methanol = 50 : 1
S 5: 2-Propanol : NH3 25 % : methanol = 5 : 2 : 1
S 7: 2-Propanol : NH3 25 % = 5 : 2
S 8: 2-Propanol : NH3 25 % = 6 : 1
S 9: Aceton : petroleum ether = 1 : 3.5
S 10: Aceton : petroleum ether = 1 : 2
Detection: -UV light at 254 nm
-UV light at 366 nm
Color reagent Ehrlichs-reagent
(1 g 4-dimethylaminobenzaldehyde, 25 mL 37 % HCl,
75 mL methanol)
6.3.1. 4 Elemental analysis
Apparatus: Vario EL from ,,Elementar Analysensysteme GmbH”
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The elemental analysis were carried out at the Pharmaceutical Institute, Endenich,
University of Bonn.
6.3.1. 5 Mass spectra
Apparatus: MS-50 A.E.I
The mass spectra were determined at the Institute of Organic Chemistry, University
of Bonn.
6.3.1. 6 Capillary electrophoresis (CE) analysis
Apparatus: Beckmann P/ACE 5000 station
Capillary: Fused silica capillary; length: 30/37 cm; diameter 75 µm
Detector: Diode-Array Detector (DAD)
Voltage: 10 kV
Buffer: a) 20 mM phosphate buffer (pH = 7.4)
b) 20 mM phosphate buffer (pH = 7.4) + 100 mM SDS
c) 50 mM phosphate buffer (pH = 7.4)
6.3.1. 7 Preparative HPLC
Pump: Preparative HPLC pump, Knauer GmbH
Precolumn: Eurospher 100, C18, 5 µm, 30× 20 mm ID
Column: Eurospher 100, C18, 10 µm, 250 × 20 mm ID
Detector: Spectrophotometer K-2600
Software: Eurochrom Version 3.05 preparative software
Mobile phase A: 35 % methanol + 65 % H2O
Mobile phase B: H2O
Gradient: 0 min: A: 50 % B: 50 % (equal: 17.5 % methanol)
20 min: A: 100 % B: 0 % (equal: 35 % methanol)
Injection speed: 10 ml/min
Elute speed: 20 ml/min
1,3-Disubstituted-5,6-diaminouracils (3a, 3b) were prepared from 1,3-dimethylurea or
1,3-dipropylurea with cyanoacetic acid followed by ring closure, nitrosation and reduction
as described.[105], [106] 3-Substituted-5,6-diaminouracils 3c - 3e were prepared from 6-
aminouracil via regioselective alkylation with the appropriate alkyl iodide followed by
nitrosation and reduction as described.[111], [112]
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6.3.2 Monographs
6.3.2. 1 6-Amino-1,3-dimethyl-5-(p-sulfobenzamido)uracil (1a)
N
N
O
O
CH3
CH3
N
H
NH2
O
SO3H
1
3 1´
4´
To a solution of 1.3 g (5.4 mmol) p-sulfobenzoic acid potassium salt in 20 mL water,
0.9 g (5.3 mmol) of 5,6-diamino-1,3-dimethyluracil and 1 g (5.2 mmol) of EDC were added
while stirring. The solution was stirred at room temperature for 1 h. Then most of the
solvent was removed in vacuo. 6-Amino-1,3-dimethyl-5-(p-sulfobenzamido)uracil 1a was
precipitated from the solution by addition of methanol, collected by filtration and washed
with methanol to obtain the pure product.
Yield: 1.8 g (67 %)
m.p.: > 300 ◦C (Lit > 300 ◦C[56])
Rf : 0.24 (S 1)
1H-NMR (DMSO-d6) δ [ppm]:
3.13 (s, 3H, N3-CH3); 3.33 (s, 3H; N1-CH3); 6.68 (s, 2H, NH2); 7.66 (d, 2H, J = 8.2 Hz,
C3’H, C5’H ); 7.91 (d, 2H, J = 8.2 Hz, C2’H, C6’H); 8.89 (s, 1H, NHCO).
13C-NMR (DMSO-d6) δ [ppm]:
27.67 (N3-CH3); 30.15 (N1-CH3); 87.66 (C5); 125.19 (C3’, C5’); 127.67 (C2’, C6’); 134.61
(C1’); 150.8, 151.02 (C2, C6); 152.41 (C4’); 159.39 (C4); 166.51 (NHCO).
6.3.2. 2 1,3-Dimethyl-8-p-sulfophenylxanthine (1b)
N
NN
N
O
O
CH3
CH3
H
SO3H
1´ 4´1
3
6-Amino-1,3-dimethyl-5-(p-sulfobenzamido)uracil 1a (0.91 g, 0.26 mmol) was dis-
solved in 25 mL of 2.5 N NaOH and heated at 70 ◦C for 15 min. After cooling down
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to 0 ◦C, the solution was adjusted to pH 6 with conc. HCl. The formed precipitate was
washed with cold 1 M HCl and recrystallized by NaOH/HCl treatment.
Yield: 0.61 g (65 %)
m.p.: > 300 ◦C (Lit >300 ◦C[56])
Rf : 0.53 (S 1)
C,H,N analysis: C13H12N4O5S · 2 H2O [372.37 g/mol]
C % H % N %
Calcd.: 41.89 4.30 15.05
Found: 41.63 4.24 14.85
1H-NMR (DMSO-d6) δ [ppm]:
3.25 (s, 3H, N1-CH3); 3.5 (s, 3H; N3-CH3); 7.7 (d, 2H, J = 8.51 Hz, C3’H, C5’H); 8.07
(d, 2H, J = 8.51 Hz, C2’H, C6’H).
13C-NMR (DMSO-d6) δ [ppm]:
27.96 (N1-CH3); 29.95 (N3-CH3); 108.01 (C5); 126.11 (C3’, C5’); 126.26 (C2’, C6’); 128.72
(C1’); 148.63 (C4), 149.47 (C8); 149.95 (C4’); 151.37 (C2); 154.38 (C6).
Determination of purity by CE:
Buffer: Phosphate 20 mM, pH 7.4
Currency: 90 µA
Retention time: 4.41 min
Purity: 100 %
6.3.2. 3 1,3-Dimethyl-8-p-chlorosulfophenylxanthine (1c)
N
N
O
O
CH3
CH3
N
N
H
SO2Cl
1
3
1´ 4´
7
1,3-Dimethyl-8-p-sulfophenylxanthine 1b (56 mg, 0.16 mmol) was dissolved in 10 mL
of SOCl2. The mixture was refluxed for 2 h. The remaining SOCl2 was removed under
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reduced pressure to yield a white solid residue. Since it is unstable, only NMR and MS
were used to confirm the structure.
Calcd. Mass: 354.77 g/mol (C13H11ClN4O4S).
EI-MS (70 eV): m/z (%): 354 (M+; 100); 255 ([M-SO2Cl]
+, 25).
1H-NMR (DMSO-d6) δ [ppm]:
3.25 (s, 3H, N1-CH3); 3.5 (s, 3H; N3-CH3); 7.7 (d, 2H, C3’H, C5’H); 8.07 (d, 2H, C2’H,
C6’H).
13C-NMR (DMSO-d6) δ [ppm]:
27.91 (N1-CH3); 29.94 (N3-CH3); 107.02 (C5); 126.08 (C3’, C5’); 126.26 (C2’, C6’); 128.76
(C1’); 148.65, 149.48, 149.88 (C4, C8, C4’); 151.34 (C2); 154.33 (C6).
6.3.2. 4 1,3,7-Trimethyl-8-p-sulfophenylxanthine (1d)
SO3H
N
N
O
O
CH3
CH3
N
N
CH3
1
3 1´
4´7
To a solution of 100 mg (0.3 mmol) 1,3-dimethyl-8-p-sulfophenylxanthine 1b in 10
mL of DMF 82.8 mg (0.6 mmol) of K2CO3 and 0.37 mL (6 mmol) of CH3I were added,
and the mixture was stirred overnight at room temperature. The formed precipitate was
filtered off and washed with DMF. After the addition of diethyl ether to the filtrate, a
white precipitate was obtained which was collected by filtration, and washed with diethyl
ether.
Yield: 0.37 g (35 %)
m.p.: >300 ◦C
Rf : 0.31 (S 1)
C,H,N analysis: C14H14N4O5S · 2.5 H2O [395.41 g/mol]
C % H % N %
Calcd.: 42.49 4.81 14.16
Found: 42.07 4.30 14.18
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1H-NMR (D2O) δ [ppm]:
3.34 (s, 3H, N1-CH3); 3.53 (s, 3H, N3-CH3); 3.97 (s, 3H, N7-CH3); 7.83 (d, 2H, J = 8.35
Hz, C3’H, C5’H); 7.99 (d, 2H, J = 8.35 Hz, C2’H, C6’H).
13C-NMR (D2O) δ [ppm]:
30.92 (N1-CH3); 32.78 (N3-CH3); 36.53 (N7-CH3); 111.91 (C5); 128.87 (C3’, C5’); 132.86
(C2’, C6’); 132.74 (C1’); 147.34 (C4); 150.85 (C8); 154.76 (C4’); 155.37 (C2); 159.2 (C6).
Determination of purity by CE:
Buffer: Phosphate 20 mM, pH 7.4
Currency: 90 µA
Retention time: 3.64 min
Purity: 100 %
6.3.2. 5 4-[[m-Nitrophenoxy]sulfonyl]benzoic acid (2)
HOOC S
O
O
O
NO2
1 4
1'
3´
Chlorosulfonic acid (50 mL) was slowly added to 5 g (21 mmol) of p-sulfobenzoic
acid potassium salt, while the temperature was kept below 30 ◦C, then the mixture
was stirred at r.t. overnight. The clear solution was carefully poured onto chipped ice,
and the granular white solid was collected by filtration and washed with cold water.
4-Sulfochlorobenzoic acid was obtained and dried.
m-Nitrophenol (1.47 g, 11 mmol) was dissolved in 50 mL of THF and 50 mL of TRIS-
buffer (50 mM, pH 9), 4-sulfochlorobenzoic acid (2.5 g, 11 mmol) in 50 mL of THF was
added drop by drop into the above solution. The pH value was kept between 9 - 10 by
addition of 2.5 M NaOH, while the reaction mixture was stirred for about 4 h at r.t.. Then
the solution was neutralized with 1 M HCl to pH 7. THF was removed in vacuo, and the
aqueous solution was further acidified to pH 1 with 1 M HCl. The formed precipitate was
filtered and recrystallized from acetone : cyclohexane (1 : 2).
Yield: 3.18 g (45 % calcd. from p-sulfobenzoic acid)
m.p.: 213.5 ◦C
Rf : 0.32 (S 2)
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C,H,N analysis: C13H9NO7S [323.28 g/mol]
C % H % N %
Calcd.: 48.30 2.81 4.33
Found: 48.22 2.69 4.42
1H-NMR (CD3COCD3) δ [ppm]:
7.56 (m, 1H, C6’H); 7.74 (t, 1H; J = 8.35 Hz, C5’H); 7.93 (t, 1H, J = 2.2 Hz, C2’H);
8.09 (d, 2H, J = 8.51 Hz, C3H, C5H); 8.25 (m, 1H, C4’H); 8.3 (d, 2H, J = 8.51 Hz, C2H,
C6H).
13C-NMR (CD3COCD3) δ [ppm]:
118.57 (C2’); 123.32 (C4’); 129.7 (C5’); 129.76 (C3, C5); 131.67 (C2, C6); 132.19 (C6’);
137.27 (C1, C4); 139.38 (C3’); 150.38 (C1’); 165.99 (COOH).
6.3.2. 6 4-[[p-Nitrophenoxy]sulfonyl]benzoic acid (7)
HOOC S
O
O
O NO2
1 4
1' 4'
Compound 7 was prepared as described for compound 2, from 5 g (21 mmol) of
p-sulfobenzoic acid potassium salt and 1.5 g (11 mmol) of p-nitrophenol.
Yield: 2.9 g (41 % calcd. from p-sulfobenzoic acid)
m.p.: 218 - 219 ◦C
Rf : 0.37 (S 2)
C,H,N analysis: C13H9NO7S [323.28 g/mol]
C % H % N %
Calcd.: 48.30 2.81 4.33
Found: 48.15 2.87 4.47
1H-NMR (DMSO-d6) δ[ppm]:
7.36 (d, J = 9.14 Hz, 2H, C3’H, C5’H); 8.02 (d, J = 8.82 Hz, 2H, C3H, C5H); 8.18 (d,
2H, J = 8.82 Hz, C2H, C6H); 8.26 (d, J = 9.14 Hz, 2H, C2’H, C6’H).
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13C-NMR (DMSO-d6) δ[ppm]:
123.81 (C3’, C5’); 126.26 (C2’, C6’); 129.06 (C3, C5); 131.03 (C2, C6); 137.12, 137.54
(C4, C1); 146.62 (C4’); 153.3 (C1’); 166.11 (COOH).
6.3.2. 7 6-Amino-1,3-dimethyl-5-[4’-[[m-nitrophenoxy]sulfonyl]benzamido]uracil
(4a)
S
O O
O
N
N
O
O
CH3
CH3 N
H
NH2
O
NO2
3
4´
1
1´
1´´
3´´
To a solution of 262 mg (1.54 mmol) 1,3-dimethyluracil 3a in 60 mL of methanol, 500
mg (1.54 mmol) of 4-[[m-nitrophenoxy]sulfonyl]benzoic acid 2 and 250 mg (1.31 mmol)
of EDC were added. After 3 h of stirring, a white precipitate was obtained by filtration.
The solid was washed with cold methanol. Recrystallization from DMF/H2O afforded
pure 4a.
Yield: 442 mg (60 %)
m.p.: 239 ◦C
Rf : 0.55 (S 2)
C,H,N analysis: C19H17N5O8S · 0.5 H2O [484.45 g/mol]
C % H % N %
Calcd.: 47.06 3.72 14.45
Found: 47.52 3.61 14.55
1H-NMR (DMSO-d6) δ [ppm]:
3.14 (s, 3H, N3-CH3); 3.35 (s, 3H, N1-CH3); 6.28 (s, 2H, NH2); 7.55 (m, 1H, C6”H); 7.71
(t, 1H, J = 8.35 Hz, C5”H); 7.99 (t, 1H, J = 2.2 Hz, C2”H); 8.05 (d, 2H, J = 8.51 Hz,
C3’H, C5’H); 8.2 (d, 2H, J = 8.51 Hz, C2’H, C6’H); 8.28 (m, 1H, C4”H); 9.24 (s, 1H,
NHCO).
13C-NMR (DMSO-d6) δ [ppm]:
27.68 (N3-CH3); 30.16 (N1-CH3); 87.06 (C5); 117.5 (C2”); 122.78 (C4”); 128.35 (C3’,
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C5’); 129.61 (C5”); 128.91 (C2’, C6’); 131.78 (C6”); 135.72 (C1’); 140.86 (C3”); 148.57,
148.94 (C2, C6); 150.74 (C1”); 152.43 (C4’); 159.29 (C4); 165.23 (NHCO).
6.3.2. 8 6-Amino-1,3-dipropyl-5-[4’-[[m-nitrophenoxy]sulfonyl]benzamido]ur-
acil (4b)
S
O O
O
N
N
O
O
N
H
NH2
O
NO21´´´
2´´´
1´´´´
2´´´´
3´´´
3´´´´
3
4´
1
1´
1´´
3´´
Compound 4b was obtained as described above for 4a, from 546 mg (2.42 mmol) of 5,6-
diamino-1,3-dipropyluracil 3b, 780 mg (2.42 mmol) of 4-[[m-nitrophenoxy]sulfonyl]benzoic
acid 2 and 461 mg (2.41 mmol) of EDC.
Yield: 700 mg (55 %)
m.p.: 245 ◦C
Rf : 0.62 (S 2)
C,H,N analysis: C23H25N5O8S · 0.5 H2O [540.57 g/mol]
C % H % N %
Calcd.: 51.06 4.81 12.95
Found: 51.55 4.65 12.45
1H-NMR (DMSO-d6) δ [ppm]:
0.83 (m, 3H, C3”’H); 0.88 (m, 3H, C3””H); 1.52 (m, 2H, C2”’H); 1.57 (m, 2H, C2””H);
3.7 (m, 2H, C1”’H); 3.84 (m, 2H, C1””H); 6.79 (s, 2H, NH2); 7.54 (m, 1H, C6”H); 7.69
(t, 1H, C5”H); 7.99 (t, 1H, C2”H); 8.05 (d, 2H, C3’H, C5’H); 8.20 (d, 2H, C2’H, C6’H);
8.22 (m, 1H, C4”H); 9.21 (s, 1H, NHCO).
13C-NMR (DMSO-d6) δ [ppm]:
10.85 (C3”’); 11.31 (C3””); 20.96 (C2”’); 20.99 (C2””); 41.99 (C1”’); 43.84 (C1””); 86.99
(C5); 117.51 (C2”); 122.78 (C4”); 128.35 (C3’, C5’); 128.91 (C5”); 129.58 (C2’, C6’);
131.78 (C6”); 135.72 (C1’); 140.83 (C3”); 148.56, 148.93 (C6, C2); 150.47 (C1”); 151.79
(C4’); 159.08 (C4); 165.17 (NHCO).
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6.3.2. 9 6-Amino-3-methyl-5-[4’-[[m-nitrophenoxy]sulfonyl]benzamido]uracil (4c)
S
O O
O
N
N
O
O
N
H
NH2
O
NO2CH3
H
3
4´
1
1´
1´´
3´´
Compound 4c was obtained as described above for 4a, from 1.12 g (7.2 mmol) of
5,6-diamino-3-methyluracil 3c, 2.35 g (7.2 mmol) of 4-[[m-nitrophenoxy]sulfonyl]benzoic
acid 2 and 3 g (6.8 mmol) of EDC.
Yield: 1.89 g (55 %)
m.p.: 268 ◦C
Rf : 0.59 (S 2)
C,H,N analysis: C18H15N5O8S · 0.5 H2O [470.42 g/mol]
C % H % N %
Calcd.: 45.92 3.40 14.88
Found: 45.92 3.31 14.92
1H-NMR (DMSO-d6) δ [ppm]:
3.07 (s, 3H, N3-CH3); 6.2 (s, 2H, NH2); 7.54 (m, 1H, C6”H); 7.7 (t, 1H, J = 8.2 Hz,
C5”H); 7.99 (t, 1H, J = 2.2 Hz, C2”H); 8.05 (d, 2H, J = 8.51 Hz, C3’H, C5’H); 8.19 (d,
2H, J = 8.51Hz, C2’H, C6’H); 8.2 (m, 1H, C4”H); 9.2 (s, 1H, NHCO); 10.55 (s,1H, N1-H).
13C-NMR (DMSO-d6) δ [ppm]:
26.64 (N3-CH3); 86.54 (C5); 117.53 (C2”); 122.8 (C4”); 128.42 (C3’, C5’); 128.93 (C5”);
129.63 (C2’, C6’); 131.79 (C6”); 135.74 (C1’); 140.82 (C3”); 148.57, 148.94 (C6, C2);
150.32 (C1”); 152.76 (C4’); 160.84 (C4); 165.07 (NHCO).
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6.3.2. 10 6-Amino-3-propyl-5-[4’-[[m-nitrophenoxy]sulfonyl]benzamido]uracil
(4d)
S
O O
O
N
N
O
O
N
H
NH2
O
NO2
H
3
4´
1
1´
1´´
1´´´
2´´´
3´´´
3´´
Compound 4d was obtained as described above for 4a, from 1.3 g (7.2 mmol) of 5,6-
diamino-3-propyluracil 3d, 2.35 g (7.2 mmol) of 4-[[m-nitrophenoxy]sulfonyl]benzoic acid
2 and 3 g (6.8 mmol) of EDC.
Yield: 2.01 g (57 %)
m.p.: 252 ◦C
Rf : 0.44 (S 2)
C,H,N analysis: C20H19N5O8S [489.47 g/mol]
C % H % N %
Calcd.: 49.08 3.91 14.31
Found: 48.88 3.93 14.24
1H-NMR (DMSO-d6) δ [ppm]:
0.82 (t, 3H, C3”’H); 1.5 (m, 2H, C2”’H); 3.65 (s, 3H, C1”’H); 6.19 (s, 2H, NH2); 7.53 (m,
1H, C6”H); 7.7 (t, 1H, C5”H); 7.98 (t, 1H, C2”H); 8.05 (d, 2H, C3’H, C5’H); 8.2 (d, 2H,
C2’H, C6’H); 8.2 (m, 1H, C4”H); 9.2 (s, 1H, NHCO); 10.48 (s, 1H, N1-H).
13C-NMR (DMSO-d6) δ [ppm]:
11.32 (C3”’); 21.09 (C2”’); 26.64 (C1”’); 86.54 (C5); 117.52 (C2”); 122.78 (C4”); 128.4
(C3’, C5’); 128.92 (C5”); 129.51 (C2’, C6’); 131.77 (C6”); 135.72 (C1’); 140.79 (C3”);
148.56, 148.93 ((C6, C2); 150.01 (C1”); 150.62 (C4’); 160.64 (C4); 165.02 (NHCO).
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6.3.2. 11 6-Amino-3-butyl-5-[4’-[[m-nitrophenoxy]sulfonyl]benzamido]uracil (4e)
S
O O
O
N
N
O
O
N
H
NH2
O
NO2
H
3
4´
1
1´
1´´
1´´´
2´´´
3´´´
4´´´
3´´
Compound 4e was obtained as described above for 4a, from 1.4 g (7.2 mmol) of 5,6-
diamino-3-butyluracil 3e, 2.35 g (7.2 mmol) of 4-[[m-nitrophenoxy]sulfonyl]benzoic acid
2 and 3 g (6.8 mmol) of EDC.
Yield: 1.53 g (42 %)
m.p.: 253 ◦C
Rf : 0.60 (S 2)
C,H,N analysis: C21H21N5O8S · 0.5 H2O [512.5 g/mol]
C % H % N %
Calcd.: 49.17 4.29 13.66
Found: 49.51 4.18 13.62
1H-NMR (DMSO-d6) δ [ppm]:
0.87 (t, 3H, CH3); 1.25 (m, 2H, C3”’H); 1.46 (m, 2H, C2”’H); 3.7 (s, 3H, C1”’H); 6.19
(s, 2H, NH2); 7.54 (m, 1H, C6”H); 7.71 (t, 1H, C5”H); 7.98 (t, 1H, C2”H); 8.05 (d, 2H,
C3’H, C5’H); 8.2 (d, 2H, C2’H, C6’H); 8.17 (m, 1H, C4”H); 9.2 (s, 1H, NHCO); 10.48 (
s, 1H, N1-H).
13C-NMR (DMSO-d6) δ [ppm]:
13.85 (CH3); 19.75 (C3”’); 30 (C2”’); 39.24 (C1”’H); 86.57 (C5); 117.52 (C2”); 122.79
(C4”); 128.4 (C3’, C5’); 128.92 (C5”); 129.51 (C2’, C6’); 131.78 (C6”); 135.72 (C1’);
140.79 (C3”); 148.56, 148.93 ((C6, C2); 150.01 (C1”); 150.62 (C4’); 160.64 (C4); 165.02
(NHCO).
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6.3.2. 12 1,3-Dimethyl-8-[4’-[[m-nitrophenoxy]sulfony]phenyl]xanthine (5a)
N
N
H
N
NO
CH3
S
CH3 O
O
O
O
NO21
3
7
1´
4´
1´´
3´´
To 300 mg (0.32 mmol) of 6-amino-1,3-dimethyl-5-[4’-[[m-nitrophenoxy]sulfonyl]benz-
amido]uracil 4a, ca. 4 g of PPSE was added. First the mixture was heated to 120 ◦C for
10 min, then the heating temperature was increased to 170 ◦C for 1.5 h. After cooling
down to r.t., the residue was treated with 20 mL of methanol and the formed precipitate
was filtered off and recrystallized from DMF/H2O.
Yield: 117 mg (40 %)
m.p.: 296 ◦C
C,H,N analysis: C19H15N5O7S [457.42 g/mol]
C % H % N %
Calcd.: 49.89 3.31 15.31
Found: 49.75 3.33 15.23
1H-NMR (DMSO-d6) δ [ppm]:
3.26 (s, 3H, N1-CH3); 3.5 (s, 3H, N3-CH3); 7.56 (m, 1H, C6”H); 7.71 (t, 1H, C5”H); 7.92
(t, 1H, C2”H); 8.05 (d, 2H, C3’H, C5’H); 8.2 (m, 1H, C4”H); 8.37 (d, 2H, C2’H, C6’H);
14.27 (s, 1H, NH).
13C-NMR (DMSO-d6) δ [ppm]:
28 (N3-CH3); 29.95 (N1-CH3); 106.77 (C5); 117.6 (C2”); 122.78 (C4”); 127.44 (C3’, C5’);
129.13 (C5”); 129.36 (C2’, C6’); 131.75 (C6”); 134.15 (C1’); 134.87 (C3”); 147.14, 147.13
(C1”, C4’); 148.51 (C8); 148.87 (C4); 151.26 (C2); 154.52 (C6).
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6.3.2. 13 1,3-Dipropyl-8-[4’-[[m-nitrophenoxy]sulfonyl]phenyl]xanthine (5b)
N
N
H
N
NO
S
O
O
O
O
NO21
3
7
1´
4´
1´´
1´´´
2´´´
3´´´
1´´´´
2´´´´
3´´´´
3´´
Compound 5b was prepared from 324 mg (0.61 mmol) of 6-amino-1,3-dipropyl-5-[4’-
[[m-nitrophenoxy]sulfonyl]benzamido]uracil 4b and ca. 4 g of PPSE as described above
for 5a.
Yield: 112 mg (36 %)
m.p.: 315 ◦C
C,H,N analysis: C23H23N5O7S · 0.5 H2O [457.42 g/mol]
C % H % N %
Calcd.: 53.82 4.59 13.40
Found: 53.51 4.52 13.46
1H-NMR (DMSO-d6) δ [ppm]:
0.86 (t, 3H, C3”’H); 0.88 (t, 3H, C3””H); 1.57 (m, 2H, C2”’H); 1.73 (m, 2H, C2””H);
3.86 (t, 2H, C1”’H); 4.01 (t, 2H, C1””H); 7.55 (m, 1H, C6”H); 7.71 (t, 1H, C5”H); 7.92
(t, 1H, C2”H); 8.1 (d, 2H, C3’H, C5’H); 8.2 (m, 1H, C4”H); 8.36 (d, 2H, C2’H, C6’H);
14.28 (s, 1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm]:
11.16 (C3”’); 11.29 (C3””); 20.95 (C2”’); 20.96 (C2””); 42.4 (C1”’); 44.66 (C1””); 109.12
(C5); 117.62 (C2”); 122.78 (C4”); 127.78 (C3’, C5’); 129.13 (C5”); 129.38 (C2’, C6’);
131.77 (C6”); 134.24 (C1’); 134.86 (C3”); 147.37, 148.36 (C1”, C4’); 148.53 (C8); 148.9
(C4); 150.75 (C2); 154.34 (C6).
102 Experimental Part
6.3.2. 14 1-Methyl-8-[4’-[[m-nitrophenoxy]sulfonyl]phenyl]xanthine (5c)
N
N
H
N
NO
S
O
O
O
O
NO2
H
CH3
1
3
7
1´
4´
1´´
3´´
Compound 5c was prepared from 92 mg (0.2 mmol) of 6-amino-3-methyl-5-[4’-[[m-
nitrophenoxy]sulfonyl]benzamido]uracil 4c and ca. 2 g of PPSE as described above for
5a.
Yield: 58 mg (65 %)
m.p.: 349 ◦C
C,H,N analysis: C18H13N5O7S · 0.4 H2O [450.61 g/mol]
C % H % N %
Calcd.: 47.94 3.06 15.53
Found: 48.35 3.19 15.19
1H-NMR (DMSO-d6) δ [ppm]:
3.2 (s, 3H, N1-CH3); 7.55 (m, 1H, C6”H); 7.7(t, 1H, C5”H); 7.92 (t, 1H, C2”H); 8.05 (d,
2H, C3’H, C5’H); 8.2 (m, 1H, C4”H); 8.34 (d, 2H, C2’H, C6’H); 12.0 (s, 1H, N3-H); 14.14
(s, 1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm]:
27.27 (N1-CH3); 108.93 (C5); 117.63 (C2”); 122.77 (C4”); 127.43 (C3’, C5’); 129.13 (C5”);
129.36 (C2’, C6’); 131.75 (C6”); 134.15 (C1’); 134.87 (C3”); 147.14, 147.13 (C1”, C4’);
148.51 (C8); 148.87 (C4); 151.26 (C2); 154.52 (C6).
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6.3.2. 15 1-Propyl-8-[4’-[[m-nitrophenyoxy]sulfonyl]phenyl]xanthine (5d)
N
N
H
N
NO
S
O
O
O
O
NO2
H
1
3
7
1´
4´
1´´
1´´´
2´´´
3´´´
3´´
Compound 5d was prepared from 100 mg (0.2 mmol) of 6-amino-3-propyl-5-[4’-[[m-
nitrophenoxy]sulfonyl]benzamido]uracil 4d and ca. 2 g of PPSE as described above for
5a.
Yield: 50 mg (50 %)
m.p.: 309 ◦C
C,H,N analysis: C20H17N5O7S · 0.5 H2O [480.46 g/mol]
C % H % N %
Calcd.: 49.95 3.75 14.57
Found: 50.08 3.67 14.60
1H-NMR (DMSO-d6) δ [ppm]:
0.87 (s, 3H, C3”’H); 1.57 (m, 2H, C2”’H); 3.81 (t, 2H, C1”’H); 7.56 (m, 1H, C6”H); 7.71
(t, 1H, C5”H); 7.92 (t, 1H, C2”H); 8.1 (d, 2H, C3’H, C5’H); 8.2 (m, 1H, C4”H); 8.34 (d,
2H, C2’H, C6’H); 11.96 (s, 1H, N3-H); 14.12 (s, 1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm] :
11.3 (C3”’); 20.98 (C2”’); 41.65 (C1”’); 108.96 (C5); 117.62 (C2”); 122.77 (C4”); 127.44
(C3’, C5’); 129.13 (C5”); 129.35 (C2’, C6’); 131.75 (C6”); 134.14 (C1’); 135 (C3”); 147.46,
147.72 (C1”, C4’); 148.51 (C8); 148.87 (C4); 151.06 (C2); 155.06 (C6).
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6.3.2. 16 1-Butyl-8-[4’-[[m-nitrophenoxy]sulfonyl]phenyl]xanthine (5e)
N
N
H
N
NO
S
O
O
O
O
NO2
H
1
3
7
1´
4´
1´´
1´´´
2´´´
3´´´
3´´
Compound 5e was prepared from 150 mg (0.3 mmol) of 6-amino-3-butyl-5-[4’-[[m-
nitrophenoxy]sulfonyl]benzamido]uracil 4e and ca. 2 g of PPSE as described above for
5a.
Yield: 122 mg (88 %)
m.p.: 313 ◦C
C,H,N analysis: C21H19N5O7S [485.48 g/mol]
C % H % N %
Calcd.: 51.96 3.94 14.43
Found: 52.57 4.05 14.25
1H-NMR (DMSO-d6) δ [ppm]:
0.88 (t, 3H, C4”’H); 1.23 (m, 2H, C3”’H); 1.56 (m, 2H, C2”’H); 3.91 (t, 2H, C1”’H); 7.56
(m, 1H, C6”H); 7.71 (t, 1H, C5”H); 7.96 (t, 1H, C2”H); 8.07 (d, 2H, C3’H, C5’H); 8.2
(m, 1H, C4”H); 8.35 (d, 2H, C2’H, C6’H); 11.96 (s, 1H, N3-H); 14.12 (s, 1H, N7-H).
13C-NMR (DMSO- d6) δ [ppm]:
13.85 (C4”’); 19.77 (C3”’); 29.85 (C2”’); 39 (C1”’); 117.62 (C2”); 122.77 (C4”); 127.43
(C3’, C5’); 129.13 (C5”); 129.35 (C2’, C6’); 131.75 (C6”); 134.12 (C1’); 135.02 (C3”);
147.45, 147.71 (C1”, C4’); 148.51 (C8); 148.87 (C4); 151.04 (C2); 155.03 (C6).
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6.3.2. 17 1-Methyl-8-p-sulfophenylxanthine (6c)
N
N
O
O
CH3
H
N
N
H
SO3Na
1
3 1´
4´7
A solution of 3 g (6 mmol) of 1-methyl-8-[4’-[[m-nitrophenoxy]sulfonyl]phenyl]xanthine
5c in 60 mL of 2 M NaOH was heated at 70 ◦C for 30 min. After cooling down to r.t.,
the pH of the mixture was carefully adjusted to 7 by conc. HCl, then the solution
was extracted with dichloromethane twice. The product precipitated when the aqueous
solution was carefully acidified to pH 4 with 1 M HCl. It was filtered off and recrystallized
by treatment with NaOH/HCl.
Yield: 1.92 g (83 %)
m.p.: >300 ◦C
Rf : 0.55 (S 1)
C,H,N analysis: C12H9NaN4O2S · 2.5 H2O [389.33 g/mol]
C % H % N %
Calcd.: 36.98 3.59 14.38
Found: 36.44 2.91 14.03
1H-NMR (DMSO-d6) δ [ppm]:
3.2 (s, 3H, N1-CH3); 7.69 (d, 2H, J = 8.51 Hz, C3’H, C5’H); 8.03 (d, 2H, J = 8.2 Hz,
C2’H, C6’H); 11.89 (s, 1H, N3-H); 13.68 (s, 1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm]:
27.20 (N1-CH3); 107.83 (C5); 126.01 (C3’, C5’); 126.21 (C2’, C6’); 128.9 (C1’); 147.79
(C4’); 149.73, 149.89 (C8, C4); 151.37 (C2); 155.11 (C6).
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6.3.2. 18 1-Propyl-8-p-sulfophenylxanthine (6d)
SO3Na
N
N
O
O
H
N
N
H
1
3 1´
4´7
1´´
2´´
3´´
Compound 6d was prepared from 3 g (6 mmol) of 1-propyl-8-[4’-[[m-nitrophenoxy]-
sulfonyl]phenyl]xanthine 5d as described above for 6c.
Yield: 1.85 g (83 %)
m.p.: >300 ◦C (Lit >300 ◦C[63])
Rf : 0.53 (S 1)
C,H,N analysis: C14H13NaN4O2S · 2.5 H2O [417.39 g/mol]
C % H % N %
Calcd.: 40.25 4.31 13.42
Found: 40.16 4.33 13.27
1H-NMR (DMSO-d6) δ [ppm]:
0.87 (t, J = 7.56 Hz, 3H, C3”’H); 1.57 (m, 2H, C2”’H); 3.81 (t, J = 7.57 Hz, 2H, C1”’H);
7.68 (d, 2H, J = 8.51 Hz, C3’H, C5’H); 8.03 (d, 2H, J = 9.1 Hz, C2’H, C6’H).
13C-NMR (DMSO-d6) δ [ppm]:
11.32 (C3”’); 21.03 (C2”’); 41.54 (C1”’); 109.76 (C5); 126.04 (C3’, C5’); 126.21 (C2’,
C6’); 128.96 (C1’); 147.78 (C4’); 148.88, 149.78 (C8, C4); 151.14 (C2); 154.95 (C6).
Determination of purity by CE:
Buffer: Phosphate 20 mM, pH 7.4
Voltage: 10 kV
Retention time: 3.48 min
Purity: 100 %
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6.3.2. 19 6-Amino-1,3-dimethyl-5-[4’-[[p-nitrophenoxy]sulfonyl]benzamido]uracil
(8a)
S
O O
O
N
N
O
O
CH3
CH3 N
H
NH2
O
NO2
3
4´
1
1´
1´´
4´´
To a solution of 450 mg (2.94 mmol) of 5,6-diamino-1,3-dimethyluracil 3a in 20 mL of
methanol, 997 mg (2.94 mmol) of 4-[[p-nitrophenoxy]sulfonyl]benzoic acid 7 and 840 mg
(4.4 mmol) of EDC were added. The reaction mixture was stirred until no more starting
material could be detected by TLC. The mixture was treated with a large amount of
water and the formed precipitate was filtered off and washed with methanol.
Yield: 1.03 g (71 %)
m.p.: >300 ◦C
C,H,N analysis: C19H17N5O8S [475.44 g/mol]
C % H % N %
Calcd.: 48.00 3.60 14.73
Found: 47.76 3.76 14.31
1H-NMR (DMSO-d6) δ [ppm]:
3.13 (s, 3H, N3-CH3); 3.34 (s, 3H, N1-CH3); 6.79 (s, 2H, NH2); 7.39 (d, J = 9.14 Hz, 2H,
C2”H, C5”H); 8.04 (d, J = 8,82 Hz, 2H, C3’H, C5’H); 8.21 (d, J = 8.51 Hz, 2H, C2’H,
C6’H); 8.27 (d, J = 9.45 Hz, 2H, C3”H, C5”H); 9.24 (s, 1H, NH2).
13C-NMR (DMSO-d6) δ [ppm]:
27.68 (N3-CH3); 30.16 (N1-CH3); 87.04 (C5); 123.45 (C3”, C5”); 126.06 (C2”, C6”);
128.28 (C3’, C5’); 129.63 (C2’, C6’); 135.8 (C1’); 140.86 (C4’); 146.34 (C4”); 150.74 (C6);
152.43 (C2); 153.22 (C1”); 159.29 (C4); 165.21 (NHCO).
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6.3.2. 20 6-Amino-1,3-dipropyl-5-[4’-[[p-nitrophenoxy]sulfonyl]benzamido]uracil
(8b)
S
O O
O
N
N
O
O
N
H
NH2
O
NO2
1´´´
2´´´
1´´´´
2´´´´
3´´´
3´´´´
3
4´
1
1´
1´´
4´´
Compound 8b was obtained as described above for 8a, from 400 mg (1.77 mmol) of 5,6-
diamino-1,3-dipropyluracil 3b, 600 mg (1.77 mmol) of 4-[[p-nitrophenoxy]sulfonyl]benzoic
acid 7 and 380 mg (1.99 mmol) of EDC.
Yield: 656 mg (68 %)
m.p.: >300 ◦C
1H-NMR (DMSO-d6) δ [ppm]:
0.83 (t, J = 7.41 Hz, 3H, C3”’H); 0.90 (t, J =7.25 Hz, 3H, C3””H); 1.50 (m, 2H, C2”’H);
1.56 (m, 2H, C2””H); 3.71 (t, J = 7.25 Hz, 2H, C1”’H); 3.84 (t, J = 7.56 Hz, 2H, C1””H);
6.25 (s, 2H, NH2); 7.39 (d, J = 9.46 Hz, 2H, C2”H, C5”H); 8.03 (d, J = 8.82 Hz, 2H,
C3’H, C5’H); 8.20 (d, J = 8.82 Hz, 2H, C2’H, C6’H); 8.27 (d, J = 9.14 Hz, 2H, C3”H,
C5”H); 9.21 (s, 1H, NH2).
13C-NMR (DMSO-d6) δ [ppm]:
10.85 (C3”’); 11.31 (C3””); 20.96 (C2”’); 20.99 (C2””); 41.99 (C1”’); 43.85 (C1””); 86.99
(C5); 123.45 (C3”, C5”); 126.06 (C2”, C6”);128.29 (C2’, C5’); 129.61 (C2’, C6’); 135.81
(C1’); 140.85 (C4’); 146.34 (C4”); 150.48 (C6); 151.81 (C2); 153.22 (C1”); 159.09 (C4);
165.16 (NHCO).
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6.3.2. 21 6-Amino-3-methyl-5-[4’-[[p-nitrophenoxy]sulfonyl]benzamido]uracil (8c)
S
O O
O
N
N
O
O
N
H
NH2
O
H
CH3
NO2
3
4´
1
1´
1´´
4´´
Compound 8c was obtained as described above for 8a, from 500 mg (3.21 mmol) of
5,6-diamino-3-methyluracil 3c, 1.09 g (3.22 mmol) of 4-[[p-nitrophenoxy]sulfonyl]benzoic
acid 7 and 612 mg (3.2 mmol) of EDC.
Yield: 892 mg (60 %)
m.p.: >300 ◦C
1H-NMR (DMSO-d6) δ [ppm]:
3.06 ( s, 3H, N3-CH3); 6.25 (s, 2H, NH2); 7.39 (d, J = 9.45 Hz, 2H, C2”H, C5”H); 8.04
(d, J = 8.51 Hz, 2H, C3’H, C5’H); 8.2 (d, J = 8.51 Hz, 2H, C2’H, C6’H); 8.27 (d, J =
9.14 Hz, 2H, C3”H, C5”H); 9.24 (s, 1H, NH2).
6.3.2. 22 6-Amino-3-propyl-5-[4’-[[p-nitrophenoxy]sulfonyl]benzamido]uracil (8d)
S
O O
O
N
N
O
O
N
H
NH2
O
H
NO2
3
4´
1
1´
1´´
4´´
1´´´
2´´´
3´´´
Compound 8d was obtained as described above for 8a, from 1.0 g (5.44 mmol) of
5,6-diamino-3-propyluracil 3c, 1.84 g (5.4 mmol) of 4-[[p-nitrophenoxy]sulfonyl]benzoic
acid 7 and 1.78 g (9.32 mmol ) of EDC.
Yield: 1.54 g (57 %)
m.p.: >300 ◦C
110 Experimental Part
1H-NMR (DMSO-d6) δ [ppm]:
0.83 (m, 3H, C3”’H); 1.50 (m, 2H, C2”’H); 3.65 (m, 2H, C1”’H); 6.25 (s, 2H, NH2); 7.38
(d, 2H, C2”H, C5”H); 8.03 (d, 2H, C3’H, C5’H); 8.19 (d, 2H, C2’H, C6’H); 8.27 (d, 2H,
C3”H, C5”H); 9.20 (s, 1H, NH2).
13C-NMR (DMSO-d6) δ [ppm]:
27.27 (C3”’); 30.92 (C2”’); 35.91 (C1”’); 123.62 (C3”, C5”); 126.04 (C2”, C6”); 127.42
(C3’, C5’); 129.25 (C2’, C6’); 135.21 (C1’); 146.34 (C4”); 151.32 (C2); 153.20 (C1”);
155.35 (C4); 162.44 (NHCO).
6.3.2. 23 6-Amino-3-butyl-5-[4’-[[p-nitrophenoxy]sulfonyl]benzamido]uracil (8e)
S
O O
O
N
N
O
O
N
H
NH2
O
H
NO2
3
4´
1
1´
1´´
4´´
1´´´
2´´´
3´´´
4´´´
Compound 8e was obtained as described above for 8a, from 500 mg (2.53 mmol) of
5,6-diamino-3-butyluracil 3e, 865 mg (5.55 mmol) of 4-[[p-nitrophenoxy]sulfonyl]benzoic
acid 7 and 600 mg (3.14 mmol) of EDC.
Yield: 870 mg (66 %)
m.p.: >300 ◦C
1H-NMR (DMSO-d6) δ [ppm]:
0.89 (t, J = 7.25 Hz, 3H, C4”’H); 1.25 (m, 2H, C3”’H); 1.46 (m, 2H, C2”’H); 3.67 (t, J =
7.41 Hz, 2H, C1”’H); 6.25 (s, 2H, NH2); 7.39 (d, J = 9.14 Hz, 2H, C2”H, C5”H); 8.04 (d,
J = 8.81 Hz, 2H, C3’H, C5’H); 8.2 (d, J = 8.82 Hz, 2H, C2’H, C6’H); 8.27 (d, J = 9.45
Hz, 2H, C3”H, C5”H); 9.24 (s, 1H, NHCO); 10.4 (s, 1H, N1-H).
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6.3.2. 24 1,3-Dimethyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine (9a)
N
N
H
N
NO
S
O
O
O
O
CH3
CH3
NO2
1
3
7
1´
4´
1´´
4´´
To 800 mg (1.63 mmol) of 1,3-dimethyl-6-amino-5-[4’-[[p-nitrophenoxy]sulfonyl]benzami-
do]uracil 8a, ca. 6.5 g of PPSE was added, and the mixture was heated at 170 ◦C for 1.5
h. After cooling down to r.t., the reaction mixture was treated with 20 mL of methanol
and the formed precipitate was filtered off and recrystallized from DMF/H2O.
Yield: 292 mg (38 %)
m.p.: >300 ◦C
C,H,N analysis: C19H15N5O7S · H2O [475.44 g/mol]
C % H % N %
Calcd.: 48.00 3.58 14.72
Found: 48.05 3.39 14.40
1H-NMR (DMSO-d6) δ [ppm]:
3.26 (s, 3H, N3-CH3); 3.5 (s, 3H, N1-CH3); 7.39 (d, J = 9.14 Hz, 2H, C2”H, C5”H); 8.04
(d, J = 8.82 Hz, 2H, C3’H, C5’H); 8.27 (d, J = 9.14 Hz, 2H, C3”H, C5”H); 8.36 (d, J =
8.51 Hz, 2H, C2’H, C5’H); 14.25 (s, 1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm]:
29.94 (N1-C); 30.80 (N3-C); 109.04 (C5); 123.62 (C3”, C5”); 126.03 (C2”, C6”); 127.52
(C3’, C5’); 129.28 (C2’, C6’ ); 134.34 (C1’); 134.84 (C4’); 146.34 (C4”); 147.15 (C4);
148.55 (C8); 151.26 (C2); 153.19 (C1”); 154.49 (C6).
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6.3.2. 25 1,3-Dipropyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine (9b)
N
N
H
N
NO
S
O
O
O
O
NO2
1
3
7
1´
4´
1´´
4´´
1´´´
2´´´
1´´´´
2´´´´
3´´´
3´´´´
Compound 9b was prepared from 500 mg (0.92 mmol) of 6-amino-1,3-dipropyl-5-[4’-
[[p-nitrophenoxy]sulfonyl]benzamido]uracil 8b and ca. 5 g of PPSE as described above
for 9a.
Yield: 150 mg (31 %)
m.p.: >300 ◦C
C,H,N analysis: C23H23N5O7S · 0.5 H2O [522.54 g/mol]
C % H % N %
Calcd.: 52.82 4.59 13.40
Found: 53.01 4.52 13.39
1H-NMR (DMSO-d6) δ [ppm]:
0.92 (t, J = 7.57 Hz, 3H, C3”’H); 0.96 (t, J = 7.56 Hz, 3H, C3””H); 1.65 (m, 2H, C2”’H);
1.82 (m, 2H, C2””H); 3.95 (t, J = 7.40 Hz, 2H, C1”’H); 4.10 (t, J = 7.25 Hz, 2H, C1””H);
7.41 (d, J = 9.14 Hz, 2H, C2”H, C5”H); 8.02 (d, J = 8.82 Hz, 2H, C3’H, C5’H); 8.29 (d, J
= 9.14 Hz, 2H, C3”H, C5”H); 8.49 (d, J = 8.82 Hz, 2H, C2’H, C5’H); 14.09 (s, 1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm]:
11.17 (C3”’); 11.30 (C3””); 20.96 (C2”’, C2””); 42.40 (C1”’); 44.67 (C1””); 123.62 (C3”,
C5”); 126.05 (C2”, C6”); 127.56 (C3’, C5’); 129.29 (C2’, C6’); 134.28 (C1’); 146.34 (C4”);
150.76 (C2); 153.21 (C1”); 154.42 (C6).
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6.3.2. 26 1-Methyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine (9c)
N
N
H
N
NO
S
O
O
O
O
NO2
CH3
H
1
3
7
1´
4´
1´´
4´´
Compound 9c was prepared from 650 mg (1.36 mmol) of 6-amino-3-methyl-5-[4’-[[p-
nitrophenoxy]sulfonyl]benzamido]uracil 8c and ca. 4.5 g of PPSE as described above for
9a.
Yield: 446 mg (93 %)
m.p.: >300 ◦C
C,H,N analysis: C18H13N5O7S · 1.5 H2O [470.43 g/mol]
C % H % N %
Calcd.: 45.92 3.40 14.88
Found: 45.69 3.07 15.65
1H-NMR (DMSO-d6) δ [ppm]:
3.23 (s, 3H, N1-CH3); 7.38(d, J = 9.14 Hz, 2H, C2”H, C5”H); 8.04 (d, J = 8.82 Hz, 2H,
C3’H, C5’H); 8.26 (d, J = 9.14 Hz, 2H, C3”H, C5”H); 8.34 (d, J = 8.82 Hz, 2H, C2’H,
C5’H); 12.0 (s, 1H, N1-H); 14.13 (s, 1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm]:
27.28 (N1-CH3); 108.96 (C5); 123.61 (C3”, C5”); 126.04 (C2”, C6”); 127.46 (C3’, C5’);
129.26 (C2’, C6’); 134.26 (C1’); 135.04 (C4’); 146.34 (C4”); 147.39 (C4); 147.66 (C8);
151.30 (C2); 153.20 (C1”); 155.24 (C6).
114 Experimental Part
6.3.2. 27 1-Propyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine (9d)
N
N
H
N
NO
S
O
O
O
O
NO2
H
1
3
7
1´
4´
1´´
4´´
1´´´
2´´´
3´´´
Compound 9d was prepared from 660 mg (1.19 mmol) of 6-amino-3-propyl-5-[4’-[[p-
nitrophenoxy]sulfonyl]benzamido]uracil 8d and ca. 5 g of PPSE as described above for
9a.
Yield: 416 mg (65 %)
m.p.: >300 ◦C
C,H,N analysis: C20H17N5O7S [471.45 g/mol]
C % H % N %
Calcd.: 50.95 3.63 14.85
Found: 50.31 4.39 15.29
1H-NMR (DMSO-d6) δ [ppm]:
0.87 (t, J = 7.40 Hz, 3H, C3”’H); 1.58 (m, 2H, C2”’H); 3.84(t, J = 7.41 Hz, 2H, C1”’H);
7.39 (d, J = 9.14 Hz, 2H, C2”H, C5”H); 8.03 (d, J = 8.82 Hz, 2H, C3’H, C5’H); 8.26 (d, J
= 9.14 Hz, 2H, C3”H, C5”H); 8.33 (d, J = 8.82 Hz, 2H, C2’H, C5’H); 11.8 (s, 1H, N1-H);
14.1 (s, 1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm]:
11.3 (C3”’); 20.99 (C2”’); 41.66 (C1”’); 108.96 (C5); 123.60 (C3”, C5”); 126.04 (C2”,
C6”); 127.49 (C3’, C5’); 129.25 (C2’, C6’); 134.30 (C1’); 135.02 (C4’); 146.33 (C4”);
147.48 (C4); 147.73 (C8); 151.07 (C2); 153.20 (C1”); 155.07 (C6).
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6.3.2. 28 1-Butyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine (9e)
N
N
H
N
NO
S
O
O
O
O
NO2
H
1
3
7
1´
4´
1´´
4´´
1´´´
2´´´
3´´´
4´´´
Compound 9e was prepared from 616 mg (1.19 mmol) of 6-amino-3-butyl-5-[4’-[[p-
nitrophenoxy]sulfonyl]benzamido]uracil 8e and ca. 5 g of PPSE as described above for
9a.
Yield: 450 mg (76 %)
m.p.: >300 ◦C
C,H,N analysis: C21H19N5O7S [485.48 g/mol]
C % H % N %
Calcd.: 51.96 3.94 14.43
Found: 51.71 4.11 14.55
1H-NMR ( DMSO-d6) δ [ppm]:
0.9 (t, J = 7.41 Hz, 3H, C4”’H); 1.3 (m, 2H, C3”’H); 1.54 (m, 2H, C2”’H); 3.87 (t, J =
7.41 Hz, 2H, C1”’H); 7.39 (d, J = 9.14 Hz, 2H, C2”H, C5”H); 8.02 (d, J = 8.82 Hz, 2H,
C3’H, C5’H); 8.28 (d, J = 9.14 Hz, 2H, C3”H, C5”H); 8.35 (d, J = 8.2 Hz, 2H, C2’H,
C5’H); 11.96 ( s, 1H, N1-H); 14.12 (s, 1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm]:
14.17 (C4””); 20.99 (C3”’); 30.18 (C2”’); 39.64 (C1”’); 123.91 (C3”, C5”); 126.34 (C2”,
C6”); 127.76 (C3’, C5’); 129.55 (C2’, C6’); 134.50 (C1’); 135.50 (C4’); 146.65 (C4”);
151.37 (C2); 153.51 (C1”); 155.43 (C6).
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6.3.2. 29 4’-(1,3-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-N-iso-
propyl-benzenesulfonamide (10a)
N
N
H
N
NO
S
O
O
NH
O
CH3
CH3
CH3
CH3
1
3
7
1´
4´
To a solution of 50 mg (0.11 mmol) 1,3-dimethyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]-
xanthine 9a in 5 mL of DMSO, 1 mL (12 mmol) of isopropylamine was added and the
mixture was first stirred at r.t. for 40 min, then it was heated at 150 ◦C for 3 h. The
remaining isopropylamine and DMSO was removed in vacuo. The residue was isolated
by flash chromatography on silica gel with dichloromethane : methanol (50 : 1).
Yield: 25 mg (61 %)
m.p.: >300 ◦C
Rf : 0.22 (S 5)
C,H,N analysis: C16H19N5O4S [377.42 g/mol]
C % H % N %
Calcd.: 50.92 5.07 18.56
Found: 50.52 5.06 18.04
1H-NMR (DMSO-d6) δ [ppm]:
0.95 (d, J = 6.62 Hz, 6H, CH3); 3.26 (s, 3H, N1-CH3); 3.53 (s, 3H; N3-CH3); 7.23 (d, J =
7.57 Hz, 1H, SO2NH); 7.92 (d, J = 8.51 Hz, 2H, C3’H, C5’H ); 8.3 (d, J = 8,82 Hz, 2H,
C2’H, C6’H ); 14.1 (br, 1H, N7H).
13C-NMR (DMSO-d6) δ [ppm]:
23.35 (CH3); 27.97 (N1-CH3); 29.95 (N3-CH3); 45.5 (CH); 108.9 (C5); 127 (C3’, C5’);
127.15 (C2’, C6’); 132.3 (C1’); 142.9 (C4’); 148.27, 148.62 (C8, C4); 151.33 (C2); 154.57
(C6).
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6.3.2. 30 4’-(1,3-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-N-phen-
ylethyl-benzenesulfonamide (10b)
N
N
H
N
NO
S
O
O
O
CH3
CH3
NH
1
3
7
1´
4´
1´´
4´´
Compound 10b was obtained as described above for 10a, from 50 mg (0.11 mmol)
of 1,3-dimethyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine 9a and 1 mL (8 mmol) of
phenylethylamine in 5 mL of DMSO. The product was purified by flash chromatography
on silica gel with dichloromethane : methanol (50 : 1).
Yield: 21 mg (44 %)
m.p.: >300 ◦C
Rf : 0.19 (S 5)
C,H,N analysis: C21H21N5O4S [439.50 g/mol]
C % H % N %
Calcd.: 57.39 4.82 15.93
Found: 57.10 4.80 15.66
1H-NMR (DMSO-d6) δ [ppm]:
2.68 (t, J = 7.41 Hz, 2H, CH2-phenyl); 3.0 (m, 2H, CH2-NH); 3.25 (s, 3H, N1-CH3); 3.62
(s, 3H; N3-CH3); 7.15 (m, 3H, C2”H, C6”H, C4”H); 7.22 (m, 2H, 3”H, 5”H); 7.8 (t, J =
5.68 Hz, 1H, SO2NH); 7.89 (d, J = 8.51 Hz, 2H, C3’H, C5’H ); 8.3 (d, J = 8.82 Hz, 2H,
C2’H, C6’H); 14.1 (s, 1H, N7H).
13C-NMR (DMSO-d6) δ [ppm]:
28.71 (N1-CH3); 30.71 (N3-CH3); 36.17 (CH2-phenyl); 44.93 (CH2-NH); 127.12, 127.72,
128.01 (aromat-C); 129.19 (C3’, C5’); 129.53 (C2’, C6’); 139.50 (C1’); 141.98 (C4’); 152.09
(C2); 155.43 (C6).
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6.3.2. 31 4’-(1,3-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-N-but-
yl-benzenesulfonamide (10c)
N
N
H
N
NO
S
O
O
O
CH3
CH3
NH
1
3
7
1´
4´
1´´
2´´
3´´
4´´
Compound 10c was obtained as described above for 10a, from 50 mg (0.11 mmol)
of 1,3-dimethyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine 9a and 1 mL (8 mmol) of
butylamine in 5 mL of DMSO. The product was purified by flash chromatography on
silica gel with dichloromethane : methanol (50 : 1).
Yield: 21 mg (44 %)
m.p.: >300 ◦C
Rf : 0.28 (S 5)
C,H,N analysis: C17H21N5O4S [391.45 g/mol]
C % H % N %
Calcd.: 52.16 5.41 17.89
Found: 53.34 5.73 17.46
1H-NMR (DMSO-d6) δ [ppm]:
0.84 (t, J = 7.4 Hz, 3H, C4”H); 1.29 (m, 2H, C3”H); 1.32 (m, 2H, C2”H); 2.76 (m, 2H,
C1”H); 3.34 (s, 3H, N1-CH3); 3.58 (s, 3H; N3-CH3); 7.73 (t, J = 5.83 Hz, 1H, SO2NH);
7.89 (d, J = 8.51 Hz, 2H, C3’H, C5’H ); 8.3 (d, J = 8.51 Hz, 2H, C2’H, C6’H); 14.21 (s,
1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm]:
13.79 (C4”); 19.54 (C3”); 28.21 (N1-CH3); 30.20 (N3-CH3); 31.33 (C2”); 42.46 (C1”);
127.12(C3’, C5’); 127.37 (C2’, C6’). 141.75 (C4’); 148.36 (C8); 148.76 (C4); 151.44 (C2);
154.69 (C6).
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6.3.2. 32 4’-(1,3-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-N-(2-hy-
droxy-ethyl)-benzenesulfonamide (10d)
N
N
H
N
NO
S
O
O
O
CH3
CH3
NH
OH
1
3
7
1´
4´
Compound 10d was obtained as described above for 10a, from 66.8 mg (0.15 mmol)
of 1,3-dimethyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine 9a and 1 mL (8 mmol) of
ethanolmaine in 5 mL of DMSO. Product was purified by flash chromatography on silica
gel with dichloromethane : methanol (20 : 1).
Yield: 28 mg (51 %)
m.p.: >300 ◦C
Rf : 0.09 (S 3)
C,H,N analysis: C15H17N5O5S · 0.8 H2O [393.82 g/mol]
C % H % N %
Calcd.: 45.71 4.72 17.78
Found: 46.13 4.78 17.33
1H-NMR (DMSO-d6) δ [ppm]:
2,90 (m, 2H, NHCH2); 3.33 (s, 3H, N1-CH3); 3.52 (s, 3H; N3-CH3); 7.76 (t, J = 5.83 Hz,
1H, SO2NH); 7.89 (d, J = 8.51 Hz, 2H, C3’H, C5’H ); 8.3 (d, J = 8.51 Hz, 2H, C2’H,
C6’H ); 14.00 (br, 1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm]:
28.18 (N1-CH3); 30.20 (N3-CH3); 45.46 (CH2NH); 60.26 (CH2OH); 126.88 (C3’, C5’);
127.25 (C2’, C5’); 141.35 (C4’); 148.60 (C8); 148.78 (C4); 151.37 (C2); 154.78(C6).
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6.3.2. 33 4’-(1,3-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-benze-
nesulfonylamino acetic acid (10e)
N
N
H
N
NO
S
O
O
O
CH3
CH3
NH COOH
1
3
7
1´
4´
Compound 10e was obtained as described above for 10a, from 57.5 mg (0.13 mmol)
of 1,3-dimethyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine 9a and 88 mg (1.17 mmol)
of glycine in 5 mL of DMSO. Product was purified by flash chromatography on silica gel
with dichloromethane : methanol (20 : 1).
Yield: 14 mg (28 %)
m.p.: >300 ◦C
Rf : 0.23 (S 3)
C,H,N analysis: C15H15N5O6S [393.38 g/mol]
C % H % N %
Calcd.: 45.80 3.84 17.80
Found: 45.69 4.67 18.68
1H-NMR (DMSO-d6) δ [ppm]:
2.46 (d, J = 5.04 Hz, 2H, CH2); 3.29 (s, 3H, N1-CH3); 3.53 (s, 3H, N3-CH3); 7.57 (t, J =
4.83 Hz, 1H, SO2NH); 7.91 (d, J = 8.51 Hz, 2H, C3’H, C5’H ); 8.3 (d, J = 8.51 Hz, 2H,
C2’H, C6’H ); 14.1 (s, 1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm] :
27.99 (CH2); 28.80 (N1-CH3); 29.97 (N3-CH3); 108.76 (C5); 127.08 (C3’, C5’); 127.48
(C2’, C6’); 132.40 (C1’); 140.35 (C4’); 148.14 (C8); 148.14 (C4); 151.32 (C2); 154.53 (C6).
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6.3.2. 34 4’-(2,6-Dioxo-1-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-N-isopropyl-
benzenesulfonamide (11a)
N
N
H
N
NO
S
O
O
O
H
NH CH3
CH3
1
3
7
1´
4´
1´´
2´´
3´´
To a solution of 60 mg (0.12 mmol) of 1-propyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xan-
thine 9d in 5 mL of DMSO, 1 mL (12 mmol) of isopropylamine was added into. The
mixture was first stirred at r.t. for 40 min, then it was heated at 150 ◦C for 5 h. The re-
maining isopropylamine and DMSO were distilled off in vacuo, the residue was suspended
in methanol and isolated by flash chromatography on silica gel with dichloromethane:
methanol (40 : 1).
Yield: 32 mg (65 %)
m.p.: >300 ◦C
Rf : 0.12 (S 4)
1H-NMR (DMSO-d6) δ [ppm]:
0.70 (t, J = 7.41 Hz, 3H, C3”H); 0.77 (d, J = 6.62 Hz, 6H, CH3); 1.38 (m, 2H, C2”H);
3.62 (t, J = 7.25 Hz, 2H, C1”H) ; 7.45 (d, J = 7.25 Hz, 1H, SO2NH); 7.88 (d, J = 8.51
Hz, 2H, C3’H, C5’H ); 8.3 (d, J = 8.51 Hz, 2H, C2’H, C6’H ); 13.98 (s, 1H, N7-H).
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6.3.2. 35 4’-(1-Propyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-N-pheneth-
yl-benzenesulfonamide (11b)
N
N
H
N
NO
S
O
O
O
H
NH
1
3
7
1´
4´
1´´
2´´
3´´
1´´´
4´´´
Compound 11b was obtained as described above for 11a, from 79 mg (0.17 mmol) of
1-propyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine 9d and 1 mL (8 mmol) of phenyl-
ethylamine in 5 mL of DMSO. Product was purified by flash chromatography on silica gel
with dichloromethane : methanol (40 : 1).
Yield: 66 mg (88 %)
m.p.: >300 ◦C
Rf : 0.07 (S 4)
Cal Mass: 453.1470 g/mol (C22H23N5O4S)
High Resolution MS: 453.1469
EI-MS m/z (%): 354 (M+; 20.76); 362 ([M - 91]+, 32);
333 ([M-NHCH2CH2-phenyl]
+, 48);
269 ([M-SO2NHCH2CH2-phenyl]
+, 100)
1H-NMR (DMSO-d6) δ [ppm]:
0.88 (t, J = 7.41 Hz, 3H, C3”H); 1.59 (m, 2H, C2”H); 2.71 (t, J = 7.57 Hz, 2H, CH2-
phenyl); 3.02 (t, J = 6.2 Hz, 2H, CH2-N); 3.83 (t, J = 7.4 Hz, 2H, C1”H); 7.2 (m, 3H,
C3”’H, C4”’H, C5”’H); 7.26 (m, 2H, C2”’H, C6”’H); 7.80 (t, J = 5.83 Hz, 1H, SO2NH);
7.88 (d, J = 8.51 Hz, 2H, C3’H, C5’H ); 8.3 (d, J = 8.51 Hz, 2H, C2’H, C6’H ); 13.98 (s,
1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm]:
11.32 (C3”); 21.03 (C2”); 35.44 (CH2-phenyl); 41.56 (C1”); 44.19 (CH2-NH); 126.37,
126.89, 127.22 (aromat-C); 128.44 (C3’, C5’); 128.79 (C2’, C6’); 138.77 (C1’); 151.16
(C2).
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6.3.2. 36 4’-(1-Propyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-N-(2-hydroxy-
ethyl)-benzenesulfonamide (11c)
OH
N
N
H
N
NO
S
O
O
O
H
NH
1
3
7
1´
4´
1´´
2´´
3´´
1´´´
2´´´
Method 1: To a solution of 75.2 mg (0.16 mmol) of 1-propyl-8-[4’-[[p-nitrophenoxy]sulfon-
yl]phenyl]xanthine 9c in 5 mL of DMSO, 1 mL (11 mmol) of ethanolamine was added.
The mixture was stirred at r.t. under argon for ca. 72 h. Remaining ethanolamine and
DMSO was distilled off in vacuo, the residue was suspended in methanol and purified by
flash chromatography on silica gel with dichloromethane : methanol (20 : 1).
Method 2: To a solution of 43.7 mg (0.09 mmol) of 1-propyl-8-[4’-[[p-nitrophenoxy]sulfon-
yl]phenyl]xanthine 9d in 5 mL of DMSO, 1 mL (11 mmol) of ethanolamine was added.
The mixture was stirred at r.t. for 30 min, then it was heated at 150 ◦C for 5 h, until
the color turned red. Remaining ethanolamine and DMSO were distilled off in vacuo,
the residue was suspended in methanol and isolated by flash chromatography on silica gel
with dichloromethane : methanol (20 : 1).
Yield: method 1 : 33 mg (53 %)
method 2 : 10 mg (28 %)
m.p.: >300 ◦C
Rf : 0.08 (S 3)
C,H,N analysis: C16H19N5O5S · 2.5 H2O [438.47 g/mol]
C % H % N %
Calcd.: 43.78 5.47 15.96
Found: 44.22 4.77 15.78
1H-NMR (DMSO-d6) δ [ppm]:
0.88 (t, J = 7.41 Hz, 3H, C3”H); 1.57 (m, 2H, C2”H); 2.81 (t, J = 6.1Hz, 2H, C2”’H);
3.81 (t, J = 7.4 Hz, 2H, C1”H); 4.69 (t, J = 5.35 Hz, 2H, C1”’H); 7.69 (t, J = 5.83 Hz,
1H, SO2NH); 7.88 (d, J = 8.51 Hz, 2H, C3’H, C5’H ); 8.3 (d, J = 8.51 Hz, 2H, C2’H,
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C6’H ); 11.94 (s, 1H, N1-H); 13.94 (s, 1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm]:
11.32 (C3”); 21.01 (C2”); 41.61 (C1”); 45.25 (C2”’); 60.05 (C1”’); 126.95 (C3’, C5’);
127.27 (C2’, C6’); 132.55 (C1’); 141.55 (C4’); 147.76 (C4); 148.50 (C8); 151.12 (C2);
155.13 (C6).
Determination of purity by CE:
Buffer: Phosphate 20 mM, pH 7.4 + 100 mM SDS
Voltage: 10 kV
Retention time: 12.13 min
Purity: 100 %
6.3.2. 37 4’-(2,6-Dioxo-1-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)benzenesulfo-
nylamino acetic acid (11d)
N
N
H
N
NO
S
O
O
O
H
NH COOH
1
3
7
1´
4´
1´´
2´´
3´´
Compound 11d was obtained as described above for 11a, from 70 mg (0.146 mmol)
of 1-propyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine 9d and 76.7 mg (1.022 mmol)
of glysine in 7 mL of DMSO. Product was purified by flash chromatography on silica gel
with dichloromethane : methanol (20 : 1).
Yield: 20 mg (34 %)
m.p.: >300 ◦C
Rf : 0.19 (S 3)
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C,H,N analysis: C16H17N5O6S [407.41 g/mol]
C % H % N %
Calcd.: 47.17 4.21 17.19
Found: 47.58 4.63 18.02
1H-NMR (DMSO-d6) δ [ppm]:
0.88 (t, J = 7.41 Hz, 3H, C3”H); 1.58 (m, 2H, C2”H); 2.44 (t, J = 5.04 Hz, 2H, CH2);
3.84 (t, J = 7.40 Hz, 2H, C1”H); 7.51 (t, 1H, SO2NH); 7.89 (d, J = 8.51 Hz, 2H, C3’H,
C5’H ); 8.3 (d, J = 8.20 Hz, 2H, C2’H, C6’H ); 11.91 (s, 1H, N1-H).
6.3.2. 38 4’-(2,6-Dioxo-1-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-N,N-dipro-
pylbenzenesulfoamide (11e)
N
N
H
N
NO
S
O
O
O
H
N
1
3
7
1´
4´
1´´
2´´
3´´
1´´´ 2´´´
3´´´
1´´´
2´´´
3´´´
Compound 11e was obtained as described above for 11a, from 50 mg (0.106 mmol)
of 1-propyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine 9d and 1 mL (7.32 mmol) of
dipropylamino in 7 mL of DMSO. Product was purified by flash chromatography on silica
gel with dichloromethane : methanol (40 : 1).
Yield: 15 mg (33 %)
m.p.: >300 ◦C
Rf : 0.26 (S 4)
Cal Mass: 433.1784 g/mol (C20H27N5O4S)
High Resolution MS: 433.1787
EI-MS m/z (%): 433.2 (M+; 30); 404.2 ([M-CH3CH2]
+, 100);
269.1 ([M-SO2N(CH3CH2CH3)2]
+, 60)
126 Experimental Part
1H-NMR (DMSO-d6) δ [ppm]:
0.81 (t, J = 7.25 Hz, 6H, C3”’H); 0.88 (t, J = 7.41 Hz, 3H, C3”H); 1.47 (m, 4H, C2”’H);
1.58 (m, 2H, C2”H); 3.12 (m, 4H, C1”’H); 3.82 (t, J = 7.41 Hz, 2H, C1”H); 7.89 (d, J =
8.51 Hz, 2H, C3’H, C5’H ); 8.27 (d, J = 8.51 Hz, 2H, C2’H, C6’H ); 11.91 (bs, 1H, N1-H);
13.96 (bs, 1H, N7-H).
6.3.2. 39 4’-(2,6-Dioxo-1-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-N-phenyl-
benzenesulfonamide (11f)
N
N
H
N
NO
S
O
O
O
H
NH
1
3
7
1´
4´
1´´
2´´
3´´
4´´´
1´´´
Compound 11f was obtained as described above for 11a, from 48 mg (0.1 mmol)
of 1-propyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine 9d and 1 mL (11 mmol) of
aniline in 7 mL of DMSO. Product was purified by flash chromatography on silica gel
with dichloromethane : methanol (20 : 1).
Yield: 17 mg (40 %)
m.p.: >300 ◦C
Rf : 0.24 (S 5)
Cal Mass: 425.1157 g/mol (C20H19N5O4S)
High Resolution MS: 425.1145
EI-MS m/z (%): 425.2(M+; 100); 426.2 ([M+1]+, 20);
383.2 ([M- CH3CH2CH2+3]
+, 45)
1H-NMR (DMSO-d6) δ [ppm]:
0.85 (t, J = 7.4 Hz, 3H, C3”H); 1.58 (m, 2H, C2”’H); 3.82 (t, J = 7.41 Hz, 2H, C1”H);
7.02 (m, 1H, C4”’H); 7.08 (m, 2H, C2”’H, C6”’H); 7.21 (m, 2H, C3”’H, C5”’H); 7.79 (d,
J = 8.51 Hz, 2H, C3’H, C5’H ); 8.15 (d, J = 8.83 Hz, 2H, C2’H, C6’H ); 11.91 (bs, 1H,
N1-H); 13.96 (bs, 1H, N7-H).
13C-NMR (DMSO-d6) δ [ppm]:
11.32 (C3”); 21.07 (C2”); 41.45 (C1”); 120.40, 124.28 (Caromat); 126.53 (C3’, C5’); 127.32
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(C2’, C6’); 129.29, 137.77 (Caromat); 148.10 (C4); 151.24 (C2); 155.17 (C6).
6.3.2. 40 4’-(2,6-Dioxo-1-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-benzenesulf-
onylaminophenyl acetic acid (11g)
N
N
H
N
NO
S
O
O
O
H
NH
COOH
1
3
7
1´
4´
1´´
2´´
3´´
4´´´
1´´´
Compound 11g was obtained as described above for 11a, from 52 mg (0.1 mmol) of
1-propyl-8-[4’-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine 9d and 120 mg (1.07 mmol) of α-
aminophenylacetic acid in 7 mL of DMSO. Product was purified by flash chromatography
on silica gel with dichloromethane : methanol (20 : 1).
Yield: 90 mg (44 %)
m.p.: >300 ◦C
Rf : 0.13 (S 5)
1H-NMR (DMSO-d6) δ [ppm]:
0.85 (t, J = 7.4 Hz, 3H, C3”H); 1.58 (m, 2H, C2”’H); 3.82 (t, J = 7.41 Hz, 2H, C1”H);
4.02 (d, J = 5.99 Hz, 1H, CH); 7.24 (m, 5H, CH-phenyl); 7.87 (d, J = 8.51 Hz, 2H, C3’H,
C5’H ); 8.22 (d, J = 8.51 Hz, 2H, C2’H, C6’H ); 11.84 (bs, 1H, N1-H); 13.96 (bs, 1H,
N7-H).
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6.3.2. 41 Sodium m-nitrophenoxide (12)
To a solution of 5 g (36 mmol) m-nitrophenol in 20 mL of methanol, 1.5 g (37.5 mmol) of
sodium hydroxide in 15 mL 85 % aq. methanol was added. The flask was stirred under
the protection of nitrogen for 5 hours. Red sodium m-nitrophenoxide was obtained after
the solvent was removed in vacuo.
6.3.2. 42 4-Benzoylamino-1-benzenesulfonic acid sodium salt (13a)
N
SO3Na
H
O
1
4
1´
4´
To a solution of 2 g (12 mmol) sulfanilic acid in 30 mL of water, 2.1 mL (18 mmol)
of benzoyl chloride in 10 mL of toluene was slowly added under vigorous stirring. During
the whole reaction time, a pH of 3 was maintained by manual addition of aqueous 1 M
aqueous Na2CO3 solution, the reaction was continued until no more sulfanilic acid could
be detected by TLC. The aqueous phase was separated, and washed with toluene until
no more benzoic acid could be detected by TLC. The aqueous phase was evaporated in
vacuo to dryness and the residue was recrystallized from water : ethanol (1 : 1).
Yield: 2.5 g (72 %)
Rf : 0.74 (S 6)
C,H,N analysis: C13H10NNaO4S · 1.5 H2O [326.31 g/mol]
C % H % N %
Calcd.: 47.81 3.98 4.29
Found: 48.02 4.41 4.31
1H-NMR (DMSO-d6) δ [ppm]:
7.52 (m, 2H, C3’H, C5’H); 7.6 (m, 3H, C2’H, C6’H, C4’H); 7.73 (d, J = 8.51 Hz, 2H,
C3H, C5H); 7.95 (d, J = 7.88 Hz, 2H, C2H, C6H); 10.25 (s, 1H, NHCO).
13C-NMR (DMSO-d6) δ [ppm]:
119.47 (C3, C5); 126.17 (C2, C6); 127.84 (C3’, C5’); 128.54 (C2’, C6’); 131.76 (C4’);
135.03 (C1’); 139.39 (C1); 143.78 (C4); 165.7 (CONH).
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6.3.2. 43 4-Benzoylamino-1-benzenesulfonic acid m-nitrophenyl ester (14a)
SO
O
O
N
H
O
NO2
1
4
1´
4´
1´´
3´´
Compound 13a (430 mg, 1.33 mmol) was dissolved in 10 mL of pyridine and 20 mL
of acetic anhydride. The mixture was stirred at r.t. overnight. A white precipitate was
obtained after 40 mL of diethyl ether was added into the above solution. The precipitate
was mixed with 4 g of PCl5, and heated at 60
◦C for 2 h. A white powder was obtained
after the mixture was carefully poured into ice-cold water. The residue was recrystallized
from toluene, yielding 4-benzamido-1-benzenesulfonylchloride.
To a solution of 92 mg (0.57 mmol) sodiumm-nitrophenoxide in 10 mL of dichlorometh-
ane, 2 mL of TEA and 170 mg (0.57 mmol) of 4-benzamido-1-benzenesulfonylchloride in
10 mL dichlormethane were added. The color of the reaction turned to white after one
hour of stirring. The reaction was completed when there was no more starting material
detectable by TLC. A white solid was obtained after the solvent was removed in vacuo,
acetone : water (1 : 1) was used for the recrystallization.
Yield: 273 mg (48 %)
m.p.: 177 ◦C
Rf : 0.36 (S 10)
C,H,N analysis: C19H14N2O6S [398.40 g/mol]
C % H % N %
Calcd.: 57.28 3.54 7.03
Found: 57.35 3.57 11.30
1H-NMR (DMSO-d6) δ [ppm]:
7.55 (m, 3H, C3’H, C5’H, C6”H); 7.62 (t, J = 7.25 Hz, 1H, C4’H); 7.7 (t, J = 8.35 Hz,
1H, C5”H); 7.9 (m, 3H, C3H, C5H, C2”H); 7.96 (d, J = 7.25 Hz, 2H, C2’H, C6’H); 8.09
(d, J = 9.14 Hz, 2H, C2H, C6H); 8.2 (m, 1H, C4”H); 10.65 (s, 1H, NHCO).
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13C-NMR (DMSO-d6) δ [ppm]:
117.55 (C2”), 120.24 (C3, C5); 122.57 (C4”); 127.24 (C1); 128.03 (C3’, C5’); 128.65 (C2’,
C6’); 129.15 (C5”); 129.89 (C4’); 131.66 (C2, C6); 132.30 (C6”); 134.36 (C3”); 145.54
(C4); 148.48 (C1”); 149.12 (C1’); 166.50(CONH).
6.3.2. 44 2-(3’,5’-Dinitrobenzoylamino)benzene-1,4-disulfonic acid monosodi-
um salt (13b)
N
SO3Na
SO3Na
H
O
NO2
NO2
1
4
1´
4´
2
To a solution of 1.5 g (5.5 mmol) 2-amino-1,4-benzenedisulfonic acid monosodium
salt in 50 mL of water, 2.5 g (10.8 mmol) of 3,5-dinitrobenzoyl chloride in 30 mL of
toluene was added under vigorous stirring. During the whole reaction time, a pH of 4.5
was maintained by manual addition of 2 M aqueous Na2CO3 solution. the reaction was
continued until no more 2-amino-1,4-benzenedisulfonic acid monosodium salt could be
detected by TLC. The aqueous phase was separated, and washed with toluene until no
more 3,5-dinitrobenzoic acid could be detected by TLC. The water phase was evaporated
in vacuo to dryness and the yellow residue was recrystallized from water : ethanol (1 :
1).
Yield: 1.66 g (62 %)
Rf : 0.58 (S 8)
C,H,N analysis: C13H7N3Na2O11S · 3 H2O [545.38 g/mol]
C % H % N %
Calcd.: 28.60 2.38 7.70
Found: 28.54 2.39 7.73
1H-NMR (DMSO-d6) δ [ppm]:
7.4 (m, 1H, C5H); 7.7 (d, 1H, C6H); 8.75 (s, 1H, C3H); 9.01 (d, 1H, C4’H); 9.05 (d, 2H,
C2’H, C6’H); 12.03 (s, 1H, NHCO).
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13C-NMR (DMSO-d6) δ [ppm]:
117.71 (C3); 121.12 (C5); 121.55 (C4’); 126.77 (C6); 127.27 (C2’, C6’); 133.87 (C1);
135.95 (C2); 137.5 (C1’); 148.74 (C3’, C5’); 149.94 (C4 ); 160.03 (NHCO).
6.3.2. 45 2-(3’,5’-Dinitrobenzoylamino)-benzene-1,4-disulfonic acid - bis-(m-
nitrophenyl)ester (14b)
O
N
S
O O
H
O
NO2
NO2
S
O O
O
NO2
O2N
3´´
3´´´
1
2
4
1´
3´
5´1´´
1´´´
Compound 13b (300 mg, 0.61 mmol) and ca. 5 g of PCl5 were heated at 150
◦C
for two hours. A yellow brown solid was obtained after the mixture was poured into
ice-cold water. This brown 2-(3’,5’-dinitrobenzyolamino)benzene-1,4-disulfonyl dichloride
was directly used for the subsequent reaction without purification.
To a solution of 222 mg (2.48 mmol) sodiumm-nitrophenoxide in 20 mL of dichlorome-
thane, 2 mL of TEA and sulfonylchloride in 20 mL of dichloromethane were added drop
by drop under vigorous stirring. The reaction was monitored by TLC and continued until
no more starting compound were detectable. The solvent was distilled off in vacuo and
the residue was purified by flash chromatography on silica gel using acetone : petroleum
ether = 1 : 3.5 as eluent.
Yield: 125 mg (18 %)
m.p. 159 ◦C
Rf : 0.33 (S 9)
C,H,N analysis: C25H15N5O15S2 [689.55 g/mol]
C % H % N %
Calcd.: 43.55 2.19 10.16
Found: 44.93 3.20 8.09
1H-NMR (DMSO-d6) δ [ppm]:
7.32 (m, 1H, C6”H); 7.58 (t, J = 8.4 Hz, 1H, C5”H); 7.65 (m, 1H, C5H); 7.69 (m, 1H,
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C6”’H); 7.75 (t, J = 8.2 Hz, 1H, C5”’H); 7.80 (t, J = 2.2 Hz, 1H, C2”H ); 7.89 (d, J =
1.9 Hz, 1H, C3H); 8.05 (t, J = 2.2 Hz, 1H, C2”’H); 8.05 (d, J = 7.5 Hz; 1H, C6H); 8,18
(m, 1H, C4”H ); 8.23 (m, 1H, C4”’H); 8.57 (d, J = 2.2 Hz, 2H, C2’H, C6’H); 8.8 (t, J =
2.2 Hz, 1H, C4’H).
13C-NMR (DMSO-d6) δ [ppm]:
117.25, 117.22 (C2”’, C2”); 120.71 (C4’); 122.83 (C4”); 123.04 (C5); 123.08 (C4”’); 123.28
(C3); 128.43 (C6”); 128.73 (C6”’); 128.93 (C2’, C6’); 129. 87 (C1); 131.61 (C5”); 132.04
(C5”’); 132.64 (C6); 133.29 (C2); 140.70 (C1’); 147.79 (C4); 147.98 (C3’, C5’); 148.4
(C3”); 148.50 (C3”’); 148.60 (C1”); 148.76 (C1”’); 157.02 (CONH).
6.3.2. 46 Isophthaloyl-N,N-bis-p-benenesulfonic acid sodium salt (15a)
SO3Na
N
H
O
SO3Na
N
H
O
1 1
4 4
1´ 3´
To a solution of 1.0 g (5.78 mmol) sulfanilic acid in 20 mL of water, 0.58 g (2.8
mmol) of isophthaloyl dichloride in 10 mL of toluene was added under vigorous stirring.
During the whole reaction, a pH of 3 was controlled by manual addition of 2 M aqueous
Na2CO3 solution. The reaction was continued until no more sulfanilic acid could be
detected by TLC. The aqueous phase was separated, and washed with toluene until no
more isophthalic acid could be detected by TLC. The water phase was evaporated in
vacuo to dryness and the yellow residue was recrystallized from water : ethanol (1 : 1).
Yield: 997 mg (66 %)
Rf : 0.5 (S 7)
C,H,N analysis: C20H14N2Na2O8S2 [520.45 g/mol]
C % H % N %
Calcd.: 46.16 2.71 5.38
Found: 45.62 2.96 5.21
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1H-NMR (DMSO-d6) δ [ppm]:
7.6 (d, J = 8.51 Hz, 4H, C3H, C5H); 7.67 (t, J = 7.72 Hz, 1H, C5’H ); 7.75 (d, J = 8.82
Hz, 4H, C2H, C6H); 8.14 (m, 2H; C4’H, C6’H ); 8.53 (t, J = 1.73 Hz, 1H, C2’H ); 10.5
(s, 1H, NHCO).
13C-NMR (DMSO-d6) δ [ppm]:
119.49 (C3, C5); 126.22 (C2, C6); 127.12 (C5’); 128.77 (C2’); 130.89 (C4’, C6’); 135.22
(C1’, C3’); 139.24 (C1); 143.91 (C4); 165.21 (CONH).
6.3.2. 47 Isophthaloyl-N,N-bis-(p-benenesulfonic acid)-m-nitrophenyl ester (16a)
O2N
S
N
H
O
S
N
H
O
O
O
O O
O
O
NO2
1 1
4 4
1´ 3´
1´´ 1´´
3´´
3´´
Compound 15a (600 mg, 1.26 mmol) and ca. 6 g of PCl5 was heated at 150
◦C for
two hours. A white solid was precipitated after the mixture was poured into ice-cold
water. This white isophthaloyl-N,N-bis(p-benenesulfonyl)dichloride was directly used for
the subsequent reaction without purification.
To a solution of 493 mg (3.06 mmol) sodiumm-nitrophenoxide in 20 mL of dichlorometh-
ane, 2 mL of TEA and sulfonyldichloride in 20 mL of dichloromethane were added drop
by drop into the above solution. The reaction was monitored by TLC until no starting
compound was detectable anymore. The solvent was distilled off in vacuo, and the residue
was purified by flash chromatography on silica gel using acetone : petroleum ether = 1 :
2 as eluent.
Yield: 150 mg (17 %)
m.p. 240 ◦C
Rf : 0.28 (S 10)
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C,H,N analysis: C32H22N4O12S2 · H2O [736.72 g/mol]
C % H % N %
Calcd.: 52.12 3.26 7.60
Found: 53.84 3.62 7.18
1H-NMR (DMSO-d6) δ [ppm]:
7.55 (m, 2H, C6”H); 7.7 (m, 3H, C5”H, C5’H); 7.89 (t, J = 2.36 Hz, 2H, C2”H); 7.92 (d,
J = 9.14 Hz, 4H, C3H, C5H); 8.1 (d, J = 9.14 Hz, 4H, C2H, C6H,); 8.2 (m, 4H, C4’H,
C6’H, C4”H); 8.55 (t, J = 1.58 Hz, 1H, C2’H); 10.9 (s, 1H, NHCO).
13C-NMR (DMSO-d6) δ [ppm]:
117.55 (C2”); 120.34 (C3, C5); 122.6 (C4”); 127.51 (C5’); 127.58 (C1); 129.05 (C2’);
129.19 (C5”); 129.97 (C2, C6); 131.58 (C4’); 131.68 (C6”); 134.67 (C3”); 145.34 (C4);
148.48 (C1”); 149.11 (C1’); 165.85 (CONH).
6.3.2. 48 Isophthaloylamino-N,N’-bis-benzene-1,4-disulfonic acid sodium salt
(15b)
N
H
O
NaO3S
SO3Na
N
H
O
NaO3S
SO3Na
1 1
4 4
1´ 3´
2 2
To a solution of 1.0 g (3.6 mmol) 2-amino-1,4-benzenedisulfonic acid monosodium salt
in 20 mL of water, 0.74 g (3.6 mmol) of isophthaloyl dichloride in 20 mL of toluene was
added into the aqueous solution under vigorous stirring. During the whole reaction time, a
pH of 3 was maintained by manual addition of 2 M aqueous Na2CO3 solution. The reaction
was continued for more than 12 hours, until no more 2-amino-1,4-benzene-disulfonic acid
monosodium salt could be detected by TLC. The aqueous phase was separated, and
washed with toluene until no more isophthalic acid could be detected by TLC. The water
phase was evaporated in vacuo to dryness and the yellow residue was recrystallized from
water : ethanol (1 : 1).
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Yield: 350 mg (23 %)
Rf : 0.78 (S 7)
C,H,N analysis: C20H12N2Na4O14S4 · 3 H2O [778.6 g/mol]
C % H % N %
Calcd.: 30.82 3.59 2.31
Found: 30.74 3.59 2.47
1H-NMR (DMSO-d6) δ [ppm] :
7.25 (m, 2H, C5H); 7.6 (m, 2H, C6H); 7.78 (t, J = 7.72 Hz, 1H, C5’H); 8.14 (m, 2H,
C4’H, C6’H); 8.58 (s, 1H, C2’H); 8.82 (d, 2H, C3H); 11.54 (s, 2H, NHCO).
13C-NMR (DMSO-d6) δ [ppm] :
117.54 (C3); 120.25 (C5); 126.54 (C6); 127.22 (C5’); 129.57 (C4’, C6’);129.61 (C2’); 134.59
(C1); 135.6 (C2); 135.66 (C1’, C3’); 149,69 (C4); 163.26 (CONH).
6.3.2. 49 4-(3’-Nitro-benzoylamino)-1-benzenesulfonic acid sodium salt (17a)
SO3Na
N
O
NO2H
1
4
1´
3´
To a solution of 2 g (1.2 mmol) sulfanilic acid in 20 mL of water, 2.5 g (1.35 mmol)
of 3-nitrobenzoyl chloride in 10 mL of toluene was added under vigorous stirring. During
the whole reaction time, a pH of 3 was maintained by manual addition of 2 M aqueous
Na2CO3 solution. The reaction was continued until no more sulfanilic acid could be
detected by TLC. The aqueous phase was separated, and washed with toluene until no
more 3-nitrobenzoic acid could be detected by TLC. The water phase was evaporated in
vacuo to dryness and the residue was recrystallized from water : ethanol (1 : 1).
Yield: 4.4 g (72 %)
Rf : 0.61 (S 7)
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C,H,N analysis: C13H9N2NaO6S · 2 H2O [380.3 g/mol]
C % H % N %
Calcd.: 41.02 3.42 7.36
Found: 40.76 3.44 7.25
1H-NMR (DMSO-d6) δ [ppm]:
7.6 (d, J = 8.82 Hz, 2H, C3H, C5H); 7.8 (m, 3H, C5’H, C2H, C6H); 8.4 (m, 1H, C6’H);
8.47 (m, 1H, C4’H); 8.8 (s, 1H, C2’H); 10.75 (s, 1H, NHCO).
13C-NMR (DMSO-d6) δ [ppm]:
119.84 (C3, C5);122.73 (C2’); 126.28 (C2, C6); 126.33 (C4’); 130.35 (C5’); 134.42 (C6’);
136.3 (C1’); 139.16 (C1); 143.85 (C4); 147.93 (C3’); 163.59 (CONH).
6.3.2. 50 4-(3’-Aminobenzoylamino)benzenesulfonic acid sodium salt (18a)
SO3Na
N
O
NH2H
1
4
1´
3´
A suspension of 1.8 g (5.3 mmol) 17a in 100 mL of H2O was adjusted to pH 8 by 2
M aqueous Na2CO3 solution, the solution was hydrogenated at a hydrogen pressure of 1
bar with Pd/C (10 % Pd) as a catalyst. The reaction mixture was filtered. The filtrate
was brought to pH 6 by 1 M HCl solution, then the aqueous solution was dried to yield
18a as white powder .
Yield: 1.6 g (95 %)
Rf : 0.68 (S 7)
1H-NMR (DMSO-d6) δ [ppm]:
5.27 (s, 2H, NH2); 6.7 (m, 1H, C4’H); 7.04 (m, 1H, C6’H); 7.08 (t, J = 2.04 Hz, 1H,
C2’H); 7.12 (t, J = 7.88 Hz, 1H, C5’H); 7.65 (d, J = 8.82 Hz, 2H, C3H, C5H); 7.7 (d, J
= 8.82 Hz, 2H, C2H, C6H); 10.1 (s, 1H, NHCO).
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13C-NMR (DMSO-d6) δ [ppm]:
113.16 (C2); 114.92 (C6’); 116.95 (C4’); 119.22 (C3, C5); 126.01 (C2, C6); 128.88 (C5’);
136.0 (C1’); 139.54 (C1); 143.61 (C4); 148.89 (C3’); 166.49 (CONH).
6.3.2. 51 4,4-(Carbonylbis(imino-1’,3’-phenylene)carbonylimino)bis-1-sulfonic
acid sodium salt (19a)
SO3Na
N
H
O
SO3Na
N
H
O
N
H
N
O
H
1
4
1´ 3´
1
4
3´ 1´
A 20 % solution of phosgene in toluene (20.5 mL, 41 mmol COCl2) was added dropwise
over 1 h at r.t. to a vigorously stirred solution of 1.3 g (4.1 mmol) 18a in 200 mL of H2O.
During the whole reaction, the mixture was strictly maintained at pH 3 by automatic
addition of 2 M aqueous Na2CO3 solution. Soon large amounts of precipitate came out
of the solution. After ca. 3 h of stirring, the precipitate was filtered off and washed with
methanol.
Yield: 606 mg (22 %)
Rf : 0.48 (S 7)
C,H,N analysis: C27H20N4Na2O9S2 · 1.5 H2O [681.62 g/mol]
C % H % N %
Calcd.: 47.53 3.37 8.22
Found: 47.68 3.50 8.28
1H-NMR (DMSO-d6) δ [ppm]:
7.42 (t, J = 8.04 Hz, 1H, C5’H); 7.55 (m, 1H, C4’H); 7.59 (d, J = 8.51 Hz, 2H, C3H,
C5H); 7.71 (m, 1H, C6’H); 7.73 (d, J = 8.82 Hz, 2H, C2H, C6H); 7.98 (t, J = 1.89 Hz,
1H, C2’H); 9.1 (s, 1H; NHCONH); 10.3 (s, 1H, NHCO).
13C-NMR (DMSO-d6) δ [ppm] :
117.99 (C2’); 119.49 (C3, C5); 121.23 (C6’); 121.58 (C4’); 126.22 (C2, C6); 129.02 (C5’);
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135.89 (C1’); 139.49 (C3’); 139.61 (C1); 143.61 (C4); 152.79 (NHCONH); 165.86 (CONH).
6.3.2. 52 2-(3’-Nitrobenzoylamino)-benzene-1,4-disulfonic acid sodium salt
(17b)
N
O
NO2H
SO3Na
NaO3S 1
4
1´
3´
2
To a solution of 1.5 g (5.5 mmol) 2-amino-1,4-benzenedisulfonic acid monosodium salt
in 40 mL of water, 1.5 g (8.1 mmol) of 3-nitrobenzoyl chloride in 30 mL of toluene was
added under vigorous stirring. During the whole reaction time, a pH of 3 was maintained
by manual addition of 2 M aqueous Na2CO3 solution. The reaction was continued until
no more 2-amino-1,4-benzene-disulfonic acid monosodium salt could be detected by TLC.
The aqueous phase was separated, and washed with toluene until no more 3-nitrobenzoic
acid could be detected by TLC. The water phase was evaporated in vacuo to dryness and
the residue was recrystallized from water : ethanol (1 : 1).
Yield: 1.72 g (71 %)
Rf : 0.62 (S 7)
C,H,N analysis: C13H8N2Na2O9S2 · 2 H2O [482.36 g/mol]
C % H % N %
Calcd.: 32.34 2.49 5.81
Found: 32.79 2.46 5.92
1H-NMR (DMSO-d6) δ [ppm]:
7.3 (m, 1H, C5H); 7.68 (d, J = 7.88 Hz, 1H, C6H); 7.9 (t, J = 8.03 Hz, 1H, C5’H); 8.34
(m, 1H, C6’H); 8.45 (m, 1H, C4’H); 8.71 (t, J = 1.89 Hz, 1H, C3H); 8.8 (t, 1H, C2’H);
11.7 (s, 1H, CONH).
13C-NMR (DMSO-d6) δ [ppm]:
117.55 (C3); 120.59 (C5); 122.09 (C2’); 126.58 (C4’); 126.61 (C6); 130.96 (C5’); 132.99
(C6’); 134.2 (C1’); 135.73 (C2); 136.31 (C1); 148.37 (C3’); 149.84 (C4); 161.85 (CONH).
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6.3.2. 53 2-(3’-Aminobenzoylamino)benzene-1,4-disulfonic acid sodium salt
(18b)
N
O
NH2H
SO3Na
NaO3S 1
4
1´
3´
2
A suspension of 17b (1.22 g, 2.7mmol) in 50 mL of H2O was brought to pH 8 by 2
M aqueous Na2CO3 solution. The mixture was hydrogenated at a hydrogen pressure of
1 bar with Pd/C (10 % Pd) as a catalyst. The reaction mixture was filtered, the filtrate
was adjusted to pH 6 by 1 M HCl and the aqueous solution was dried to get light-yellow
powder of 18b.
Yield: 1.6 g (95 %)
Rf : 0.74 (S 7)
1H-NMR ( DMSO-d6) δ [ppm]:
6.75 (m, 1H, C4’H); 7.04 (m, 1H, C6’H); 7.14 (m, 2H, C2’H, C5’H); 7.3 (m, 1H, C5H);
7.64 (d, J = 8.2 Hz, 1H, C6H); 8.77 (t, J = 1.58 Hz, 1H, C3H); 11.1 (s, 1H, NHCO).
13C-NMR (DMSO-d6) δ [ppm]:
112.84 (C2’). 113.88 (C6’); 117.23 (C4’); 117.36 (C3); 119.66 (C5); 126.4 (C6); 129.2
(C5’); 134.99 (C1’); 135.45 (C2); 135.75 (C1); 149.26 (C3’); 149.55 (C4); 164.83 (CONH).
6.3.2. 54 2,2-(Carbonylbis(imino-1’,3’-phenylene)carbonylimino)-bis-1,4- disul-
fonic acid sodium salt (19b)
N
O
H
N
O
H
SO3Na
N
NaO3S
H
N
O
H
SO3Na
NaO3S1
4
1´ 3´
1
4
1´3´
2 2
A 20 % solution of phosgene in toluene (8 mL, 16 mmol COCl2) was added dropwise
over 1 h at r.t. to a vigorously stirred solution of 1.14 g (2.7 mmol) of 18b in 100 mL of
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H2O. During the whole reaction time, the mixture was maintained at pH 3 by automatic
addition of 2 M aqueous Na2CO3 solution. After all phosgene had been added and no
more amine could be detected by TLC, stirring was continued for 30 min and the pH
was adjusted to 6 by 1 M HCl. A light-yellow solids was obtained after the mixture was
evaporated to dryness.
Yield: 1.59 g (68 %)
Rf : 0.58 (S 7)
1H-NMR (DMSO-d6) δ [ppm]:
7.32 (m, 1H, C5H); 7.45 (t, J = 7.88 Hz, 1H, C5’H); 7.52 (m, 1H, C6’H); 7.64 (d, J =
8.20 Hz, 1H, C6H); 7.84 (m, 2H, C4’H); 7.98 (t, J = 1.89 Hz, 1H, C2’H); 8.8 (t, J = 1.58
Hz, 1H, C3H); 9.7 (s, 1H, NHCONH); 11.3 (s, 1H, NHCO).
13C-NMR (DMSO-d6) δ [ppm]:
117.36 (C2’); 117.46 (C3); 119.72 (C5); 119.98 (C6’); 121.43 (C4’); 126.5 (C6); 129.38
(C5’); 134.81 (C1’); 135.55 (C2); 123.59 (C1); 140.57 (C3’); 149.57 (C4); 152.84 (NHCONH);
164.02 (NHCO).
Determination of purity by CE:
Buffer: Phosphate 50 mM, pH 7.4
Voltage: 10 kV
Retention time: 20.58 min
Purity: 95.5 %
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6.3.2. 55 4-(3’,5’-Dinitro-benzoylamino)-1-benzenesulfonic acid sodium salt
(20)
N
SO3Na
H
O
NO2
NO2
1
4
1´
4´
To a solution of 1 g (5.78 mmol) sulfanilic acid in 20 mL of water, 2.66 g (11.5 mmol)
of 3,5-dinitrobenzoyl chloride in 10 mL of toluene was added under vigorous stirring.
During the whole reaction time, a pH of 4.5 was maintained by manual addition of 2 M
aqueous Na2CO3 solution. The reaction was continued until no more sulfanilic acid could
be detected by TLC. The aqueous phase was separated and washed with toluene until no
more 3,5-dinitrobenzoic acid could be detected by TLC. The water phase was evaporated
in vacuo to dryness and the residue was recrystallized from water : ethanol (1 : 1).
Yield: 2.1 g (92 %)
Rf : 0.6 (S 8)
C,H,N analysis: C13H8N3Na2O8S · 4 H2O [461.36 g/mol]
C % H % N %
Calcd.: 34.49 3.49 9.10
Found: 32.79 3.21 9.13
1H-NMR (DMSO-d6) δ [ppm]:
7.6 (d, J = 8.83 Hz, 2H, C3H, C5H); 7.75 (d, J = 8.83 Hz, 2H, C2H, C6H); 8.98 (t, J =
2.21 Hz, 1H, C4’H); 9.2 (d, J = 1,89 Hz, 2H, C2’H, C6’H); 10.9 (s, 1H, NHCO).
13C-NMR (DMSO-d6) δ [ppm]:
119.94 (C3, C5); 121.27 (C4’); 126.33 (C2, C6); 128.26 (C2’, C6’); 137.59 (C1’); 138.54
(C1); 144..55 (C4); 148.29 (C3’, C5’); 161.54 (CONH).
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6.3.2. 56 4-(4’-Nitro-benzoylamino)-1-benzenesulfonic acid sodium salt (21a)
N
O
H
SO3Na
NO2
1
4
1´
4´
To a solution of 1 g (5.8 mmol) sulfanilic acid in 30 mL of water, 1.5 g (8.1 mmol) of
4-nitrobenzoyl chloride in 20 mL of toluene was added under vigorous stirring. During
the whole reaction, a pH of 3 was controlled by manual addition of 2 M aqueous Na2CO3
solution. The reaction was continued until no more sulfanilic acid was detectable by TLC.
The aqueous phase was separated, and washed with toluene until no more 4-nitrobenzoic
acid could be detected by TLC. The water phase was evaporated in vacuo to dryness and
the residue was recrystallized from water : ethanol (1 : 1).
Yield: 1.72 g (87 %)
Rf : 0.6 (S 8)
C,H,N analysis: C13H9N2NaO6S · 2 H2O [380.32 g/mol]
C % H % N %
Calcd.: 41.02 3.42 7.36
Found: 41.54 3.31 7.33
1H-NMR (DMSO-d6) δ [ppm]:
7.60 (d, J = 8.51 Hz, 2H, C3H, C5H); 7.72 (d, J = 8.82 Hz, C2H, C6H); 8.19 (d, J = 8.82
Hz; C2’H, C6’H); 8.34 (d, J = 8.82 Hz, C3’H, C5’H); 10.61 (s, 1H, NHCO).
13C-NMR (DMSO-d6) δ [ppm]:
119.64 (C3, C5); 123.67 (C3’, C5’); 126.27 (C2, C6); 129.41 (C2’, C6’); 138.92 (C1’);
140.68 (C1); 144.23 (C4); 149.33 (C4’); 164.06 (CONH).
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6.3.2. 57 4-(4’-Amino-benzoylamino)-1-benzenesulfonic acid sodium salt (22a)
NH2
N
SO3Na
H
O
1
4
1´
4´
A suspension of 4-(4’-nitro-benzoylamino)-1-benzenesulfonic acid sodium salt 21a (0.8
g, 2.3 mmol) in 80 mL of H2O was adjusted to pH 8 by 2 M aqueous Na2CO3 solution.
It was hydrogenated at a hydrogen pressure of 1 bar with Pd/C (10 % Pd) as a catalyst.
The reaction mixture was filtered, and the filtrate was adjusted to pH 6 by 1 M HCl, then
the aqueous solution was dried to yield 22a as white powder .
Yield: 0.5 g (69 %)
Rf : 0.62 (S 7)
C,H,N analysis: C13H12N2NaO4S · 0.5 H2O [323.33 g/mol]
C % H % N %
Calcd.: 48.25 3.71 8.66
Found: 48.61 3.83 8.61
1H-NMR ( DMSO-d6) δ [ppm]:
5.72 (s, 2H, NH2); 6.59 (d, J = 8.51 Hz, 2H, C3’H, C5’H ); 7.52 (d, J = 8.51 Hz, 2H,
C2’H, C6’H); 7.68 (d, J = 8.51 Hz, 2H, C3H, C5H); 7.72 (d, J = 8.82 Hz, C2H, C6H);
9.78 (s, 1H, NHCO).
13C-NMR (DMSO-d6) δ [ppm]:
112.71 (C3’, C5’); 119.1 (C3, C5); 121.14 (C1’); 126.0 (C2, C6); 129.51 (C2’, C6’); 139.97
(C1); 143.08 (C4); 152.31 (C4’); 165.41 (CONH).
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6.3.2. 58 2-(4’-Nitro-benzoylamino)benzene-1,4-disulfonic acid sodium salt (21b)
NO2
N
SO3Na
SO3Na
H
O
4´
1
4
1´
2
To a solution of 1 g (3.6 mmol) of 2-amino-1,4-benzene disulfonic acid monosodium
salt in 20 mL of water, 0.5 g (4.3 mmol) of 4-nitrobenzoylchloride in 10 mL of toluene was
added under vigorous stirring. During the whole reaction time, a pH of 3 was maintained
by the manual addition of 2 M aqueous Na2CO3 solution. The reaction was continued until
no more 2-amino-1,4-benzenedisulfonic acid monosodium salt was detectable by TLC. The
aqueous phase was separated, and washed with toluene until no more 4-nitrobenzoic acid
could be detected by TLC. The water phase was evaporated in vacuo to dryness and the
residue was recrystallized from water : ethanol (1 : 1).
Yield: 0.99 g (61 %)
Rf : 0.56 (S 8)
C,H,N analysis: C13H8N2Na2O9S2 · 3 H2O [500.39 g/mol]
C % H % N %
Calcd.: 31.17 2.80 5.60
Found: 31.03 2.77 5.60
1H-NMR (DMSO-d6) δ [ppm]:
7.38 (m, 1H, C5H); 7.69 (d, J = 8.20 Hz, 1H, C6H); 8.26 (d, J = 9.14 Hz, 2H, C2’H,
C6’H); 8.42 (d, J = 8.82 Hz, 2H, C3’H, C5’H); 8.78 (t, J = 1.58 Hz, 1H, C3H); 11.63 (s,
1H, CONH).
13C-NMR (DMSO-d6) δ [ppm]:
117.59 (C3); 120.68 (C5); 124.33 (C3’, C5’); 126.64 (C6); 128.65 (C2’, C6’); 134.25 (C2);
135.82 (C1); 140.39 (C1’); 149.62 (C4); 149.77 (C4’); 162.36 (CONH).
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6.3.2. 59 2-(4’-Aminobenzoylamino)benzene-1,4-disulfonic acid sodium salt
(22b)
NH2
N
SO3Na
SO3Na
H
O
4´
1
4
1´
2
A suspension of 2.82 g (6.3 mmol) 2-(4’-nitro-benzoylamino)benzene-1,4-disulfonic acid
sodium salt 21b in 50 mL of H2O was adjusted to pH 8 by 2 M aqueous Na2CO3 solution.
It was hydrogenated at a hydrogen pressure of 1 bar with Pd/C (10 % Pd) as a catalyst.
The reaction mixture was filtered, and the filtrate was adjusted to pH 6 by 1 M HCl, then
the aqueous solution was dried to get a light-yellow powder.
Yield: 2.6 g (98 %)
Rf : 0.54 (S 7)
1H-NMR (DMSO-d6) δ [ppm]:
5,81 (s, 2H, NH2); 6.61 (d, J = 8.82 Hz, 2H, C3’H, C5’H); 7.25 (m, 1H, C5H); 7.63 (m,
3H, C6H, C2’H, C6’H); 8.79 (t, J = 1.58 Hz, 1H, C3H); 11.01 (s, 1H, CONH).
13C-NMR (DMSO-d6) δ [ppm]:
113.04 (C3’, C5’); 117.16 (C3); 119.13 (C5); 121.18 (C1’); 126.45 (C6); 128.96 (C2’, C6’);
134.96 (C2); 135.57 (C1); 149.52 (C4); 152.57 (C4’); 164.22 (CONH).
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6.3.2. 60 2-(4’-(4”-Nitrobenzoylamino)benzoylamino)benzene-1,4-disulfonic acid
sodium salt (23b)
NO2
N
N
NaO2S
SO3Na
H
O
O
H
4´1
4
1´
2 1´´
4´´
1´´´
1´´´´
To a solution of 1.05 g (2.52 mmol) 2-(4’-amino-benzoylamino)-benzene-1,4-disulfonic
acid sodium salt 22b in 20 mL of H2O, 0.9 g (4.8 mmol) of 4-nitrobenzoyl chloride in 10
mL of toluene was added under vigorous stirring. During the whole reaction, a pH of 3
was maintained by manual addition of 2 M aqueous Na2CO3 solution. The reaction was
continued until no more 22b could be detected by TLC. The aqueous phase was separated,
and washed with toluene until no more 4-nitrobenzoic acid could be detected by TLC.
The water phase was evaporated in vacuo to dryness and the residue was recrystallized
from water : ethanol (1 : 1).
Yield: 1.14 g (80 %)
Rf : 0.72 (S 7)
1H-NMR (DMSO-d6) δ [ppm]:
7.38 (m, 1H, C5H); 7.69 ( d, J = 8.20 Hz, 1H, C6H); 7.95 ( d, J = 8.82 Hz, 2H, C3’H,
C5’H); 8.00 (d, J = 8.82 Hz, 2H, C2’H, C6’H); 8.26 (d, J = 8.82 Hz, 2H, C2”H, C6”H);
8.36 (d, J = 8.82 Hz, 2H, C3”H, C5”H); 8.78 (t, J = 1.58 Hz, 1H, C3H); 10.96 (s, 1H,
NHCO); 11.37 (s, 1H, NHCO-arom-NO2).
13C-NMR (DMSO-d6) δ [ppm]:
117.32 (C3); 119.86 (C5); 120.21 (C3’); 123.67 (C3”); 126.49 (C6); 127.98 (C2’); 129.62
(C2”); 130.1(C1’); 134.87 (C2); 135.37 (C1); 140.44 (C1”); 142.18 (C4’); 149.44 (C4);
149.71 (C4”); 163.46 (C1””); 164.45 (C1”’).
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6.3.2. 61 2-(4’-(4”-Aminobenzoylamino)benzoylamino)benzene-1,4-disulfonic
acid sodium salt (24b)
NaO3S
SO3Na
N
H
O
N
O
H NH2
4´
1
4
1´
2 1´´
4´´
1´´´´
1´´´
A suspension of 1 g (1.77 mmol) of 2-(4-(4-nitrobenzoylamino)-benzoylamino)benzene-
1,4-disulfonic acid sodium salt 23b in 50 mL of H2O was adjusted to pH 8 by 2 M aqueous
Na2CO3 solution. It was hydrogenated at a hydrogen pressure of 1 bar with Pd/C (10 %
Pd) as a catalyst. The reaction mixture was filtered, the filtrate was adjusted to pH 6 by
1 M HCl, then the aqueous solution was dried to yield 24b.
Yield: 0.9 g (95 %)
Rf : 0.59 (S 7)
1H-NMR (DMSO-d6) δ [ppm]:
5.81 (s, 2H, NH2); 6.61 (d, J = 8.82 Hz, 2H, C3”H, C5”H); 7.66 (d, J = 7.88 Hz, 2H,
C6H); 7.76 (d, J = 8.82 Hz, 2H, C2”H, C6”H); 7.89 (d, J = 8.83 Hz, 2H, C3’H, C5’H);
7.96 (d, J = 8.82 Hz, 2H, C2’H, C6’H); 8.81 (t, J = 1.58 Hz, 1H, C3H);10.96 (s, 1H,
NHCO); 11.37 (s, 1H, NHCO-arom-NO2).
13C-NMR (DMSO-d6) δ [ppm]:
112.73 (C3”, C5”); 117.3 (C3); 119.61 (C3’, C5’); 119.73 (C5); 120.79 (C1”); 126.48 (C6);
127.82 (C2’, C6’); 128.73 (C1’); 129.75 (C2”, C6”); 135.0 (C2); 135.33 (C1); 143.40 (C4’);
149.65 (C4); 152.61 (C4”); 163.46 (C1””); 164.45 (C1”’).

Chapter 7
Summary
Synthesis, stability tests and pharmacological tests of the sulfonate derivatives of P1
(adenosine) receptor antagonists and P2 receptor antagonists were successfully performed.
P1 (adenosine) receptor antagonists
• m-Nitrophenyl sulfonate esters of p-sulfophenylxanthine derivatives were designed
and synthesized. It was proven that the modified synthetic route was a very convenient
way for the synthesis of this kind of xanthine sulfonate esters, since the yield of the
ring closure, which normally is the most difficult step during the synthesis of xanthine
derivatives, reached more than 50 % on average. The purification of the synthesized
sulfonate esters could be easily performed by recrystallization with DMF/water.
• A new synthetic strategy which is suitable for the preparation of gram amounts
of 1-substituted-8-p-sulfophenylxanthine derivatives was developed. That is, hydrolysis
of the 1-substituted-8-[4’-[[m-nitrophenoxy]sulfonyl]phenyl]xanthine to produce the corre-
sponding 1-substituted-8-p-sulfophenylxanthine derivatives, yields of the isolated hydroly-
sis products reached ca. 80 %. Altogether more than 8 g of 1-propyl-8-sulfophenylxanthine
were synthesized by using the new strategy.
• 8-p-Sulfonamidophenylxanthine derivatives were also synthesized by using p-
nitrophenyl as a new leaving group for the aminolysis, which has never been reported
before. Altogether 12 differently N-substituted 8-p-sulfonamidophenylxanthine deriva-
tives were synthesized, these amines ranging from relatively reactive primary amines to
unreactive secondary amines. It was proven that the newly developed method is a very
efficient and practical synthetic method, since the synthetic route is easy and the yields
are satisfying.
• In vitro stability tests of these m-nitrophenyl sulfonate esters of p-sulfophenylxan-
thine derivatives were performed in chemical and biological media. It was concluded
150 Summary
that these synthesized xanthine m-nitrophenyl sulfonate esters are relatively stable, since
the half-lives of these esters in 0.001 M NaOH at 37 ◦C reach 20 h on average. In
the biological in vitro test, the 1-propyl-8-[4-[[m-nitrophenoxy]sulfonyl]phenyl]xanthine
5d did not hydrolyze in simulated gastric acid within 4 hours of incubation at 37 ◦C.
That means it can resist to acidic media before it reaches the blood stream across the
gastrointestinal wall. It remains as an intact ester when it reaches in the blood stream
since the half-life of it in fetal calf serum reaches 16.4 h. At last it would be hydrolyzed
in the liver through enzymatic biotransformation to the parent m-nitrophenol and 8-p-
sulfophenylxanthine drug, the half-life in rat liver homogenate being about 41 min.
• All of the synthesized sulfonate esters and sulfonamidoxanthine derivatives were
tested in radioligand binding assays for their affinity to A1, A2A and A3 adenosine recep-
tor. It was proven that compared to the 8-p-sulfophenylxanthine, all the sulfonate esters
and sulfonamide derivatives are more potent at A1 and A2A adenosine receptors, but the
selectivity A1/A2A of these sulfonate xanthine derivatives is not high, ranging from 3-fold
(5e) to 30-fold (9e). Most of the compounds are not active at A3 ARs. Two compounds
(5d, 9d) have been tested at A2B ARs, and it was proven that they possess high A2B
affinity.
P2 receptor antagonists
• New XAMR and NF023 analogues using sulfanilic acid and 2-amino-1,4-benzenedi-
sulfonic acid monosodium salt as the starting materials were synthesized. The m-nitro-
phenyl sulfonate esters of the XAMR analogues and some NF023 analogues were subse-
quently synthesized by chlorination and esterification of the sulfonic acid derivatives.
• The inhibitory potency of some synthesized potential P2 receptor antagonists was
tested at P2Y2 receptor of NG108-15 cells. Compound 4-benzoylamino-benzenesulfonic
acidm-nitrophenyl ester 14a has an IC50 of 8.6 µM . The other sulfonic acids and sulfonate
esters were virtually inactive at P2Y2 receptors.
• Like the pharmacological properties of the P1 antagonists, the sulfonate esters of
XAMR and NF023 analogues show a higher antagonistic affinity as the corresponding sul-
fonic acids. That means that with the increase in lipophilicity of the sulfonate derivatives,
the antagonistic activity of these derivatives increased as well.
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Abbreviations
AC Adenylate cyclase
ADA Adenosine deaminase
ADP Adenosine diphosphate
ADPβ35S [35S]Adenosine 5’-O-2-thiodiphosphate
AMP Adenosine monophosphate
ARs Adenosine receptors
ATP Adenosine triphosphate
CADO 2-Chloroadenosine
cAMP Cyclic adenosine monophosphate
[3H]CCPA [3H]2-Chlor-N6-cyclopentyladenosine
CE Capillary electrophoresis
[3H]CHA [3H]N6-Cyclohexyladenosine
CHO Chinese hamster ovary
CNS Central nervous system
COSY Correlation spectroscopy
DEPT Distortionless enhancement of polarization transfer
DIDS 4,4’-Diisothiocyanatostilbene-2,2’-disulfonic acid
DMF N,N-Dimethylformamide
DMSO Dimethylsulfoxide
DPBS Dulbeccco’s phosphate buffered saline
DPCPX 1,3-Dipropyl-8-Cyclopentylxanthine
EDC N-(Dimethylaminopropyl)-N’-ethylcarbodiimide-HCl
EDTA Ethylenediamine tetraacetic acid
HMDS 1,1,1,3,3,3-Hexamethyldisilazane
HMQC Heteronuclear multiple quantum correlation
HPLC High pressure liquid chromatography
IU International unit
KN-62 1-N,O-bis-1,5-isoquinolinesulfonyl-N-methyl-L-tyrosly-4-phenylpiperazine
MRS 2179 2’-Deoxy-N6-methyladenosine-3’,5’-bisphosphate
MRS 2220 Cyclic pyridoxine-4,5-monophosphate-6-azophenyl-2’,5’-disulfonic acid
166 Abbreviations
[3H]MSX-2 [3H]3-((3-Hydroxypropyl)-8-m-methoxystyryl)-7-methyl-1-propargyl
xanthine
NECA N-Ethylcarboxamidoadenosine
NF023 8,8’-(Carbonylbis(imino-3,1-phenylene))bis-1,3,5-naphthalene
trisulfonic acid
NMR Nuclear magnetic resonance
PBS-buffer Phosphate buffered saline buffer
PEI Polyethylenimine
[3H]PIA [3H]-N6-Phenylisopropyladenosine
PPADS pyridoxalphosphate-6-azophenyl-2’,4’-disulfonic acid
PPSE Polyphosphoric acid trimetylsilyl ester
PSB-1115 1-Propyl-8-p-sulfophenylxanthine
[3H]PSB-11 [3H]2-(2’,3’,5’-trichlorophenyl)8-ethyl-4-methyl-(8R)-4,5,7,8-tetrahydro
-1H -imidazo-[2,1.i]purin-5-one
r.t. Room temperature
SDS Sodium dodecylsulfate
SEM Standard error of the mean
Suramin 8-(3-Benzamido-4-methylbenzamido)naphthalene-1,3,5-trisulfonic acid
TEA Triethylamine
TFA Trifluoroacetic acid
THF Tetrahydrofuran
TLC Thin layer chromatography
TMS Tetramethylsilane
TNP-ATP 2’,3’-O-(2,4,6-Trinitrophenyl)adenosine triphosphate
TRIS Tris(hydroxymethyl)aminomethane
UDP Uridin-5’-diphosphate
UMP Uridin-5’-monophosphate
UTP Uridin-5’-triphosphate
Uracil 1,2,3,4-Tetrahydro-2,4-pyrimidine
UV Ultraviolet
XAMR0716 8-(Phenylenecarbonylimino)-1,3,5-naphthalene trisulfonic acid sodium
salt
XAMR0721 8-(3,5-Dinitrophenylenecarbonylimino)-1,3,5-naphthalene trisulfonic
acid sodium salt
Xanthine 2,3,6,7-Tetrahydro-2,6(1H,3H )-purindione
[3H]ZM214385 [3H]4-(2-((7-Amino-2-(furyl)1,2,4-triazolo[2,3-a]-1,3,5-triazin-5-yl)amino)-
-ethyl)phenol
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